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Abstract
“Antimicrobial Resistance is a fundamental threat to global health and safety”
(WHO, 2016).
Nisin, a 34 amino acid lanthipeptide, is currently used as a food preservative
worldwide and has been used for decades without significant bacterial resistance
having developed. It is an extremely active molecule which kills a range of different
bacterial species. However nisin, along with some other similar peptides, suffers from
low stability and solubility at physiological pH, which severely restricts its possible
use in human and veterinary medicine. This research is concerned with increasing the
stability of nisin in physiological pH systems; the stability of the dehydroalanine (Dha)
at position 33 was examined as one of the project aims, along with the generation of
novel analogues of the nisin tail and also the incorporation of a cyclopropyl amino
acid as a Dha bioisostere moiety conserving the native conformation. This
derivatisation of the tail region of nisin may increase its stability while preserving its
bioactivity. These peptides were studied to examine their stability, reactivity and
conformational changes using NMR, UV-vis and Circular Dichroism (CD)
spectroscopies. The ionic strength effect on both Nisin A and Z was examined using
a variety of NMR techniques and CD spectroscopic studies using a wide variety of
salts, varying the charge density of anions and cations present in solution. The results
of these studies are outlined within this report. Using 1H NMR, nisin was also studied
in different pH environments in attempt to shed light onto the cause of the solubility
issues encountered at physiological pH. The pH region in which nisin starts to break
down is in the region in which the pKa of the histidine side-chain lies. Using 1H NMR
the pKa values of the histidine imidazole side-chains of both nisin A were also
investigated. While displaying nisin’s ability to bind metal ions in solution at
physiological pH, and the observed increase in the solubility of nisin in physiological
pH systems, could allow for nisin to be used in either therapeutic or veterinary
medicine, its solubility at physiological pH needs to be investigated and above all
increased.
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Chapter I
Introduction
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1.0.

Introduction

The overuse of general broad-spectrum antibiotics has led to an increase in the
occurrence of antibiotic-resistant organisms. The rise in bacterial resilience has
created a major health issue in hospitals worldwide, as often patients are already
immuno-compromised and are prime candidates to contract infection. A number of
bacteria found in hospitals have become resistant to many conventional antibiotics
including Methicillin-resistant staphylococcus aureus (MRSA) and vancomycinresistant enterococci (VRE), which are the most common pathogens found in hospital
settings.1
During the twentieth century, with dramatic advances in the diagnosis, management
and treatment of antibacterial infections, many believed that infectious diseases caused
by bacteria would be eliminated by the turn of the century. The over-prescription and
misuse of antibiotics has led to conventional therapies becoming inadequate, and has
become known as the “The Antibiotic Paradox”.2
Antibiotic resistance is now recognised as one of the primary global threats to public
health; a report from the World Health Organisation (WHO) released in September
2017 states that “the world is running out of antibiotics”.3 There is a lack of new
antibiotic therapies in the pipeline, as the majority of drugs currently in clinical trials
are derivatives of current antibiotic compounds. The report puts into perspective the
over-arching need for the development of new antibiotics which have novel
mechanisms of action, to aid in the combating of these antibiotic-resistant bacteria.3
The diminished pharmaceutical investment in antibiotic research is only one factor
that has contributed to the increase in antibiotic-resistant bacteria, and the reduction in
the output of new antibiotics. Antibiotic treatments are only administered for a limited
duration, making them less profitable than drugs used to treat chronic illness/ disease.4
This project investigates nisin, a naturally-occurring peptide produced by Lactococcus
lactis used as a defence strategy against Gram-positive bacteria. Nisin is of interest
due to its very high activity, in the nanomolar range, against Gram-positive bacteria
including some antibiotic-resistant bacteria such as MRSA and VRE.5 Although nisin
displays high activity, it suffers from stability and solubility issues at physiological
pH, limiting its use as a therapeutic agent. The generation of novel nisin tail analogues
2

was undertaken to investigate the breakdown of the nisin tail at physiological pH,
while hopefully preserving its bioactivity at such pH’s.

1.1.

Bacterial Cells

Bacterial cells are unicellular prokaryotic microorganisms which differ from
eukaryotic cells as they do not have a membrane-enclosed nucleus.6 Bacteria have the
ability to live and survive on surfaces through attachment mechanisms using their pili
and flagella (Figure 1).7

Figure 1: Bacterial Cell Structure7,8

1.2.

Bacterial cell walls

The bacterial cell wall is one of the main components of all bacterial species, with a
number of critical functions apart from giving the cell its shape and structure.9 It is
also involved in cellular functions which are crucial for its survival, including
reproduction, cell division, protection of the bacterial cellular contents and it is the
main barrier for bacteria against the external environment, preventing cell rupture and
osmotic shock.10 Bacteria are categorised into two bacterial types, Gram-positive and
Gram-negative, with this differentiation being based on the bacterial cell wall
composition and its response to Gram-staining procedures utilised in microbiology.
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Gram-positive cells stain dark purple and Gram-negative cells stain red/pink when
under Gram staining.11

1.2.1 Gram-positive bacterial cell wall
The cell wall of Gram-positive bacteria contains a multitude of peptidoglycan layers
(Figure 2) creating a thick layer of peptidoglycan. Woven into the porous
peptidoglycan matrix are teichoic acids, which are polymers of sugar alcohol
phosphate, only found in Gram-positive bacteria.12 Teichoic acids, and similar
molecules, constitute around 50% of the Gram-positive cell wall, with some teichoic
acids having a lipid attached (lipoteichoic acid or LTA).13 These acids play a role in
the innate immune system and also stabilize and strengthen the cell wall.14 They are
anionic in nature and scavenge metals which are required for bacterial growth.15 Also
present in the Gram-positive bacterial cells is Lipid II, which is a precursor of bacterial
cell wall synthesis and a target in the mechanism of action of various antibiotics.16

Figure 2: Cell wall composition of Gram-positive bacteria17

1.2.2 Gram-negative bacterial cell wall
The cell wall of Gram-negative bacterial cells differs greatly from that of their Grampositive counterparts. The cell wall can be broken into three main structural
components, i) the outer membrane, ii) thin layer of peptidoglycan (periplasm in
Figure 3) and iii) an inner membrane.17 Gram-negative bacteria contain a unique
component in the outer membrane, the lipopolysaccharide layer (LPS), which is
composed of a hydrophobic domain known as lipid A (endotoxin), a “nonrepeating
core” and a distal polysaccharide.18,19 The main structural difference between Gram4

positive and Gram-negative cells is that Gram-negative contains a thin peptidoglycan
layer situated in the periplasm of the cell, situated between the outer membrane and
the cytoplasmic membrane. The outer membrane of Gram-negative cells also contains
lipopolysaccharide (LPS) components protruding from the cell (Figure 3).20

Figure 3: Cell wall composition of Gram-negative bacteria20

1.3.

Cytoplasmic membrane of bacterial cells

The cytoplasmic membrane has a key structural role in both prokaryotic and
eukaryotic cells.21 It is composed of proteins and lipids, with the most abundant being
the phospholipid component, forming a lipid bilayer.22 The main role and function of
the cytoplasmic membrane is to act as a selective barrier to the cell, regulating the
entry and exit of molecules. An important property of the lipid membrane is that it
behaves like a two-dimensional fluid where the individual molecules are free to rotate
and move within the bilayer (Figure 4).23

Figure 4: Mobility of phospholipids within the cytoplasmic membrane23
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1.3.1 Lipid bilayer structure
The lipid bilayer of bacterial cells is composed mainly of phospholipids, which
contains two main components. The first is a hydrophilic phosphate head group and
the second is a hydrophobic fatty acid tail or lipid, which align to form two layers
(Figure 5).24

Figure 5: The phospholipid bilayer25
The self-assembly of the double layer phospholipid shell known as the lipid bilayer16
is driven by the propensity of the hydrophobic tails to interact and is entropically
driven by water in the aqueous environment.25,26 The bilayer membrane is involved in
the transport of molecules within the cell, including small peptides, ions and proteins,
which can either diffuse through the membrane in some instances, or by way of ion
channels.27 The lipid is very important for the mechanism of action of some
antibacterial peptides which create pores within the bilayer, disrupting its cellular
function and altering its permeability.

6

1.3.2 Lipid II
Lipid II is a membrane-anchored precursor molecule associated with the biosynthesis
of the rapidly growing bacterial cell wall. It consists of one N-acetylglucosamine-Nacetylmuramic

acid

(GlcNAc-MurNAc)-pentapeptide

subunit

linked

by

a

pyrophosphate group to a polyisoprenoid anchor (Figure 6).28,29 After translocation to
the periplasmic side of the membrane, the penicillin-binding protein (PBP) catalyses
the polymerisation of the sugar subunits, using lipid II as a substrate, in the synthesis
of the bacterial cell wall.30
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Figure 6: Structure of the lipid II precursor for bacterial cell wall synthesis,
highlighting the different binding sites of nisin and vancomycin31
A number of natural antimicrobial agents have been shown to target the lipid II,
allowing for one of the bacterial defences to be turned into an offensive strategy and
an antibiotic target to treat bacterial infections.32 The pentapeptide subunit of the lipid
II has been altered by bacteria, where changing one of the D-alanine amino acids (AAs)
gives rise to resistance to vancomycin. The pyrophosphate linker moiety has remained
evolutionarily unchanged, which could be a reason that little resistance has been
reported for antimicrobial agents which target the pyrophosphate.24 Lipid II has been
described as the “Achilles’ heel of bacteria”, with a wide variety of bioactive
compounds targeting this cell wall precursor.33
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1.4.

Antibiotics

Antibiotics are synthetic or natural compounds which are used to treat and combat
bacterial infections. They are compounds which usually target either the biosynthesis
of the bacterial cell wall, or DNA replication, or they can cause bacterial cell death.34

1.4.1 Antimicrobial Resistance
Antimicrobial resistance occurs when microorganisms such as bacteria, viruses, fungi
and parasites change in ways that render the medications used to cure the infections
that they cause ineffective.35 While antibiotic resistance is more commonly known, it
is a subset of antimicrobial resistance relating only to bacterial species.
Antibiotic resistance is when the bacterial target is altered in such a way that the
antibiotic’s efficacy is reduced or becomes less effective against the bacterial
pathogen. The alteration of the bacterial target inhibits the antibiotic’s mechanism of
action.36
Antibiotics have been used since the 1940s to treat bacterial infections worldwide;
they have hugely reduced the deaths related to many bacterial infections.37 However,
years of misuse and over-prescribing has led to resistant bacteria rendering
conventional antibiotics less effective, and in some cases having no effect against the
bacteria. There are three fundamental mechanisms of antimicrobial resistance; i)
enzymatic degradation of the antibiotic compound, ii) alteration of the antibiotic
targets, and iii) changes to the membrane permeability of the cell and using efflux
pumps to eliminate the antibiotic compounds from the cell. These mechanisms have
been associated with the development of multi-drug resistance (MDR).38’39
Each year in the United States there are over 2 million cases of patients with a bacterial
infection which is antibiotic-resistant, and at least 23,000 people die each year as a
direct result of these antibiotic-resistant bacterial infections,40 creating a human health
issue. It has been recently predicted that by 2050 worldwide 10 million lives will be
lost per year, with an economic cost of 100 trillion USD to treat these drug-resistant
bacterial infections, highlighting the need for novel antibacterial therapies to be
developed as a matter of extreme urgency.41
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The causes of the antibiotic resistance crisis include the overuse and inappropriate use
of conventional antibiotics driving the evolution of resistant bacteria, and the acquiring
of resistance from bacteria that possess resistance genes. The take up of plasmids
allows for the transfer of genes between bacteria, or through spontaneous mutation.
Antibiotics eliminate drug-sensitive bacteria, while leaving the resistant bacteria
behind to reproduce, as a result of natural selection.
It is estimated that over 80% of antibiotics sold in the United States are used
prophylactically in agriculture, primarily for animals, to stimulate growth and prevent
infections, as treating livestock with antibiotics is said to improve the health of the
animals and produce a greater yield of product.38 The antibiotics used to treat livestock
remain in the product and can then be ingested by humans, transferring resistant
bacteria to humans from farm livestock. This was first reported over 35 years ago,
where a high level of resistant bacteria where found in the gut flora of livestock and
farmers in the United states.42
A lack of novel antibiotics has led to resistance against conventional antibiotics, e.g.
penicillins. The “Golden Age” of antibiotics began in 1928, with the majority of the
modern antibiotic classes being discovered between 1940-1980.43 The increase in
antibiotic-resistant infections highlights the need for investment and the creation of
new antibiotic therapies.

1.4.2 Prevention of antimicrobial-resistant infections
To stop the rise of antimicrobial-resistant organisms, there is firstly a supply and
demand issue which needs to be resolved. Currently the supply of new antibiotic
therapies is insufficient to keep up with the increase in drug resistance. The demand
for these drugs is badly managed on a global scale, and huge quantities of
antibacterials are wasted on both patients and animals that do not need the treatment.
Antibiotics are being used prophylactically rather than as a treatment and so microbes
evolve to resist the antibiotics’ mechanisms of action.44
“Antimicrobial stewardship” refers to co-ordinated interventions and a fundamental
change in the way antibiotics are prescribed and consumed globally, to preserve the
efficacy of existing antibiotic drugs, increase their lifetime and reduce the urgency of
discovery and development of novel antibiotic treatments.45
9

1.4.3 Bacteriocins
Bacteriocins are defined as extracellular substances, usually peptides/proteins
produced by one bacterial strain, as a method of defence against another bacterial
strain. These bacteriocins are ribosomally synthesised peptides which can either act as
a bactericidal or bacteriostatic agent46; they could be described as antibiotics but are
not defined entirely in this class, due to the fact that bacteriocins have a narrow
spectrum of activity.47
A large number of both Gram-positive and Gram-negative bacteria produce
bacteriocins, with the bulk of characterised bacteriocins being identified in Grampositive bacterial species.47 During their growth they produce either proteins or
polypeptides which possess antimicrobial properties,48 which are usually restricted to
bacteria of the same strain.49

1.4.4 Antimicrobial Peptides (AMPs)
Antimicrobial Peptides (AMPs) are isolated from a variety of natural sources, and are
also referred to as Host defence peptides (HDPs).50 These peptides are associated with
the innate immune system and are found in both eukaryotic and prokaryotic cell types
including bacteria, insects, plants and mammals. AMPs are, for the most part, small
molecular weight peptides with a broad spectrum of activity against bacteria, fungi,
viruses and in some cases they have shown activity against cancerous cells.51 AMPs
are usually the first line of defence, for a multitude of organisms, including bacteria.
Production of AMPs is associated with the innate immune system where smaller
antimicrobial peptides usually act by disrupting the structure and function of cellular
membranes.52
The rapid development of increasing resistance towards conventional antibiotics
suggests that we are en route to a “post-antibiotic era”, meaning that current antibiotic
therapies will no longer be relevant.52 Thus, peptide antibiotics may have future
potential for use as alternatives to conventional antibiotics, including penicillins and
erythromycin.53
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1.5.

Lanthipeptides (Lanthionine-containing peptides)

Lanthipeptides are ribosomally synthesised peptides which are then posttranslationally modified to contain a lanthionine within the polypeptide structure. The
common feature of the lanthionine moiety (Ala-S-Ala) is two “alanine” residues
which are cross-linked via their β-carbons by a thioether linkage, as a monosulfide
analogue of cystine.54 Also, the polypeptide may contain the β-methyllanthionine
(Abu-S-Ala) which is similar to lanthionine but the cross-link is of “alanine” and 2aminobutyric acid.55 (Figure 7). Both the lanthionine and β-methyllanthionine
moieties are formed via a dehydration reaction of serine (lanthionine) or threonine (βmethyllanthionine). The dehydrated AA then acts as a Michael-acceptor in the
presence of cysteine, forming the thio-ether crosslink.43
OH

H2N

O

H2N

S

O

(R) COOH

NH2
Lanthionine

NH2

OH

H2N

Dhb

Dha

HOOC (S)

OH

O
Abu

HOOC (S)
(S) S
NH2

(R) COOH

NH2

β-methyllanthionine

Figure 7: Chemical Structures of Dehydroalanine (Dha), Dehydrobutyrine
(Dhb), Lanthionine and β-Methyllanthionine
Other common structural features of many lanthipeptides include the unusual AA
residues of dehydroalanine (Dha) and dehydrobutryine (Dhb) shown in Figure 7,
which are achiral α,β-unsaturated amino acids.56 The “alanine” residues within the
lanthionine contain two stereocentres (S,R), as the meso structure, while the βmethyllanthionine possess three stereocentres (S,S,R), due to the methyl group on the
β-carbon of the lanthionine moiety. These have been studied extensively by the Van
Der Donk group, who have highlighted the critical importance of the stereochemistry
of the lanthionine and β-methyllanthionine moieties for biological activity.57
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A subset of the lanthipeptides are the lantibiotic peptides (peptide antibiotics
containing a lanthionine residue), which contain between two and five lanthionine or
β-methyllanthionine moieties; thus, they contain a number of small ring structures
within their overall linear structure. Lantibiotics can be sub-divided into two
categories, Type A or Type B.55 Since the discovery of the first lantibiotic nisin, in the
1920s, well over fifty different lantibiotics have been identified and characterised.29

1.5.1 Classification of Lanthipeptides
Lanthipeptides are divided into four classes, with the most recent classification being:
Class I-IV. Lantibiotic peptides are divided into each classification or sub-division
based on their physiochemical properties, mode of action, biosynthetic production
pathway and the enzymes involved in lanthionine synthesis.58 The most recent method
of classifying lanthipeptides is based on the enzymes used in the dehydration and
cyclisation steps forming the lanthionine and β-methyllanthionine residues.

1.5.2 Class I Lanthipeptides
Class I lantibiotics are cationic AMPs produced by bacilli, staphylococci and
lactococci bacterial species. Structurally they are composed of elongated, flexible and
amphipathic peptides with masses usually exceeding 2100 Da.59 All class I lantibiotics
contain between two and five lanthionine and/or β-methyllanthionine ring motifs
within their structures. The lanthionine and β-methyllanthionine moieties contained in
all class I peptides are formed from two distinct enzymes, a dehydratase (LanB) and a
cyclase (LanC).60 The cationic peptides within the class I group are generally poreforming bacteriocins, which interact with, and alter the electrical potential of the target
cellular membranes. This pore-formation and change in the electric potential of the
membrane causes leakage of the cellular components and ultimately cell death.10
Gram-positive bacteria are responsible for the biosynthesis of a significant proportion
of lantibiotics including nisin, subtilin, and gallidermin (Figure 8).61,62 In 2015, the
structure and activity of pinensin A and B was described as the first naturally occurring
Gram-negatively produced lantibiotics, produced by Chitinophaga pinensis and they
have displayed activity against fungi and yeast.63
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Figure 8: Primary amino acid structure of gallidermin and subtilin64
Gallidermin, as shown in Figure 8, is a tetracyclic 21 AA peptide produced by
Staphylococcus gallinarum,65,66 while subtilin is a pentacyclic 32 AA peptide
produced by Lactococcus subtilis.67 Similar to other class I lantibiotics, subtilin is a
pore-forming antibacterial peptide. It is of note that the B-ring is a conserved sequence
in class I lantibiotics, as depicted in Figure 8 (red circles).68 The C-terminal tail, which
is essential for nisin pore formation, is absent from Gallidermin. Rather, its C terminus
is compact due to a double-ring system involving an aminovinyl cysteine residue
resulting from oxidative decarboxylation of the terminal ring, similar cyclisation is
also present in mersacidin a class II Lanthipeptide (Figure 9). Another example of a
class I lantibiotic is nisin which will be discussed in greater detail in Section 1.6.

1.5.3 Class II Lanthipeptides
Class II lanthipeptides are globular and are more rigid molecules than class I
lanthipeptides, which inhibit enzymatic functions through the interaction with specific
substrates, usually the lipid II in the cell wall. The globular nature of class II
lantibiotics is due to their interlocking thioether rings (lanthionine and βmethyllanthionine moieties).69 When compared to class I lanthipeptides, although both
bind to lipid II, class II lanthipeptides can bind without forming pores in the
membrane. In class II, there is a multifunctional lanthionine synthetase (LanMs)
enzyme which carries out both the dehydration and cyclisation steps forming the
13

Lys

lanthionine residues.70 Examples of class II lanthipeptides include mersacidin and
actagardine (Figure 9).71
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Figure 9: Structure of class II lantibiotics Mersacidin and Actagardine71

1.5.4 Class III Lanthipeptides
Class III lanthipeptides, unlike their class I and II counterparts, lack antimicrobial
activity. Instead, these peptides have morphogenetic and signalling functions in vivo.72
Similarly to the class II lanthipeptides, the post-translational modifications of the
lanthionine and β-methyllanthionine motifs occur via a multifunctional synthase
LanKC. They are also one of the smallest classification groupings; examples of class
III lanthipeptides include SapB and the labyrinthopeptins, shown in Figure 10.73
Labyrinthopeptins contain a Labionine (Lab) bridge, in which the cross-linking is
composed of a methylene group within the peptide structure instead of lanthionine;
these moieties consist of a carbacyclic side-chain linkage, with a methylene group
crosslinked between the α-carbons of two AAs within the structure. These highly
complex linkages are unprecedented in peptides and proteins.74
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1.5.5 Class IV Lanthipeptides
The final class of lanthipeptides is class IV which are similar to class III, in that both
biosynthetic pathways use a multifunctional lanthionine synthase. The lanthionine
synthase used during both the dehydration and cyclisation of the lanthionine moiety is
LanL.75 This class has been recently assigned through the discovery of the
lanthipeptide venezuelin, which is produced by Streptomyces venezuelae.76 The major
difference between class III and IV lanthipeptides is that in class IV the LanL contains
a zinc-binding motif in the cyclisation domain of the enzyme. This motif is thought to
activate the thiol side-chain of Cys, promoting the nucleophilic attack on the Dha/Dhb,
where the dehydrated AA acts as a Michael-acceptor in the presence of cysteine,
forming the thioether crosslink.43,77 An example of a class IV lanthipeptide is
Streptocollin (Figure 11).
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Figure 11: Structure of Class IV Lanthipeptide, Streptocollin77

1.6.

Nisin

Nisin is a 34 amino acid polycyclic lantibiotic which belongs to the class I
lanthipeptide family, exhibiting high antimicrobial activity against Gram-positive
bacterial species.78 It has been extensively studied, with over 4,000 peer-reviewed
publications to date, making it the most comprehensively studied lantibiotic. Nisin has
been used a food preservative (E234) for over 50 years, without the development of
significant antimicrobial resistance.79
It is used as a food preservative in over 50 countries mainly in the meat and dairy
industry.80 Importantly, it is active against a wide variety of Gram-positive bacteria
which include some resistant bacterial strains, such as Streptococcus pneumoniae and
vancomycin-resistant Enterococcus faecium.81,82 It is ribosomally synthesised,
followed by a series of sequence-specific dehydrations of serine and threonine
residues to form Dha and Dhb residues, respectively. The lanthionine moieties are
formed via stereoselective thioether formation by intramolecular Michael addition
reactions of the thiolates of cysteine residues to the dehydrated AAs (Dha and Dhb)
forming the lanthionine (A ring) and the β-methyllanthionine links (B-E rings), shown
in Figure 12.83
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The formation of the lanthionine and β-methyllanthionine follows a general
mechanism for all lanthionine-containing peptides described in section 1.5 and is not
specific to nisin alone.

1.6.1 Structure of nisin
Nisin A and nisin Z are the two most common natural forms of the bacteriocin, being
almost identical in structure apart from a single AA substitution at position 27; nisin
A contains a histidine (His) residue whereas in nisin Z it is an asparagine (Asn). Nisin
contains a number of distinct and unusual structural features; the polypeptide contains
five intra-chain thioether crosslinks, with a lanthionine crosslink in the A ring and βmethyllanthionines (Figure 12) in the B-E rings. Also contained within the structure
are three dehydrated AA residues, with a Dha at positions 5 and 33, and a Dhb at
position 2. The presence of these unusual residues in a number of lantibiotic peptides
suggests that they play a significant role in the antimicrobial mode of action.84 Also,
unusually nisin does not contain any aromatic residues such as Phe, Tyr or Trp. In
addition, of the 34 residues in the nisin structure, 13 of them are unusual residues, a
very high proportion. Nisin is very hydrophobic with only 3 Lys residues (+ charged)
and 2 His residues (nisin Z only 1), so both display low water solubility at
physiological pH. Interestingly there are no negatively charged residues (aspartic or
glutamic acids), with only the C-terminus COOH being present, which is also highly
unusual.
The A ring of nisin contains five AAs and is the only lanthionine thioether ring
containing a dehydrated residue (Dha 5). The B ring of nisin contains four residues
joined by a β-methyllanthionine; this ring system is interesting as a large number of
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lantibiotics, from a variety of disparate sources, share an identical B ring (e.g. subtilin,
gallidermin and epidermin).85 Both the A and B rings of nisin are involved in the
binding of nisin to lipid II (see section 1.6.2).86 The portion of nisin between the C and
D rings is known as the hinge region, consisting of a three AA sequence (Asn20Met21-Lys22). The hinge region is highly flexible and hydrophilic, and has been
associated with pore formation within bacterial cell membranes.87 The complex
interlocking D and E rings of nisin also play a role in pore formation, with the chemical
synthesis of these interlocking D and E rings being particularly difficult.88

1.6.1.1 Dehydroamino acid residues
Dehydroamino acids (dhAAs) are non-coded AAs that are present in a range of natural
products, including bioactive peptides.89 Nisin contains three dhAAs, two at the Nterminal end of the peptide and one present in the tail region. Although dhAAs are not
included in the 20 proteinogenic AAs, they are abundant in nature. This simple
functionality can greatly impact the structure and function of the biomolecules that
contain dhAAs.90 Structurally they assume a roughly planar geometry with their main
structural feature being the carbon-carbon double bond between the α and β-carbon
atoms (Figure 13).91 The planar geometry at the α,β-carbons has a significant effect
on the structure of peptides which contain dehydrated AAs. They are also electrophilic
in nature acting as Michael acceptors,92 since the introduction of the double bond leads
to a conjugated system, and significantly affects the conformation of the peptide
backbone.93 Due to the unsaturated alkene function within dehydrated AAs, they do
not contain a stereocentre at the α-position like the saturated AAs do, (with the
exception of glycine). The overall preferred trans-orientation of β-substituted dhAAs
promotes conformations within peptides and proteins which are not allowed with
saturated AA residues.94
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Figure 13: General structure of α,β-dehydroamino acid residues
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1.6.2 Nisin’s Mechanism of Action
Class I lanthipeptides, such as nisin, carry a net positive charge at physiological pH,
which is due to the number of lysine and/or arginine residues in the polypeptide
structure.95 Due to the cationic nature of the peptide, nisin is attracted to the surface of
Gram-positive bacteria which contain a high concentration of negatively charged
teichoic acid residues in their cell walls96 (i.e. teichoic acids in carboxylate form).
Nisin displays a dual mode of action against Gram-positive bacteria. Initiation of its
mechanism involves nisin binding to the pyrophosphate moiety of the lipid II
component (Figure 14) present in the bacterial cell wall and, following binding, it then
inserts into the membrane, creating a pore.97

Figure 14: Nisin-Lipid II pyrophosphate cage98
Binding of nisin to lipid II via 5 hydrogen bonds forms a complex known as the
“pyrophosphate cage”,98 with the A and B rings being involved in its formation. As
shown in Figure 14, in yellow are the intermolecular hydrogen bonds involving the
amide N-Hs within the nisin backbone to the oxygens of the pyrophosphate.99 As a
result of nisin binding to the lipid II molecule, which as stated before is a precursor of
bacterial cell wall synthesis, nisin-lipid II complex formation inhibits the synthesis of
the cell wall, prior to pore formation.100
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Figure 15: Binding and pore formation of nisin101
After formation of the pyrophosphate cage the peptide folds, using the hinge region,
into the bacterial cell leading to rapid membrane depolarisation and cell death (Figure
15);102 once anchored the C-terminus is parallel to the cell membrane and is then
inserted into the membrane, forming pores.103 The pore is thought to cause rapid
dissipation of the transmembrane electrostatic potential.104 Eight individual nisin
peptide molecules and four lipid II molecules are involved in the formation of a stable
pore, with a diameter of between 2.0 and 2.5 nm.105 The formation of the membrane
pore causes detrimental effects, resulting in an efflux of ions, AAs, ATP (adenosine
triphosphate) and collapse of the proton motive-force.106 It is thought that the slow
development of resistance to nisin from bacteria may stem from its dual mode of
action.79
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Figure 16: ''Hot Spots'' within nisin determined using 1 and 2D NMR
experiments33
Recently Breukink used solid state NMR techniques to investigate the nisin-lipid II
pore complex and described a number of pharmaceutical “Hot Spots” within the nisin
structure (Figure 16).107 These hot spots lie in the hinge region and the lysine linker
between the B and C thioether rings. Both regions are flexible and aid in pore
formation and nisin’s ability to adapt to complex cell membranes. Also highlighted is
the Ser29 residue located in the tail region of nisin, which also seems to anchor the
peptide and interact with the bacterial cell wall. Mutations within these regions have
been shown to modulate the bioactivity of nisin in a strain-specific manner.108

1.6.3 Aqueous Solubility and Stability of nisin
The solubility of nisin in aqueous solution is highly pH dependent; as the pH of the
aqueous solution increases the solubility of nisin decreases dramatically, as shown in
Figure 17.109 Nisin is a highly hydrophobic peptide which affects its aqueous
solubility. At pH 2 it has a solubility of 57 mg/ml, but when the pH is increased to pH
6 its solubility decreases to only 1.5 mg/ml.110 The common natural forms nisin A and
Z also display differences in solubility, with nisin Z having greater aqueous solubility,
even near physiological pH.111
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Figure 17: Aqueous solubility of nisin A as a function of increasing pH109
Nisin is quite stable between pH 2 and 3 but suffers a 90% loss in activity at pH 6.8,
so at elevated pH both the solubility and stability of nisin are compromised after 18
days.112 It has been long known that nisin becomes unstable in alkaline pH systems.
The Dha residue at position 33 is most susceptible to hydrolytic attack above pH 6,
leading to the cleavage of residues 33 and 34, generating nisin1-32.84 In highly basic
conditions, e.g. above pH 12, both the Ser29 hydroxyl group and ammonium
containing side-chains, i.e. lysines, are deprotonated which can then cause
intramolecular and intermolecular reactions with the Dha5 and 33 (Figure 18).84
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Figure 18: Intramolecular nucleophilic attack on Dha 33 of nisin at high pH84
The stability issues of nisin at physiological pH limits its use as a human or veterinary
therapeutic, so the development of nisin analogues with increased stability at
physiological pH could allow for its medicinal application as an antibiotic in order to

22

help to address the global AMR crisis. Achieving higher solubility through such
modifications would also facilitate access to effective therapeutic concentrations.

1.7.

Incorporation of Dha into peptides

In order to study the stabilisation of the Dha33 moiety located in the tail region of
nisin A and Z, it is necessary to be able to synthesise efficiently the Dha moiety within
the peptide structure. Several methods have been employed for the insertion of a Dha
residue into desired peptide targets. Access to dehydroamino acids in nature is
predominantly via dehydration reactions of serine and threonine residues, with both
being demonstrated as intermediates en route to Dha and Dhb formation.113 The
coupling of a Dha residue directly into peptides is difficult as it suffers from a stability
issue caused by the reactive α,β-unsaturated centre, which can act as a Michaelacceptor under a variety of reaction conditions. This reactivity causes the residue to
be prone to decomposition during peptide synthesis, so the late-stage conversion of
standard AAs has been utilised to generate the Dha, via a β-elimination reaction.114

1.7.1 Synthesis of Dha from phenylselenocysteine by oxidative elimination
Van der Donk and co-workers developed a synthesis of the Dha residue via the
oxidative elimination of the Fmoc-Se-phenylselenocysteine moiety (Scheme 1). The
required Fmoc-Se-phenylselenocysteine 4 was prepared, i) by treating Fmoc-serine
allyl ester 1 with tosyl chloride in pyridine forming the tosylate intermediate 2; ii) this
intermediate was treated with phenyl selenol and 1 mole equivalent of NaOH, to form
the fully protected Fmoc-Se-phenylselenocysteine allyl ester 3; iii) the removal of the
allyl protecting group was performed with palladium tetrakis(triphenylphosphine)
[Pd(PPh3)4], which gave 4 as a free carboxylic acid ready for used in solid-phase
synthesis peptide (SPPS).115

23

O

H
N

Fmoc

i

O

Fmoc

O

H
N

O
OTs

OH

2

1

ii

Fmoc

H
N

O
OH

iii

Fmoc

H
N

O
O

Se

Se

4

3
o

i) p-Tosyl chloride, pyridine 0 C; ii) Phenylselenol, NaOH (1M), acetone, DMF, rt;
iii) Pd(PPh3)4, morpholine, THF, rt

Scheme 1: Synthesis of Fmoc-phenylselenocysteine 4, from protected serine 1115
After the Fmoc-Se-phenylselenocysteine 4 was incorporated into a peptide sequence
using SPPS, the product was cleaved from the resin after coupling. This peptide was
then treated with either sodium periodate or hydrogen peroxide, oxidising the Sephenylselenocysteine to the selenoxide and prompting its spontaneous β-elimination,
forming Dha 6, within the peptide structure (Scheme 2).116
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1.7.2 Synthesis of a Dha via the Hofmann elimination reaction
Shiba and co-workers employed a Hofmann elimination in their total synthesis of nisin
to incorporate the Dha into both the A ring and tail region.117 The A ring was
synthesized with 2,3-diaminopropionic acid (A2pr) 7 in place of the Dha at position 5.
The β-amino group of the side-chain was then dimethylated by reductive amination,
using formaldehyde and sodium cyanoborohydride in methanol, to give 8 (Scheme 3).
The dimethylated residue was then quaternerised by treatment with methyl iodide and
eliminated on treatment with potassium hydrogen carbonate, to form the Dha 9 in 62%
yield.118
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Scheme 3: Hofmann elimination of 2,3-diaminopropionic acid 8, to form Dha 9118
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1.7.3 Synthesis of a Dha via an Asparagine residue
α,β-Unsaturated AAs, as described above, are usually derived from both serine and
threonine amino acid residues. In 1994, Blettner described the incorporation of a
masked Dha during peptide synthesis, in the form of an asparagine residue.119 It was
converted to the Dha via a series of Hoffmann-type degradation reactions (Scheme 4).
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Scheme 4: Formation of Dha via a masked asparagine residue119
The method involves 1.5 equivalents of PhI(OCCF3)2[bis(trifluoxacetoxy)
iodobenzene] being added for each asparagine residue present within the peptide to
facilitate a Hoffmann rearrangement,120 followed by a Hoffmann-type elimination to
afford the Dha residue on the Merrifield resin solid support. This method allows for
the site-specific incorporation of Dha residues into peptides on solid support resins.
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1.7.4 Synthesis of a Dha via β-elimination of a sulfonate intermediate
In 1963 Photaki and co-workers reported on the formation of Dha 9 via tosylation of
serine 12 and subsequent β-elimination of the tosylate 13, on treatment with
diethylamine (Scheme 5).121
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Scheme 5: Formation of Dha 9 from serine 12121
The method developed by Photaki was later adapted in 2007 by the Vederas group,
for the incorporation of Dha and Dhb residues into peptides.122 For the synthesis of
lactocin S, dipeptide 14 was treated with mesyl chloride, forming the di-mesylated
peptide 15. The mesyl groups where then eliminated using DBU in dichloroethane
(DCE) to produce the dehydrodipeptide 16, with both Dha and Dhb residues present
(Scheme 6).123,124
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1.7.5 Synthesis of Dha via oxidative elimination of cysteine thioethers
The preparation of a Dha through the oxidative elimination of cysteine thioethers was
reported in 2008 by Bernardes and co-workers. S-Ethyl cysteine 17 was converted to
Boc-Dha-OMe 18, after treatment with O-mesitylenesulfonyl-hydroxylamine (MSHinduced oxidative elimination), Scheme 7. Peptides, which contained a thioether, were
treated with MSH and base in DMF, with conversion to the Dha moiety in up to 79%
yield.125
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Scheme 7: Oxidative elimination of thioether 17 to generate Dha 18125
The Davis group has used this method for the effective conversion of a free cysteine
to a Dha in 98% yield, allowing for the conversion of a cysteine, on the surface of
peptides and proteins, to a Dha moiety.125 Nucleophilic and radical additions to the
Dha then lead to peptide and protein derivatives in excellent yields. The oxidative
elimination of cysteine is a perfect example of a site-specific functionalisation within
peptides and proteins. Post-translational modification of proteins is prevalent
throughout nature, which contributes to the increasing diversity of protein structure
and function by two orders of magnitude.126 It has been stated that the ability to modify
a particular AA or site, among a sea of reactive functional groups (amides, carboxylic
acids, amines and alcohols) has the potential to “herald new modes of Biology and
Medicine”.126,127 These protein modifications are often utilised to study both the
structure and functions of particular residues within peptides and proteins.128

28

1.7.6 Synthesis of a Dha moiety within peptides via cysteine bis-alkyl
elimination.
In 2015 Morrison and co-workers reported a strategy for the conversion of a cysteine
to a dehydroalanine residue via a bis-alkylation/elimination reaction, using methyl2,5-dibromovalerate 20 (Scheme 8). A cyclic sulfonium intermediate 22 is formed
through the double alkylation of the cysteine thiol 19, where the cyclic intermediate
22 then underwent spontaneous β-elimination to generate the Dha-containing product
23.129
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Scheme 8: Bis-alkylation/elimination of a cysteine by reaction with 2,5dibromovalerate129

1.8 Solution-phase peptide synthesis
In the early twentieth century Curtius and Fischer separately began investigating the
synthesis of small peptides, as until then the synthesis of peptides had been a challenge
to chemists for over 100 years.130 The strategy for peptide synthesis in solution
involves the use of orthogonally protected AAs, and coupling reagents to form the
activated acid to aid the formation of the amide bond. Similar to SPPS (see section
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1.9), peptide coupling in solution is a repetitive process of deprotection and coupling
steps to control the addition of the next protected AA to form the desired peptide
sequence. The steps involved in solution-phase synthesis are shown in Figure 19.
Firstly, the protected amino group of AA2 is deprotected, followed by coupling to the
activated carboxylic acid group of AA1. This pre-activation is achieved using coupling
agents.
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Figure 19: The process and steps involved in solution-phase peptide synthesis
A drawback of solution-phase peptide synthesis is that it is labour intensive. After each
coupling step rigorous purification is required before continuing to the next stage of
the synthesis. There are also issues associated with the solubility of fully protected
AAs in the solvents used in solution-phase synthesis (acetonitrile and DCM), since
DMF is difficult to remove after the coupling step.131
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1.9 Solid-phase peptide synthesis (SPPS)
In the early 1960s solid-phase peptide synthesis (SPPS) was developed by Bruce
Merrifield, and it is the most widely employed method for the chemical synthesis of
peptides, for which Merrifield won the Nobel Prize in 1984. The synthesis of the
desired linear peptide makes use of a solid support (resin), where the peptide is
elongated in a step-wise manner by the sequential addition of protected AAs, from the
C-terminus to the N-terminus.132,133 Attached to the resin is a linker bridging the
peptide to the solid support; the type of linker employed during the synthesis dictates
the cleavage conditions to recover the synthesised peptide, with the most common
cleavage method being acidic treatment with TFA.134 The advantages of the SPPS
technique over classical solution phase is the speed and simplicity of execution. Prior
to the development of SPPS, peptide synthesis was not only difficult but also labour
intensive. However, using a solid-support resin has allowed for the automation of
peptide synthesis of in some cases very complex peptides.135 The swelling of SPPS
resins is critical as 99% of the coupling sites are within the resin matrix, so swelling
is essential for optimal permeation of activated N-protected AAs and reagents.136 The
steps involved in removal of the temporary protected α-amino group, acid activation
and coupling, are shown in Figure 20.137
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In peptide synthesis there are two main AA protecting-group strategies used, namely
the

acid-labile

Boc

(tert-butoxycarbonyl)

and

the

base-labile

Fmoc

(fluorenylmethyloxycarbonyl) chemistries, with the Fmoc protection strategy being
employed in this project. The Fmoc strategy is the most common because this method
does not require specialised reaction equipment [e.g. using hydrofluoric acid (HF) for
Boc chemistries require stainless steel reaction vessels].

1.9.1 2-Chlorotrityl Chloride Solid Support Resin (2-CTC)
One of the most widely used solid supports in the SPPS of biomolecules, like peptides
and proteins, is the polystyrene-based 2-chlorotrityl chloride (2-CTC) resin, composed
of a polystyrene core and a 2-chlorotrityl linker.139 The 2-CTC resin is acid labile,
which is very compatible with the base-labile Fmoc SPPS strategy (Section 1.9.3).
The loading of the first AA is via an esterification reaction between the free carboxylic
acid group and the reactive trityl group on the solid support resin, in the presence of
base, DIPEA (N,N-diisopropylethylamine) shown in Scheme 9.140
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Scheme 9: Loading of Fmoc-protected amino acid onto the 2-CTC resin
Some of the advantages of using 2-CTC resins during SPPS include (i) the fast
attachment of the first amino acid, (ii) prevention of diketopiperazine (DKP) formation
during the synthesis; and (iii) the cleavage of peptide from the resin can be achieved
using mildly acidic conditions to afford a free carboxylic acid.141 The mild acidic
cleavage is also one of the main limitations of the 2-CTC resin, as premature cleavage
of fully protected peptides can be observed if only a small amount of acid is present;
as low as 1% TFA has been reported to cleave peptides from the resin.142 Another
disadvantage of the 2-chlorotrityl resin is that it is prone to hydrolytic cleavage when
compared to other resins.
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1.9.2 Wang Solid Support Resin
Another commonly used resin is the Wang resin, which again consists of a polystyrene
core but with a Wang linker composed of a p-alkoxy benzyl alcohol (Scheme 10).143
Similarly to the 2-CTC resin, cleavage using TFA generates a free carboxylic acid.
The liberation of peptides from the Wang resin requires a minimum of 50% TFA
solution, showing the greater stability of the Wang linker in comparison to the 2chlorotrityl linker.144
Fmoc-AA-OH
O

OH

DIPEA + KI

O

O

AA-Fmoc
O

AA= Amino Acid

Scheme 10: Loading of Fmoc Amino acid onto Wang resin144
Although the Wang resin is commonly used in SPPS there are two main disadvantages
to its use: 1) the esterification step of loading the Fmoc-amino acid can be
accompanied by significant racemisation, and 2) loss of the C-terminal dipeptide via
diketopiperazine formation.145

1.9.3 Fmoc SPPS strategy
The 1970s saw the development of Fmoc chemistry by Eric Atherton and Bob
Sheppard, who introduced the Fmoc group as a temporary protecting group on the Nterminus of a growing peptide.146 The Fmoc group is a base-labile protecting group
often removed using piperidine. This allows for milder removal conditions to be used
in comparison to Boc chemistry (which requires HF) for both the deprotection
throughout the synthesis and the resin cleavage step, to obtain the final peptide
product.147
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Figure 21: Mechanism of deprotection of the Fmoc group using piperidine148
The Fmoc group is readily removed when treated with secondary amines, e.g.
piperidine, which abstracts the relatively acidic proton from the fluorenyl ring system
(Figure 21). This deprotonation leads to a β-elimination to form CO2 (rendering the
reaction irreversible), dibenzofulvene (DBF) and the free amine.149 The piperidine has
a dual role during the deprotection step, acting as both a base for the removal of the
Fmoc group, and also as a scavenger to trap the liberated DBF. The use of a large
excess of piperidine (20% solution) prevents reaction of the free amine product with
DBF, which would prevent further reaction of the free amine group.150
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1.9.4 Estimation of Resin Loading
The removal of the Fmoc protecting group is also used for measuring resin loading, as
the accurate determination of resin loading dictates the yield of the final peptide
product. The base-labile Fmoc group is quantitatively removed using 20% piperidine
in DMF, forming a dibenzofulvene-piperidine adduct (Figure 22).151 This adduct
exhibits UV absorbance maxima at two distinct wavelengths, at λ = 301.0 and 289.8
nm. The absorbance measured at either of the wavelengths, in conjunction with the
respective molar absorptivity/ extinction coefficient (mL.mmol-1.cm-1), allows for
calculation of the resin loading (mmol/g).152,153
H
N

N

+

dibenzofulvene adduct in
supernatant

Figure 22: Dibenzofulvene-piperidine adduct equilibrium154
Due to the distinct UV absorbance of the dibenzofulvene-adduct, approximately 1020 mg of dried resin is sufficient for the estimation of resin substitution. The resin is
swollen in DMF and treated with 20% piperidine, the supernatant is then measured at
either distinctive wavelength, with the 290 nm wavelength being reported to be more
reilable.151 To determine the resin loading the mass of resin (m), UV cell path length
(cm) and dilution factor of the supernatant (D) must be taken into account, as well as
the molar absorptivity (ε) also known as extinction coefficient at the specified
wavelength and an equation (Figure 23) derived from the Beer-Lambert law (A = ε.c.∧,
where c = molar concentration) is employed.155,156
A = absorbance
ε = molar absorptivity at wavelength λ (mL.mmol-1.cm-1
or L.mol-1.cm-1)
V = volume (mL)
D = dilution factor
Λ = path length (cm)
d
i ( )

Figure 23: Equation for estimation of resin loading155
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1.9.5 Cleavage of peptides from solid support resins
The cleavage of synthesised peptides from the solid support resin is achieved using a
cleavage cocktail. Due to the prevalence of the Fmoc peptide synthesis strategy
(Section 1.9.3), the most commonly used cleavage method is an acid treatment (Figure
24). The TFA-based cleavage cocktails are composed of TFA and scavengers like
water, anisole and triisopropylsilane (TIPS). Cleavage is one of the most critical steps
during peptide synthesis and the treatment of a peptide resin is not one simple step,
but a series of competing reactions. Therefore, the choice and selection of suitable
reagents and scavengers is vital.157
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Figure 24: Cleavage mechanism of Wang resin using TFA
Scavengers like TIPS are used in cleavage mixtures in a concentration between 1-5%
and are used to suppress side reactions attributed to removal of side-chain protecting
groups and the reactive Wang linker during the global deprotection of the peptide
during cleavage.157 They scavenge cations like t-butyl and trityl which could possibly
react irreversibly with amine functionality within the peptide.158 For post-acidic
cleavage, in some cases, peptides can be precipitated from cold ethers, for example
diethyl ether (Et2O) or methyl tert-butyl ether (MTBE), before being purified, usually
by preparative HPLC.159,160

1.10 Coupling reagents utilised during peptide synthesis
In biological systems, peptide and protein syntheses are extremely complex and
facilitated by the ribosomes.161 Synthetically, the amide bonds are typically prepared
from the reaction between a carboxylic acid derivative and an amine (amidation).
However, on its own these chemicals would produce a salt and so does not happen
spontaneously.162 Usually, without the use of a coupling reagent, the conditions
employed for amide bond formations are harsh and require high temperatures to drive
the condensation and subsequent elimination of water forming the amide bond.
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Figure 25: Activation of a free carboxylic acid and amide bond formation
In synthesis the first step involves activation of the free carboxylic acid of one AA and
the second step involves nucleophilic attack by the free amino group of another AA
(Figure 25). The carboxylic is converted to an activated species, creating a “hyper”
leaving group, thus accelerating the formation of the amide bond.

1.10.1 Carbodiimide coupling reagents
The use of carbodiimide coupling reagents, such as dicyclohexylcarbodiimide (DCC,
Figure 26), is the traditional method employed for the formation of peptide bonds.
Carbodiimides contain two nitrogen atoms and are weakly basic; this is enough to
initiate the reaction forming the activated ester, which is reactive and readily
undergoes aminolysis, when in the presence of a free amine, to return the desired
peptide.163 One issue with using DCC is the difficultly in removing the dicyclohexyl
urea (DCU) by-product which is formed.164
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Figure 26: Structure of DCC (24) and EDC (25) coupling reagents164, 165
In response to solubility issues during purification, a number of other carbodiimides
have been developed with their corresponding urea by-product having greater water
solubility, and these include EDC (25). EDC has proven to be a popular alternative to
the conventional DCC coupling reagent, as the by-product is easily removed by an
aqueous extraction.165
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A common problem in the use of carbodiimides as coupling reagents is the
epimerisation of the α-proton, via intramolecular reactions at the site of acid activation.
The most common mechanism of epimerisation involves the formation of azlactones
(Figure 27).166 The formation of the azlactone ring lowers the pKa of the α-proton,
which facilitates deprotonation, caused by the now more acidic proton. The reprotonation of the α-carbon can occur on either face of the enolate, thus giving rise to
epimerisation.
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Figure 27: Peptide epimerisation of azlactones by intramolecular attack at the
activated acid167,168
In attempts to overcome the epimerisation issues, coupling reagents and additives have
been developed which are used to increase the reactivity of the activated carboxylic
acid, while suppressing the epimerisation at the α-position during peptide coupling.169

1.10.2 Additives and reagents used in peptide coupling reactions.
The most common additive used in peptide coupling is 1-hydroxybenzotriazole
(HOBt, 24), which is either used in combination with carbodiimide coupling reagents
or designed into stand-alone coupling reagents. The use of HOBt alongside
carbodiimide reagents increases the reactivity of the activated ester, inhibiting the
side-reaction and thus reducing epimerisation of the peptide.170
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Figure 28: Chemical structures of HOBt (26) and HOAt (27) additives
Although HOBt has been extensively used for over twenty years, it is explosive in its
anhydrous form and is now difficult to obtain commercially. The benzotriazole
coupling reagents including HOBt and HOAt (1-hydroxy-7-aza-benzotriazole) are
very reactive, accelerating peptide coupling, but have been restricted in their use
(usefulness) due to their explosive nature.171
After extensive study, in 1973, Castro and co-workers reported the applicability and
efficient replacements for HOBt based coupling reagents, benzotriazol-1yloxytris(dimethylamino)phosphonium hexafluorophosphate (BOP 28) and (1HBenzotriazol-1-yloxy)tri-1-pyrrolidinylphosphonium hexafluorophosphate (PyBOP
29) to be used as alternative peptide coupling reagents.172 These phosphonium-based
coupling reagents had the advantage of not forming guanidinium by-products
associated with aminium/uronium coupling reagents (see below). However, BOP
generates Hexamethylphosphoramide (HMPA 30) as a by-product which has been
classified as a potential carcinogen. 173,174
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Figure 29: Phosphonium-based peptide coupling reagents and the by-product
HMPA (30)
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Another family of coupling reagents are the uronium-type (urea form) based salts,
many of which are salts of HOBt like the 2-(1H-benzotriazol-1-yl)-1,1,3,3tetramethyluronium hexafluorophosphate (HBTU 31) and the HOAt salt like
1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium3-oxide-hexafluorophosphate (HATU 32). The true form of these coupling reagents depends on the
solvent, isolation and also the counter-ion used.175 HBTU, HATU and other
aminium/uronium based coupling reagents exist predominantly in the N-form
(guanidinium), which is less reactive than the corresponding O-form (uronium), but
both isomers are very effective coupling reagents, with little epimerisation, due to their
highly reactive nature.176
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1.11 Project Aims and Objectives
One of the main project aims was the synthesis of analogues of the nisin tail region
residues 29-34, in order to study the effect of the surrounding AAs on the stability of
the Dha33 moiety. Due to the reactive properties of the Dha33 in nisin it can undergo
cleavage in aqueous solution at pH 6-7 (Figure 31).79
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Figure 31: Currently accepted mechanism for the decomposition of nisin.79
As shown in Figure 31, the currently accepted literature mechanism for the cleavage
of Dha33, by acid-catalysed Markovnikov hydration in the physiological pH range, is
not consistent with the fact that nisin shows its maximum stability at the more acidic
pH values of 3-4. Therefore, the synthesis of the native nisin tail, and of analogues, to
study the stability of the Dha33 may shed light on the mechanism and ways to slow it
down considerably. It was proposed that the synthesis of peptide fragments, by either
SPPS or solution-phase peptide synthesis would be employed for the synthesis of the
tail of nisin (residues 29-34). Furthermore, intermediates during the synthesis would
contain either the Dha or its cyclopropyl AA replacement (AC3C, Figure 32) as a
structural mimic for the Dha, which would not undergo hydrolysis and therefore could
increase its stability.
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Figure 32: Structure of Dha and its cyclopropyl amino acid replacement
Replacement of Dha33 with the AC3C AA makes use of the commercially available
Fmoc-protected 1-aminocyclopropane-1-carboxylic acid (AC3C), which has been
used previously to develop metabolically stable, conformationally constrained
peptides.177 This may allow it to be a structural mimic for the dehydrated amino acid
as it would not be involved in acid-catalysed Markovnikov hydration. Structurally
AC3C is a possible replacement for the Dha as the bond angle at the α-carbon lies
between 115-118o while the Dha has ~120o bond angle,178 possibly maintaining the
conformational properties, but increasing the stability. For each of the peptide
fragments synthesised (Figure 33), both their conformation and stability in aqueous
solutions between pH 2-7.5 could be examined, using a range of spectroscopic
techniques including NMR, HPLC, LC-MS/MS, circular dichroism (CD)
spectroscopy and UV-visible spectroscopy.

Ile

29

His

Val X

34

Lys

Ser
X= Dha, AC3C

Ile

29

His

Val Dha

34

X

Ser
X= Lysine, Histidine

Figure 33: Structures of the nisin tail and tail analogue targets
As seen previously, nisin suffers a dramatic loss in activity and aqueous solubility as
the pH increases from acidic to physiological pH. From reported CD studies, the
conformation of nisin is also thought to change at a pH of ~6, which may be
responsible for the reduction in its activity.179 The imidazole side-chain of histidine
has a pKa value at around this pH,180 and so this could have an effect on the
conformational

change

when

the

side-chain

becomes

deprotonated.

The

conformational change, along with overall charge reduction, may lower its solubility
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and in turn its activity. The effect of the histidine on the stability and solubility of nisin
at physiological pH could be examined using HPLC, NMR and CD analysis.
These conformational changes could be studied in detail using both NMR and CD
analysis, to examine if there are any interactions which may stabilise or destabilise the
Dha moieties at physiological pH. Understanding the possible effects of the flanking
AAs on the stability of the dehydrated AAs in nisin may aid in the design and
development of novel nisin analogues with greater stability at physiological pH. For
example, replacing the terminal lysine residue with controls such as glycine, alanine
or phenylalanine. This would allow for the investigation of possible interactions of the
lysine ammonium side-chain, with the Dha33 residue. The lysine side-chain could be
involved in the protection of the Dha from hydrolysis, in acidic environments via a
cation-π interaction.181 Studying the presence of such interactions may increase the
therapeutic potential of nisin, and help to address the growing issue of antibiotic
resistance.
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Chapter II
Synthesis of the Nisin29-34 tail and its
analogues
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2.0 Introduction
This chapter describes the synthetic efforts employed toward the synthesis of the
native nisin tail, and its analogues, as proposed in section 1.10, which include the
incorporation of a Dha residue into the target peptide. The methodologies used, as well
as the synthesis and characterisation of described target peptides are outlined.

Synthesis of the Dha precursor Fmoc-phenylselenocysteine-O-Allyl
As described in section 1.7.1, the incorporation of a Dha into target peptides using
Fmoc-Se-phenylselenocysteine was reported by Van Der Donk, as a route to Dha
formation by oxidative elimination of the selenide, post peptide synthesis.115 This
method involves replacement of the O-H of serine by a phenylseleno functional group,
which can then be oxidised, using either hydrogen peroxide or sodium periodate,
followed by β-elimination to form the desired Dha residue within the synthesised
peptide fragment. The proposed synthetic route is shown in Scheme 11.
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Scheme 11: Synthesis of Fmoc-phenylselenocysteine-OH 4115
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The first intermediate required in the synthesis of Fmoc-Se-phenylselenocysteine-OH
was Fmoc-Ser-O-Allyl 1, which was formed in a biphasic solvent system of DCM and
water (1:1 ratio) from Fmoc-Serine-OH, using Aliquat 336 (methyltrioctylammonium
chloride), a phase transfer catalyst, and allyl bromide, giving compound 1 in 94%
yield. NMR spectroscopy and mass spectrometry confirmed the formation of 1. After
successful synthesis of 1, the -OH of the Fmoc-Ser-O-Allyl was reacted with p-tosyl
chloride in pyridine giving 2 in a low yield of 31% (literature yield between 8595%).115
After reaction of tosylate 2 with phenylselenoxide, as per the reported method, to form
3, no product was identified by either HRMS or 1H NMR analysis, as it may have
eliminated to form the Dha during purification. Coupling reactions involving the
COOH of Dha residues are known to be problematic giving low yields and byproducts. The Dha was seen by HRMS analysis with the observed mass [M+H]+ of
350.1381, compared to the calculated m/z of 350.1387. Many attempts were made to
perform and optimise this reaction but unfortunately in our hands without success.

Synthesis of N-acetyl-Dha methyl amide
The synthesis of N-acetyl-Dha-methyl amide (38, Scheme 12) was attempted to study
the reactivity and stability of an isolated Dha moiety which is not within a peptide,
since the flanking AAs could protect the Dha from reaction in acidic pH environments.
Therefore, 38 would give a “baseline value” of Dha stability. Nisin contains three
dehydrated AA residues and it could be thought that in acidic environments these
residues should be hydrolysed, but this is not consistent with experimental findings,
so a comparative study of reactivity of the Dha would be performed to determine the
mechanism of degradation and stability of the Dha.
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Scheme 12: Synthesis of N-acetyl-Dha-methyl amide
The synthesis of 38 was attempted starting from L-serine methyl ester 35 which was
treated with methylamine to form amide 36. The formation of 36 was confirmed by
HRMS, with the observed mass [M+H]+ of 119.0821, compared to the calculated m/z
of 119.0820. Compound 36 proved very difficult to purify by column chromatography,
so the crude product was carried forward without purification and reacted with acetic
anhydride in pyridine, for acetylation of the free amino group to produce 37, but this
product was never detected post synthesis. Instead the presence of Dha 38 was
observed indicating that elimination of the alcohol had occurred. The formation of 38
was confirmed by HRMS with the observed mass [M+H]+ of 145.0970, compared to
the calculated m/z of 145.0972.
Compound 38 was formed during the acetylation step, and so the dehydration of the
alcohol using EDC and copper(II) chloride, as shown in Scheme 12, was not required.
It is most likely that Dha 38 formed by β-elimination of the acetoxy derivative 39 due
to the acetate group being a better leaving group. To date no NMR identification of
the isolated product 38 has been achieved, as purification by column chromatography
proved highly problematic, possibly due to decomposition on the slightly acidic silica.
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Solution-phase peptide synthesis of nisin tail fragments
The synthesis of fragments of the nisin tail, and their derivatives, was undertaken using
a dual approach of both solution and solid-phase peptide synthesis. The solution phase
was initially employed due to the length of peptide sequences and the higher quantity
of material that could be generated. SPPS was utilised due to the ease of removing
reagents, along with no requirement for purification of peptide intermediates, until the
final stage of synthesis. The materials isolated were analysed using UV-Vis, IR,
HRMS, NMR, and CD spectroscopy.

Synthesis of Fmoc-Lys (Boc)-O-Allyl for solution-phase synthesis
As the amino acid at position 34 of the nisin tail is a lysine residue, the synthesis must
generate a fully protected lysine. Using the same method as described in section 2.1,
Fmoc-Lys(Boc)-O-Allyl 41 was obtained in 80% yield using a biphasic solvent system
of DCM and water (1:1 ratio), from commercially available Fmoc-Lys(Boc)-OH 40,
using allyl bromide and Aliquat 336 as a phase transfer catalyst.
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Scheme 13: Synthesis of Fmoc-Lys(Boc)-O-Allyl (41)
Using HRMS analysis the formation of 41 was confirmed (Table 1), while the
formation the O-allyl functional group was seen at 4.64 ppm, typical for an O-allyl
rather than an N-allyl, which would be more upfield. The O-allyl is seen as a multiplate
due to the non-first order coupling within the alkene system.
Observed Adduct
Expected m/z
Observed m/z
+
[M+H]
509.2646
509.2649
[M+Na]+
531.2466
531.2473
+
[M+K]
547.2205
547.2205
Table 1: HRMS analysis of orthogonally protected lysine 41
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Synthesis of the dipeptide Fmoc-Cys(Trt)-Lys(Boc)-O-Allyl
Having successfully obtained the required precursor 41, it was then used to prepare
the dipeptide fragment of the nisin tail. Fmoc-Cys(Trt)-OH was used as the Cys
residue could undergo elimination at a later stage, to generate the required Dha moiety.
NHBoc

NHBoc

1. 20% piperidine, DCM
Fmoc

OAllyl

N
H

O

41

2. Fmoc-Cys(Trt)-OH,
PyBop, HOBt,
Et
3N, ACN

Fmoc

H
N

O

TrtS

N
H

OAllyl
O

42

Scheme 14: Peptide coupling to synthesise Fmoc-Cys(Trt)-Lys(Boc)-O-Allyl 42
Removal of the Fmoc protecting group was performed using 20% piperidine in DCM
for 30 minutes with the resulting mixture being washed with 10% aqueous citric
acid,182 with subsequent coupling of commercially available Fmoc-Cys(Trt)-OH,
using PyBop and HOBt as the coupling reagents, in the presence of Et3N. After two
hours there was no indication of the formation of 42 by either TLC or HRMS analysis,
so a study of the coupling reaction was conducted (Table 2). Fmoc-S-Methyl cysteine
was also used, as oxidation of the thioether function would allow for the selective
generation of the Dha moiety in the target peptides. Examples of peptide coupling
methods which were used in the study are summarised, and were chosen based on
literature methods for peptide synthesis in the solution-phase.164,171,183
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PyBOP/ HOBt
(1 mole eq.)171

DIEA

Not observed

DIC/EDC164

DIPEA

19%

COMU183

Et3N

24%

HOBt171

DIEA

Not observed

43
NHBoc

Fmoc

H
N

MeS

O
N
H

O
O

44
Fmoc

H
N

O
N
H

MeS

O
O

45
Fmoc

H
N

MeS

O
N
H

O
O

45

Table 2: Process optimisation of the dipeptide coupling reaction163
For reactions using HOBt and PyBOP, either alone or in combination, no product was
observed, but the use of di-isopropyl carbodiimide (DIC) or EDC showed a slight
improvement with an isolated yield of 19% being obtained. The best isolated yield
was only 24% using COMU (1-cyano-2-ethoxy-2-oxoethylidene)amino]oxymorpholin-4-ylmethylidene]-dimethylazanium hexafluorophosphate), an uroniumtype coupling reagent. One possible reason for these low yields could be due to
incomplete removal of the piperidine and the piperidine-DBF adduct, leading to the
AAs reacting with by-products due to the large excess of these reagents.
Coupling reactions using HBTU in acetonitrile (ACN), with Et3N as the base, have
previously been shown within our research group to be a promising approach to
solution-phase peptide synthesis.183 The procedure is described in the following
section.
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Fmoc deprotection using tris-(2-aminoethyl)amine (TAEA)
During conventional Fmoc SPPS the deprotection methods use piperidine in DMF,
but the presence of piperidine and DMF proves extremely difficult to remove in
solution-phase syntheses. A report by Carpino, using tris-(2-aminoethyl)amine 46
(TAEA, Figure 34) for the removal of the Fmoc group has been published for use in
solution phase, as it can be removed by washing with phosphate buffer at pH 5.5. The
large excess of TAEA also scavenges the liberated DBF. After washing with the
phosphate buffer the primary amine groups of TAEA and the DBF-TAEA adduct are
protonated and transfer into the aqueous phase for efficient removal.184
H 2N

NH2

N
NH2

46

Figure 34: Structure of tris(2-aminoethyl)amine (TAEA)184

Synthesis of the dipeptide Fmoc-Cys(Me)-Lys(Boc)-O-Allyl
Due to the issues involved with the removal of the large excess of piperidine and DMF
normally used for Fmoc group deprotection, TAEA was used according to the methods
of Carpino and co-workers,184 while using 1.2-1.5 mole equivalents of the Fmocprotected AA (Scheme 15).
NHBoc

NHBoc

Fmoc

OAllyl

N
H

O

41

1. TAEA, DCM
2. Fmoc-Cys(Me)-OH,
HBTU, Et3N, ACN

Fmoc

H
N

O
N
H

MeS

OAllyl
O

74% yield

47

Scheme 15: Synthesis of Fmoc-Cys(Me)-Lys(Boc)-O-Allyl (47)
It was found in the reaction work-up that washing the deprotected product with
phosphate buffer pH 5.5 proved very difficult as each time an intractable emulsion
was formed. Therefore, TAEA was used for the deprotection of the Fmoc group,
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followed by washing with 10% aqueous ammonium chloride solution (pH 4.5, which
did not form an emulsion as was seen with the phosphate buffer). The coupling
reaction was then stirred at 0oC for one hour and at room temperature for a subsequent
two hours, giving compound 47 in a vastly improved isolated yield of 74%. 1H NMR
spectroscopy and MS analysis confirmed the formation of dipeptide 47. Using 1H
NMR, the O-allyl functional group can be seen as a multiplet at 4.61 ppm, while the
S-methyl is seen as a broad singlet at 2.20 ppm.

Synthesis of dipeptides as precursors for nisin29-34 analogues
Having successfully prepared the dipeptide required for the natural nisin tail, attention
was turned to the preparation of the other analogues, in tandem. Starting from
commercially available amino ester hydrochloride salts, dipeptides were prepared and
in each case NMR and MS analysis confirmed their successful preparation (see Table
3). The replacement of the terminal lysine was to study the effect of the basic sidechain on the pH stability of the generated Dha residue.
Synthesised dipeptide

Fmoc

H
N

O
N
H

MeS

Fmoc

H
N

Fmoc

MeS

NMR

HRMS

79%

✓

✓

76%

✓

✓

78%

✓

✓

OtBu
O

48

O
N
H

MeS

H
N

Isolated
Yield

OtBu
O

49

O
N
H

OtBu
O

50

Table 3: Synthesised dipeptide precursors for preparation of nisin tail analogues
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The glycine analogue was chosen to remove the side-chain completely; alanine was
chosen to have a small hydrophobic residue and the phenylalanine was to introduce an
aromatic residue. The aromatic side-chain may be able to interact with the Dha moiety
(e.g. via aryl-vinyl interaction). In each case the t-butyl ester was used as the carboxyl
protecting group, for ease of removal post-synthesis, to obtain the free carboxylic acid.

Synthesis of the tripeptide Fmoc-Val-Cys(Me)-Lys(Boc)-O-Allyl
Having successfully prepared a series of dipeptides incorporating the Dha moiety
precursor S-methyl cysteine, the same method was then used for the preparation of the
tripeptides. In the nisin tail the next AA is valine, so Fmoc-Val-OH (1.2 mole
equivalents) was used for the synthesis of the desired tripeptides (Scheme 16).
NHBoc

Fmoc

H
N

O
N
H

MeS

OAllyl
O

NHBoc

1. TAEA, DCM
2. Fmoc-Val-OH,
HBTU,
Et
3N, ACN
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HN

O

H
N

N
H

Fmoc O

SMe

OAllyl
O

51

Scheme 16: Synthesis of Fmoc-Val-Cys(Me)-Lys(Boc)-O-Allyl (51)
Due to solubility issues not seen during the coupling step of the dipeptide syntheses,
DCM (10%) was added in order to solubilise all of the reactants fully. Although a new
spot was observed by TLC analysis, along with the absence of starting material,
unfortunately attempts to purify 51 were unsuccessful, due to the solubility of the
tripeptide products and their crystallisation on a silica gel column, causing blockage.
Extractions were attempted using both DCM and EtOAc to recover the product from
the silica but were not successful. Therefore, significant further development would
be required for the purification of 51. The crystallisation of the tripeptide products on
the column indicates that solids are formed, suggesting that it may be possible to use
crystallisation as a means of purification. However, many attempts at purification by
crystallisation were also unsuccessful.
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Synthesised Tripeptide

Fmoc

O

H
N

N
H

N
H

O

SMe

OtBu
O

Isolated
Yield

NMR

HRMS

Not
isolated

X

✓

Not
isolated

X

✓

Not
isolated

X

✓
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Fmoc

H
N

N
H

O
N
H

O

SMe

OtBu
O

53

Fmoc

N
H

H
N

O
N
H

O

SMe

OtBu
O
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Table 4: Target tripeptide precursors for preparation of nisin tail analogues
As shown in Table 4, although each of the tripeptides 52-54 were observed by HRMS,
it was not possible to isolate these compounds using column chromatography. In each
case, solubility issues were encountered during purification resulting in blocking of
the silica column.
Due to the issues encountered during column chromatography no tripeptides were
isolated for the full NMR characterisation or stability studies required, so an
alternative approach using SPPS was employed, and is discussed in section 2.4.
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SPPS of nisin tail fragments
As stated in section 1.9, SPPS involves the synthesis of the desired peptides uses a
solid support (resin), to which the peptide is bound covalently for the duration of the
synthesis. SPPS consists of repetitive deprotection and AA coupling cycles to give the
desired peptide sequence. In this study, the nisin tail and analogues were targeted using
SPPS due to the high yields and ease of purification of the desired peptides when
bound to the insoluble matrix (resin). For the SPPS of the cyclopropyl AA-containing
nisin tail, commercially available Fmoc-L-Lys(Boc)-2CTC resin was used, as it is preloaded with lysine, the required C-terminal AA in the peptide sequence of the native
nisin tail. This resin type has been successfully used previously for SPPS within the
Kelleher research group.185 For the synthesis of fragments containing the Dha moiety,
a Wang resin was used due to its increased stability towards undesired hydrolytic
cleavage in acidic solutions.

Loading of Fmoc AAs to pre-loaded resin
The loading during SPPS is a critical step and dictates the quantities of reagents
required during the synthesis and the overall theoretical yield of the final peptide. The
calculation of resin loading is a vital parameter and there have been several methods
described to determine the loading, including gravimetric, elemental analytical and
photometric methods.153 As described in Section 1.9.1, during our SPPS syntheses the
photometric method was employed, and measured at 290 nm, to quantify the amount
of Fmoc-amino acid attached to the resin based on generation of the DBF-piperidine
adduct. The two commercially available pre-loaded Wang resins; i) Fmoc-L-Lys(Boc)
55 loaded, and ii) Fmoc-L-His(Trt) 56 were used (Figure 35).

Figure 35: Pre-loaded Lysine and Histidine resins
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The Fmoc-His(Trt)-Wang 56 resin was used as a precursor, where the C-terminal
lysine residue is replaced with a histidine residue. Changing the lysine may give some
insight into why nisin breaks down at physiological pH. The Dha33 in the nisin tail
region has been reported to degrade first; the replacement of lysine by histidine is to
study the effect of the side-chain pKa on the stability of the nisin tail region.

Loading of Fmoc-Ser(Trt)-OH to Lysine preloaded Wang resin
The resin was swollen using DCM and Fmoc deprotection was attempted using 40%
piperidine in DMF for 30 minutes. The first step in the synthesis (Scheme 17) was
coupling of the commercially available Fmoc-Ser(Trt)-OH AA to the pre-loaded
lysine (side-chain Boc protected) on the solid support. The concentration of piperidine
was increased to 40% in an attempt to increase the yield and coupling of the next AA
in the target sequence.
HN

Fmoc

N
H

O
O

Boc

HN

i
ii

Fmoc

H
N

55

Boc

O
N
H
OTrt

O
O

57

i) 40% piperidine, DMF
ii) Fmoc-Ser(Trt)-OH, COMU, Oxyma Pure, NMM, DMF

Scheme 17: Coupling of Fmoc-Ser(Trt)-OH onto pre-loaded Lysine resin
A coupling solution containing 3 mol. equivalents of Fmoc-Ser(Trt)-OH, COMU,
Oxyma-Pure and 6 mol. equivalents of Et3N in DMF was added to 55 and stirred for
1 h to afford 57.186 This step gave a loading of between 0.42-0.46 mmol/g using
analyses of the piperidine-DBF adduct, compared to the manufacturers capacity of 0.7
mmol/g; the formation of the dipeptide 57 was confirmed by HRMS analysis (Table
5). This dipeptide (57) was a common starting material for several tail fragments and
analogues of the nisin tail; details are presented further on in the chapter.

56

Observed Adduct
Expected m/z
Observed m/z
[M+H] +
456.2129
456.2131
+
[M+Na]
478.1949
478.1944
[M+K] +
494.1688
494.1684
Table 5: HRMS analysis confirming dipeptide (57) formation

Loading of Fmoc-Ser(Trt)-OH to Fmoc-His(Trt)-Wang Resin
Using the same methodology as described for the formation of 57, Fmoc-Ser(Trt)-OH
was coupled onto to a Fmoc-His(Trt)-preloaded Wang resin to afford the resin bound
dipeptide 58 (Scheme 18). The initial step using this particular preloaded resin gave a
loading of 0.508 mmol/g. As with all SPPS strategies conducted within this research,
0.5 g of Fmoc-His(Trt)-Wang resin was used for the assembly of the desired peptide
target, and so based on the determined loading, the theoretical yield of desired peptide
is calculated to be 0.254 mmol.
N
Fmoc

N
H

N Trt
O

O

N
i
ii

Fmoc

O

H
N

56

N Trt

N
H
OTrt

O
O

58

i) 40% piperidine, DMF
ii) Fmoc-Ser(Trt)-OH, COMU, Oxyma Pure, NMM
Scheme 18: Coupling of Fmoc-Ser(Trt)-OH onto pre-loaded histidine resin
As seen in Table 6 the successful overall coupling of the desired resin-bound dipeptide
was shown by HRMS analysis.
Observed Adduct
[M+H] +
[M+Na] +
[M+K] +

Expected m/z
465.1769
487.1588
503.1327

Observed m/z
465.1759
487.1576
503.1232

Table 6: HRMS analysis confirming formation of dipeptide 58
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Synthesis of tripeptide fragments
Following on from the successful formation of dipeptide 57, the next step was the
Fmoc deprotection and subsequent coupling of the next Fmoc protected AA, Fmoc-LVal-OH. Using the same methodology as used to prepare 57, the successful formation
of 59 was confirmed by HRMS analysis. Post coupling of Fmoc-L-Val-OH to the
resin-bound peptide 59, the Fmoc protecting group was removed using piperidine in
DMF, and the resulting free amine was acetylated using acetic anhydride in DMF,
with a catalytic amount of DMAP. The acetylation (capping) of the amine resulted in
formation of the tripeptide 60. The optimisation of the Dha formation on the resin is a
key step in the generation of the peptide targets. However, it is likely to be performed
at a late stage in the tail fragment synthesis, to avoid possible side reactions during the
syntheses.
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i) 40% Piperidine, DMF
ii) Fmoc-Val-OH, COMU, Oxyma Pure, NMM, DMF
iii) Ac2O, DMAP, DMF
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H
N
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N
H

Ser

60

Lys

NHBoc

Scheme 19: Synthesis of Ac-Val-Dha-Lys-OH (60)
Compound
Expected m/z
Observed m/z
59
555.2813
555.2815
60
375.2238
375.2242
Table 7: HRMS analysis of Fmoc-Val-Ser-Lys-OH (59) and Ac-Val-Ser-Lys-OH
(60)
All HRMS analyses were conducted after acidic cleavage of a small sample of the
resin; therefore, all of the observed ions are as their free carboxylic acids. HRMS
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analysis showed the observed [M+H]+ at 375.2242 m/z when compared to the
expected [M+H]+ of 375.2238 m/z, confirming the successful overall coupling and
acetylation reactions to give the desired tripeptide 60. As seen in Scheme 19, peptide
60 contains a serine residue rather than a Dha moiety, which would require
dehydration of the serine to form the desired Dha.

Formation of a Dha residue on a solid support resin
During the synthesis of the tail fragments of nisin, there is a requirement to form a
Dha in a specific position of the AA sequence. The use of Fmoc-Dha-OH is not
possible due to the formation of an imine following Fmoc deprotection. This reactive
imine species is prone to hydrolysis and breakdown, forming ammonia and a pyruvate
structure, as shown in Figure 36.
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H
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Figure 36: Imine formation and hydrolytic cleavage of Dha residue after Fmoc
deprotection
In order to overcome this synthetic barrier, and to facilitate formation of the desired
target peptide products, a masked Dha in the form of a protected serine residue was
used, to incorporate the unusual AA in the desired position. To selectively dehydrate
the serine residue several different methodologies were examined, which involved
conversion of the serine side-chain alcohol (OH) to a better leaving group, for βelimination, and formation of the desired Dha on the solid support resin. These include
acetylation of the free alcohol using acetic anhydride and DMAP in DMF (5 mL), then
formation of a bromoalanine on the resin was attempted using 2 mol. equivalents of
triphenylphosphine (PPh3), carbon tetrabromide (CBr4) in dry DCM (5 mL), but the
presence of Dha was not observed using HRMS analysis.
After the unsuccessful attempt of Dha formation on the resin via a bromoalanine
intermediate, its formation was then attempted with the serine being converted to a
mesylate intermediate, followed by a base-mediated β-elimination to generate the Dha
(Table 8).
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Intermediate for Dha Formation
NHBoc

O
N
H

H
N
O

Base used for
Elimination

Dha present by
HRMS

DBU

X

DBU

X

DBU

✓

O

O

N
H

O
O

O
61
NHBoc

O
N
H

H
N
O

O

Br

N
H

O
O

62

NHBoc

O
N
H

H
N
O

O
N
H

O
O S O

O
O

63

Table 8: Attempted formation of Ac-Val-Dha-Lys-COOH on a solid-support
resin
It was found that both the acetylation of the serine alcohol 61 and bromination to give
the bromoalanine 62 did not produce the desired Dha product, as evidenced by HRMS.
The third method used methanesulfonyl chloride and Et3N to convert the serine -OH
to a mesylate intermediate, which was confirmed by HRMS analysis (Table 9).
Observed Adduct
Expected m/z
Observed m/z
[M+H] +
453.2014
453.2019
+
[M+Na]
475.1833
475.1840
[M+K] +
497.1573
479.1579
Table 9: HRMS analysis confirming the formation of mesylate 63
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As can be seen in Scheme 20, the trityl (Trt) protecting group can be selectively
removed using 2% TFA solution [TFA (2%): TIPS (2%): DCM (96%)]. After the
removal of the O-Trt protecting group, the resulting free alcohol was then converted
to the mesylate intermediate 63. The DBU deprotonates the α-hydrogen of the serine
mesylate causing the β-elimination to afford the desired Dha 64.
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i) Trityl deprotection: TFA:TIPS:DCM (2:2:96)
ii) Methanesulphonyl chloride, Et3N, DCM
iii) DBU, DCM
iv) Global deprotection: TFA:TIPS:DCM (96:2:2)

Scheme 20: Formation of Dha containing tripeptides 64 & 65 via a mesylate
intermediate (63)
The successful formation of tripeptide 65 was confirmed by HRMS analysis which
showed [M+H]+ at 357.2142 m/z when compared to the expected [M+H]+ of 357.2130
m/z. In Figure 37 the observed m/z for peptide 65, as well as its sodium and potassium
adducts, are shown to be present. In addition to the Dha-containing peptide 65, there
was also a significant amount of serine-containing peptide 60 observed by LC/MS
analysis. It is not clear whether the observed serine is i) unreacted starting material; ii)
the hydrolysis product of the mesylate intermediate; or iii) hydration of the Dha under
the basic reaction conditions. With both the serine- and Dha-containing peptides being
present in significant amounts, as shown by LC/MS analysis, their isolation was
attempted using semi-preparative HPLC.
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Figure 37: Extracted Mass Spectrum of Ac-Val-Dha-Lys-OH (65)
Although the preparation of 65 was confirmed, the purification of this tripeptide
fragment proved problematic by semi-preparative chromatography. The tripeptide 65
is more hydrophobic when compared to the longer peptide fragments, which are
discussed later. For this reason, precipitation of the compound from cold diethyl ether,
a widely used peptide purification method, was unsuccessful and an intractable
mixture was formed. This mixture proved extremely difficult to separate using semipreparative HPLC due to co-elution of the tripeptide 65 with DBU. However, due to
the successful conversion of the serine to the mesylate intermediate and subsequent βelimination, this method was used throughout the remainder of the project for the
incorporation of the Dha moiety into the target tail fragments.

62

Synthesis of Ac-Val-Ser-His-OH on a Wang resin
Using the same method previously described for AA coupling, Fmoc-L-Val-OH was
coupled to the resin bound dipeptide 58 to generate tripeptide 66 (Scheme 21). The
replacement of the terminal Lys residue with a His residue was to study the effect of
the lower side-chain pKa of the imidazole ring, in comparison to the lysine amine. It
is at physiological pH that the nisin tail is reported to breakdown, which is in the region
in which the histidine side-chain pKa lies.187 Thus, replacement of the lysine allowed
for investigation of the impact protonated AA side-chains might have on the stability
of the nisin tail.
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Scheme 21: Coupling of Fmoc-L-Val-OH to resin-bound dipeptide 58
By HRMS analysis peptide 66 was observed with a [M+H]+ of 564.2445 m/z, as well
as its sodium and potassium adducts (Table 10). As was the case with peptide 65 the
precipitation from cold diethyl ether was not possible, as the peptide is more
hydrophobic than its tetra-, penta- and hexa-peptide counterparts.
Observed Adduct
Expected m/z
[M+H] +
564.2453
+
[M+Na]
586.2280
[M+K] +
602.2012
Table 10: HRMS analysis of Fmoc-Val-Ser-His-OH (66)

Observed m/z
564.2445
586.2284
602.1944

This peptide fragment was not isolated, as it is the precursor to the longer peptide tail
fragments, so no NMR data for peptide 66 was obtained.
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Synthesis of tetrapeptide tail fragments
Following on from the successful synthesis of the tripeptide fragments, using the same
procedure the tetrapeptide fragment of the nisin tail was prepared. The coupling of
Fmoc-L-His(Trt)-OH to tripeptide 59 was conducted followed by capping, resulting in
the formation of tetrapeptides 67 and 68 (Table 11).
Tetrapeptide Fragment
NH2

H
N

O

H
N

N
H

O

N

HN

O

HRMS

HPLC

NMR

✓

✓

✓

✓

✓

✓

O
N
H
OH

OH
O

67

Ac-His-Val-Ser-Lys-COOH
NH2

H
N

O

H
N

N
H

O
HN

N

O

O
N
H

OH
O

68

Ac-His-Val-Dha-Lys-COOH
Table 11: Synthesis of tetrapeptide fragment of the nisin tail, 68, and its
precursor, 67
A small portion of resin was taken for analysis, confirming the formation of both the
Ser (67) and Dha (68) tetrapeptides which are shown in Table 11. After confirmation
using HRMS analysis (Table 12), the tetrapeptide fragments were purified using semipreparative HPLC.
Compound
Expected m/z
67
512.2840
68
494.2722
Table 12: HRMS analysis of tetrapeptides 67 and 68

Observed m/z
512.2844
494.2741
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Following on from purification of both tetrapeptides 67 and 68, their characterisation
was carried out using both LC-MS/MS and 1H NMR spectroscopy, which was aided
by Total Correlation Spectroscopy (TOCSY) NMR. The 1H NMR assignment of
tetrapeptide 68 is presented in Table 13.
1

H

Residue

N-H

α

β

His

8.63

4.45

2.99

Val

8.06

4.19

1.79

Dha

9.68

Lys

7.93

γ
C2
8.57

δ
C4
7.21

ε

Exchangeable

1.39

3.02

7.54 (NH3+)

1.37

5.66
4.01

2.86

1.70

Table 13: 1H NMR characterisation of Dha-containing tetrapeptide 68
The mass spectrum of the cleaved peptide 68 shows the m/z of 494.2741 for [M+H]+,
but also a di-charged ion species [M+H]2+, present in greater abundance (Figure 38).
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Figure 38: Mass spectrum of Ac-His-Val-Dha-Lys-OH (68)
Interestingly, the presence of a second charged AA species dramatically changed the
overall polarity of the molecule and so helped facilitate the precipitation of the peptide
from cold diethyl ether post acidic cleavage. There was also a significant amount of
the serine precursor 67 present in the crude precipitate and so, during the purification
by semi-preparative HPLC both peptides 67 and 68 were isolated in yields of 17.9 mg
(16.9 %) and 30.8 mg (28.9 %), respectively. The pH stability of these peptides will
be examined and discussed in Chapter III.
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In order to investigate the effects of the charged AA side-chains on the stability of the
tail region of nisin, two tetrapeptides were prepared in which the charged side-chains
were changed. The tetrapeptide 69 was synthesised by removal of the Fmoc protecting
group and subsequent coupling of Fmoc-L-His(Trt)-OH to resin-bound tripeptide 66.
This deprotection and coupling cycle afforded tetrapeptide 69, in which the terminal
Lys residue was replaced by a His residue. Tetrapeptide 70 containing two Lys
residues (Table 14), prepared by deprotection and coupling of Fmoc-L-Lys(Boc)-OH
to resin-bound tripeptide 59, gave a Lys residue in place of His.
Tetrapeptide Fragment

Fmoc

H
N

O

H
N

N
H
HN

N

O

HN

O
N
H
OH

HRMS

HPLC
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✓

X

X

✓

X

X

N
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NH2
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H
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H
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O
N
H
OH

OH
O

70

Fmoc-Lys-Val-Ser-Lys-COOH
Table 14: Synthesis of Lys-for-His tetrapeptide fragments of the nisin tail, 70,
and its precursor 69
The formation of both peptide precursors 69 and 70 were confirmed using HRMS
analysis as shown in Table 15. These peptides were not isolated but were used in the
generation of the subsequent pentapeptide fragments.
Compound
Expected m/z
Observed m/z
69
701.3042
701.3055
70
683.3763
683.3760
Table 15: HRMS analysis of Fmoc-protected tetrapeptides 69 and 70
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Synthesis of pentapeptide tail fragments
Using the same method for SPPS as previously discussed, a series of pentapeptide
fragments and analogues of the nisin tail were prepared. As can be seen in Table 16,
both the Ser (71) and Dha (72) pentapeptides were successfully isolated.
Pentapeptide Fragment

HRMS

Expected
m/z

Observed
m/z

✓

625.3668

625.3689

✓

607.3562

607.3428

NH2

O
N
H

H
N

O

H
N

N
H

O

N

HN

O

O
N
H
OH

OH
O

71

Ac-Ile-His-Val-Ser-Lys-COOH
NH2

O
N
H

H
N

O

H
N

N
H

O
HN

N

O

O
N
H

OH
O

72
Ac-Ile-His-Val-Dha-Lys-COOH
Table 16: Synthesis of pentapeptide fragment of the nisin tail, 72, and its
precursor 71
During the purification by semi-preparative HPLC, the peptides 71 and 72 were
isolated in yields of 20.5 mg (14.8%) and 11.6 mg (8.65%), respectively.
The formation of 71 and 72 was confirmed using HRMS, shown in Table 16,
observing the molecular ions for both peptide derivatives and their adducts. As well
as the HRMS analyses, MS/MS fragmentation of the molecular ion was also carried
out for further confirmation of successful preparation of the pentapeptides 71 and 72.
By way of example the MS/MS spectrum of the Dha-containing pentapeptide 72 is
shown in Figure 39.
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To aid in the characterisation of isolated peptide fragments, the observed [M+H]+ at
607.3428 was targeted during the MS/MS analysis and provided with a collision cell
energy of 40 V, causing fragmentation of the peptide sequence between the amide
bonds. This generated b and y ions to aid in the identification of the target peptide.188
b ions

Residue

y ions

156.1058

I

Not Observed

293.1650

H

452.2637

392.2322

V

315.2060

461.2522

Dha

216.1381

Not Observed

K

147.1165

Table 17: MS/MS analysis of Ac-Ile-His-Val-Dha-Lys-OH (72)
Table 17 shows b ions (cleavage from the N-terminus) which can be prominently seen
in Figure 39, and y ions (cleavage from the C-terminus) which are present but not in
great abundance which corresponds to the predicted fragmentation pattern for peptide
72.
x10

6

+ESI Product Ion (1.665 min) Frag=175.0V CID@40.0 (607.3635[z=1] -> **) Ac--IleHis-Val-Dha-Lys-OH (MSMS).d
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Figure 39: MS/MS fragmentation of [M+H]+ ion of peptide 72
MS/MS analysis was carried out on all isolated peptide fragments, with the MS/MS
fragmentation of the serine analogue, Ac-Ile-His-Val-Ser-Lys-OH, pentapeptide 71
described in Chapter VII-Experimental Procedures.
Other pentapeptide fragments prepared include the fragment with replacement of the
Lys34 residue with a His residue. Using the resin-bound His-containing tetrapeptide
69, the fragment was elongated to prepare Ser 73 and Dha 74 pentapeptide derivatives
(Table 18).
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Pentapeptide Fragment
HN
O
N
H

H
N

O

H
N

N
H

O

O

N

HN

N
H

H
N

H
N

N
H
HN

Observed
m/z

✓

634.3307

634.3305

✓

616.3202

616.3203

OH

N
H
OH

O

73

O

O

Expected
m/z

N

O

Ac-Ile-His-Val-Ser-His-COOH
O

HRMS

N

O

OH

N
H

O

N

HN

O

74

Ac-Ile-His-Val-Dha-His-COOH
Table 18: Synthesis of di-His-containing pentapeptide tail fragments, 74, and its
precursor 73
The formation of the di-histidine containing pentapeptides 73 and 74 were confirmed
by HRMS, LC-MS/MS and also using 1H NMR spectroscopy. The 1H NMR
assignment of pentapeptide 74, aided by TOSCY NMR, is shown in Table 19, with
pentapeptide 73 described in Chapter VII-Experimental Procedures.
1

Residue

N-H

α

β

γ

δ

Exchangeable

Ile

8.07

4.42

3.07

His

8.51

4.69

3.10

1.98
C2
8.46

0.76
C4
7.18

Val

7.88

3.97

1.59

0.65

Dha

9.53

-COOH not observed

H

5.55

C2
C4
His
8.53
4.72
3.15 8.42 7.14
Table 19: 1H NMR assignment of Dha-containing pentapeptide 74

During the purification via preparative HPLC both peptide 73 and 74 were isolated in
a yield of 8.7 mg (5.40%) and 8.5 mg (5.43%), respectively.
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There are notable chemical shift changes observed between the Dha-containing
tetrapeptide 68 and pentapeptide 72 after the addition of the Ile AA residue, and after
the incorporation of a second His residue (74). Table 20 shows the observed chemical
shifts after the addition of the Ile residue to prepare 72, where there are downfield
shifts of 0.07 ppm and 0.05 ppm for the Dha amide N-H and C-H vinyl protons,
respectively, in comparison to tetrapeptide 68. The valine amide N-H was more
deshielded, moving downfield by 0.23 ppm.
AA Residue
N-H
α
β
C2
C4
β
N-H
α
β
N-H
C-H (vinyl)

Ile
His
Val
Dha
Table 20:

68
(ppm)
N/A
8.57
7.21
2.99
8.06
4.19
1.79
9.68
5.66

72
(ppm)
8.35
4.37
1.96
8.60
7.33
3.25
8.29
4.16
2.16
9.75
5.71

74
(ppm)
8.07
4.42
3.07
8.46
7.18
3.10
7.88
3.97
1.59
9.53
5.55

H NMR chemical shift comparison of tetrapeptide 68 and
pentapeptides 72 and 74

1

There are also notable changes observed after replacement of the Lys residue of 72
with the His residue, seen in pentapeptide 74. These changes can be seen in Figure 40,
with the changes in the chemical shifts of Dha and His residues being highlighted.
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Figure 40: 2D-TOCSY NMR spectral stack of pentapeptide 72 (blue) and 74 (red)
Shown in Figure 40, is the TOCSY 2D-spectral stack of pentapeptide 72 and 74, with
the top and side spectra shown corresponding to pentapeptide 72. Interestingly, the
chemical shifts of AAs in the di-histidine-containing pentapeptide 74 show upfield
movements, with the amide N-H of Val moving upfield by 0.41 ppm, while the Dha
amide N-H moved upfield by 0.22 ppm. These changes in the observed chemical shifts
could indicate that there may be changes in the local environment. The effect of these
AA changes on the pH stability of each peptide fragment will be studied in Chapter
III.
In parallel, pentapeptide fragments with the replacement of the His residue with a Lys
residue were also prepared. Both the Ser (75) and the Dha (76) derivatives of the dilysine containing fragments were prepared by elongation of the resin-bound tripeptide
59.
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Pentapeptide Fragment

HRMS

Expected
m/z

Observed
m/z

✓

616.4009

616.4011

✓

598.3910

598.3904

NH2

O
N
H

H
N

O
N
H

O

H
N
O

O
N
H
OH

OH
O

NH2

75

Ac-Ile-Lys-Val-Ser-Lys-COOH
NH2

O
N
H

H
N
O

O
N
H

H
N
O

O
N
H

OH
O

NH2

76

Ac-Ile-Lys-Val-Dha-Lys-COOH
Table 21: Synthesis of di-Lys-containing pentapeptide tail fragment, 76, and its
precursor
Both peptides 75 and 76 were precipitated using cold diethyl ether and their formation
was confirmed using HRMS, as shown in Table 21, as well as using LC-MS/MS
analysis. The NMR spectra and MS/MS fragmentation pattern (b and y ions observed)
confirmed the successful formation of 75 and 76, details of which are presented in
Chapter VII.
After confirming the successful formation of both 75 and 76, purification was carried
out using semi-preparative HPLC, with peptides 75 and 76 isolated in yields of 26.6
mg (16.3%) and 24.5 mg (15.5%), respectively.
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Figure 41: HPLC chromatogram of 76 using a DAD detector at 214 nm
After purification of pentapeptide 76 by semi-preparative HPLC using a reverse phase
C18 column, each purified peptide fragment was analysed by analytical HPLC using a
diode array detector (DAD) at 214 nm. The HPLC trace of pentapeptide 76 is shown
in Figure 41, with the peptide eluting from the column at 7.84 minutes, while the Sercontaining pentapeptide 75 eluted from the column at 5.57 minutes.

Synthesis of hexapeptide tail fragments
The native nisin tail next contains a serine residue at position 29 (see Figure 12), so
requires a slightly different approach, as addition of the second serine, prior to the
formation of the mesylate intermediate would result in the β-elimination of both serine
residues, affording two Dha residues within the peptide structure, when only one (at
position 33) is required.
In order to overcome this issue, Dha formation was carried out prior to coupling of the
final OTrt-protected Ser residue (Ser). After β-elimination of the mesylate leading to
Dha formation, the resin-bound peptide was then Fmoc deprotected and the final serine
residue was coupled to the resulting free amine. The synthesised hexapeptides 76 (Ser)
and 77 (Dha) are shown in Table 22.
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Hexapeptide Fragment

HRMS

Expected
m/z

Observed
m/z

✓

712.3945

712.3937

✓

694.3883

694.3868

NH2

H
N
O

O
N
H
OH

H
N

O
N
H
N

O

H
N
O

HN

O
N
H
OH

OH
O

77

Ac-Ser-Ile-His-Val-Ser-Lys-COOH

NH2

H
N
O

O
N
H
OH

H
N

O
N
H
N

O

H
N
O

O
N
H

OH
O

HN

78

Ac-Ser-Ile-His-Val-Dha-Lys-COOH
Table 22: Hexapeptide fragment of the nisin tail, 78, and its precursor 77
The successful formation of the hexapeptide fragments 77 and 78 were confirmed by
HRMS and LC-MS/MS. Following precipitation of the hexapeptide from the TFA
solution, using cold diethyl ether, the crude peptide mixture was purified by semipreparative HPLC. The hexapeptide 77 was isolated in a yield of 33.1 mg (20.7%),
while hexapeptide 78 was isolated in a crude yield of 4.0 mg (2.6%), which is
extremely low in comparison to other peptide fragments discussed previously.
Although HRMS confirmed the formation of hexapeptide 78, the material isolated
unfortunately was not pure by analytical HPLC, displaying a purity of 32% after
purification by semi-preparative HPLC. It appears that the presence of the second
serine residue decreases the stability of the native tail fragment, so the compound may
have decomposed prior to analysis by analytical HPLC.
The LC/MS trace of the di-serine hexapeptide 77 is shown in Figure 42, and it eluted
from the C18 column at 4.54 minutes. Although hexapeptide 77 was not fully purified
by semi-preparative HPLC, it was shown to be present in 86% purity.
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Figure 42: LC/MS chromatogram of hexapeptide 77
The peak present at 3.912 minutes is interesting, as the ions observed are similar to
the observed ions seen during the MS/MS fragmentation of hexapeptide 77, with the
ion in highest abundance being 470.2740 m/z. This ion corresponds to the y ion after
cleavage at the amide bond between the His and Ile residues, which is possibly another
indication that the incorporation of an additional Ser residue may impact or diminish
the stability of the tail fragment.

Synthesis of an AC3C-containing analogue of the nisin tail fragment
So far, the SPPS synthesis has focussed on the effect of the flanking AAs on the Dha
moiety and the possible stability of the tail region. Therefore, replacement of the Dha
moiety was investigated by incorporation of a 1-aminocyclopropane-1-carboxylic acid
(AC3C) residue, which contains a cyclopropyl group as its side-chain (as stated in
Section 1.11 in Chapter I).
Using similar methodology to that previously described, commercially available
Fmoc-AC3C-OH was coupled onto the preloaded H-Lys(Boc)-chlorotrityl resin; no
deprotection step is required as this resin contains a free amine. The synthesis of the
AC3C-containing fragment was conducted using 0.501 g of resin, with the loading of
Fmoc-AC3C-OH being determined to be 0.397 mmol/g. The synthesis of the full
AC3C-containing hexapeptide fragment is shown in Scheme 22.
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i) Deprotection - 40% piperidine/ DMF
ii) Coupling - Fmoc-AA-COOH, PyBOP, HOBt, NMM, DMF, 2 h
iii) Ac2O, DMAP, DMF
iv) TFA:TIPS:DCM (96:2:2)

Scheme 22: SPPS synthesis of nisin29-34 with replacement of Dha 33 with an AC3C
residue
After each coupling cycle a small amount of the resin was treated with the cleavage
cocktail and analysed by HRMS, confirming the formation of each peptide fragment
81-85, as shown in Scheme 22 and Table 23.
Peptide Intermediate
Expected m/z
Observed m/z
81
452.2184
452.2167
82
551.2869
551.2853
83
688.3458
688.3456
84
801.4299
801.4278
85
708.4045
708.4054
Table 23: HRMS analysis of AC3C-containing peptide fragments 81-85
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COOH

Following precipitation from TFA, using cold diethyl ether, the peptide mixture was
purified by semi-preparative HPLC, with the hexapeptide 85 being isolated in a yield
of 70.2 mg (50%). This significantly higher yield than the Ser- or Dha-containing
analogues was possibly due to the overall increase in the stability of the AC3Ccontaining peptide fragments.
In addition to LC-MS/MS, the characterisation of each peptide fragment was aided by
TOCSY NMR spectroscopy. The use of TOCSY NMR allows for the assignment of
protons located in crowded regions of the NMR spectrum. The 2D TOCSY spectrum
of hexapeptide 85 is shown in Figure 43. The NMR spectra were collected in 10%
D2O: 90% H2O, at 25oC with the solution pH measured as 3.0.

Figure 43: The downfield region (N-Hs) of the TOCSY NMR spectrum of
Ac-Ser-Ile-His-Val-AC3C-Lys-OH (85)
Each AA in the peptide sequence behaves as an isolated spin system, and so there is
no coupling between neighbouring residues. As can be seen in Figure 43, each vertical
grouping of signals corresponds to a separate AA residue. The TOCSY coupling can
be from the N-H proton all the way along the side-chain protons. This allows for the
characterisation of all the proton resonances associated with a particular AA residue.
77

1

H

Residue

N-H

α

β

γ

δ

ε

Exchangeable
8.85 (COOH)

C-terminus
Ser

8.15

4.29

3.68

Not Observed

Ile

7.94

4.04

1.65

1.17

0.69

His

8.49

4.60

3.00

C2
8.47

C4
7.16

Val

8.03

3.81

1.91

0.74

AC3C

7.78

Lys

7.53

2.85 +
2.70
4.20

2.83

1.74

1.54

1.22

7.353 (NH3+)

Table 24: 1H NMR characterisation of AC3C-containing hexapeptide fragment
85
The 1H NMR assignment of hexapeptide 85 is presented in Table 24, with all the
resonance signals assigned with the exception of the serine O-H.
The AC3C N-H signal is a singlet (at 7.78 ppm), because of the absence of an α-proton,
while the β-protons of the cyclopropyl side-chain of AC3C can be seen as two peaks
at 2.85 and 2.70 ppm. The N-H of the His residue is seen overlapping with the His C2
proton; using the C2 proton signal at 8.47 ppm, the α (4.60 ppm), β (3.00 ppm) and C4
protons (7.16 ppm) of the His residue were determined.
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For comparison, and in the absence of the native nisin tail fragment, the 1H NMR
spectral stack of the Ser33-(77) and AC3C33-containing (85) hexapeptide fragments
are shown in Figure 44, conducted in 10% D2O: 90% H2O, pH 3.0 at 25oC.

Figure 44: 1H NMR spectral stack of the N-H region of the Ser (77, top) and AC3C
(85, bottom) hexapeptide fragments
It can be seen clearly that there are noticeable differences in both appearance and
chemical shift of the AA residues, showing that the replacement of only one AA
residue has a dramatic affect on the observed 1H NMR chemical shifts.
For 85 the resonance signals of the N-Hs are resolved from one another completely,
while for 77 the N-H region is crowded, with some of the amide N-Hs overlapping.
This indicates that the overall solution conformation of the hexapeptides changes
significantly due to the replacement of only one AA residue.
This might have significant implications for the conformation of the full nisin
molecule and any possible AA residue changes in the tail region, with a knock-on
effect on its biological activity.
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Chapter Conclusions
In Chapter II the synthetic strategies for the synthesis of the native nisin tail and
analogues are detailed. During the optimisation studies of the solution phase synthesis
it was found that the removal of piperidine, used in the Fmoc deprotection step, proved
difficult and so a change in the base was undertaken, using a water-soluble amine base
(TAEA). This allowed for not only the removal of the Fmoc protecting group, but this
base could also be easily removed using an aqueous ammonium chloride (page 52)
washing step prior to the coupling of the next AA residue. The optimisation of the
deprotection and coupling reactions for the dipeptides in the solution-phase proved
successful, as yields of these reactions were increased from 24% up to 79%. Although
the synthesis of dipeptides 47-50 was successful and they were isolated in good yields,
unfortunately no tripeptides have been isolated, due to the issues encountered during
their purification by column chromatography. Alternative solvent systems, as well as
purification by crystallisation, were used in many attempts to purify the tripeptide
compounds. Although this presented a major draw-back, each tripeptide was present
(as indicated by HRMS), showing the formation of the desired target after synthesis.
Solution phase peptide synthesis proved not to be the appropriate approach for the
synthesis of the nisin peptide tail fragments.
Following on from this SPPS was employed as an alternative approach which proved
to be very successful for the generation of a number of nisin tail fragments and
derivatives in varying isolated yields. The SPPS method also eliminated the need for
purification after each intermediate coupling step, as the compound is bound to a resin.
Using a double deprotection and coupling strategy, each of the desired peptide targets
were successfully prepared and their formation confirmed using HRMS.
The formation of the Dha residue, as discussed in Section 2.4.2.1, proved to be
challenging on the Wang solid support resin. Its formation from a serine AA was
optimised using three different methods: i) acetylation of the Ser -OH; ii) formation
of a bromoalanine and iii) mesylate formation. This optimisation study showed the use
of a mesylate intermediate facilitated the successful conversion of the serine to the
desired Dha residue, by β-elimination of the mesylate. Even though the Dha moiety
was formed while on the solid support resin, a significant amount of the serinecontaining peptide analogue was isolated in all cases.
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Following on from the successful purification of tail fragments by semi-preparative
HPLC, all of these peptides were used for the stability studies which are described in
Chapter III.

Possible future synthetic work
The coupling procedure used for solution-phase synthesis was adequate for generating
peptide targets but generated a limited amount of material in some cases. So,
optimisation and scale-up of the described methodologies is desirable to assess these
compounds using a wider variety of analytical techniques including circular dichrosim
(CD) and more in-depth NMR analysis. This would help to fully elucidate the
structural changes, if any, based on altering one AA within the sequence. The use of
preparative LC could be an option to overcome the issues associated with silica
purification but would involve PLC purification after each coupling step.
There has been success in the SPPS of a variety of peptide fragments of the nisin tail,
but optimisation is still required for the formation of the Dha moiety on the resin. The
formation and β-elimination of a mesylate derivative to form a Dha has been found
not to fully convert the serine to the desired Dha residue (Figure 45). This could be
due to restricted access to the serine β-hydroxyl group by methanesulfonyl chloride,
due to the incomplete swelling of the solid support resin and an alternative solvent
may increase conversion due to a better swelling profile of the SPPS resin. Further
studies of the mesylate formation is also required, to ascertain whether the serine
observed post Dha formation is a result of hydrolysis of the mesylate or by basecatalysed hydration of the Dha residue (Figure 45).

N
H

H
N

HO
H2O (Base)

O

N
H

H
N
O

Figure 45: Hydration of the Dha moiety to a serine residue under basic conditions
Another possible reason for the incomplete formation of the Dha could be the
inefficient removal of the trityl protecting group from the serine, so this step may
require a slightly higher TFA concentration, to ensure complete side-chain
deprotection. However, removal of the other acid-labile protecting groups and
cleavage from the resin must be avoided.
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In addition to the tail fragments shown in Chapter II, an examination of the length of
the lysine side-chain could be undertaken by preparing the shorter Dap, Dab and
ornithine analogues. This could help the study of the importance of this chain length
on Dha stability in aqueous solution, as the side-chains would still be protonated at
physiological pH.
In order to fully examine the stability of the Dha residue, other similar lantibiotic tails
should be targeted. For example, the tail region of subtilin and nisin F both contain a
Dha moiety, with subtilin displaying higher stability than nisin at physiological pH.189
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32
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34
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Figure 46: Tail fragments of Subtilin and Nisin F190
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Chapter III
Stability Studies of Synthesised Peptide
Fragments using LC/MS

83

3.0 Introduction
The synthesised peptide fragments of the nisin tail which are described in Chapter II,
were used to examine the effect of changing the flanking AAs on the stability of the
Dha residue, following their purification by preparative HPLC. As previously
outlined, Dha33 in the tail region of both nisin A and Z is not stable at physiological
pH, so establishing the relative stability of the nisin tail region at different pH values
is required in understanding its breakdown. This region of the nisin tail is involved in
the formation of pores and so is critical in its mechanism of action.191
The pH stability studies of the various nisin tail derivatives and analogues were
conducted using an Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS
equipped with an electrospray ionisation source. The use of LC/MS in the study of
peptide stability is common, especially for nisin due to the lack of a chromophore.192
The use of a mass spectrometry detector is extremely useful as it allows not only for
observation of the molecular ion of the target peptide, but also further characterisation
using MS/MS fragmentation.193 The analysis can also be quantitative, which allows
for its utilisation in the stability studies of synthesised peptide fragments and has
become an established platform for protein quantification.194
For the stability studies, in all cases the samples were prepared in deionised water with
a peptide concentration of 0.5 mg/mL. Each peptide was studied in three different pH
environments (pH 3, 5 and 7), in the absence of any buffers with pH adjustment carried
out using HCl and NaOH (0.1 M) prior to injection. For the duration of the stability
trials all samples were stored away from light at 25oC, to avoid any photolytic
degradation. The pH of each solution was checked on a weekly basis with very little
pH changes observed throughout the duration of the stability experiments, this could
be due to self-buffering on the solutions by the protonated side-chains contained
within the peptide fragments.
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Stability of tetrapeptide fragments of the nisin tail
For the Ac-His-Val-Dha-Lys-OH (68) tetrapeptide fragment of the nisin tail, the
stability profile data is plotted, tracking the percentage of tetrapeptide 68 remaining,
based on the relative % peak area using LC/MS due to the lack of a chromophore in
the synthesised peptide fragments. The Dha-containing tetrapeptide is shown in Figure
47, examining and tracking the parent peak at 4.07 minutes.

Ac-His-Val-Dha-Lys-OH (68)
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Figure 47: Stability Profile of Ac-His-Val-Dha-Lys-OH (68) at pH 5 and 7
Interestingly, the peptide sample prepared at pH 3 appeared to break down instantly,
as the peak at 4.07 minutes was absent. The breakdown of the peptide resulted in a
molecular ion which corresponds to the m/z of the serine derivative, with a retention
time of 3.77 minutes, very similar to the serine-containing tetrapeptide 67. It cannot
be determined from the stability experiments what the exact position of substitution
of the alcohol (O-H’s), i.e. be it an α-hydroxy-alanine (α-OH-Ala) or a β-hydroxyserine (Figure 48).
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α
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Figure 48: Possible hydration products of the Dha moiety, β-hydroxy-serine and
α-hydroxy-alanine
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From studies of nisin degradation products, it is known that Dha residues can undergo
an acid-catalysed Markovnikov addition of a water molecule to the double bond,
resulting in the formation of an α-OH-Ala residue.195 However, this compound was
only formed at neutral pH and cleaved to give two fragments.
As displayed in Figure 47, the stability data is plotted for both the pH 5 and 7 sample
for the tetrapeptide (68). The trend in the plotted data indicates that there is a decline
in the tetrapeptide peak at 4.07 minutes (retention time), with the pH 7 sample
decreasing after 8 days while the pH 5 is slightly more stable until day 15. Overall,
both peaks decreased significantly. The pH 5 and 7 samples seem to behave in a very
similar fashion and based on our observations, comparing the breakdown ions
observed for the pH 5 and pH 7 samples shows they are very similar with 446.1815,
384.1648 and 297.1571 m/z present in both samples. The largest breakdown product
observed again has the ion at 512 m/z, at 3.77 minutes which may correspond to the
“serine” derivative, 67 due to the similar observed retention time. With only slight
differences observed in the stability of the peptide in changing the pH of the aqueous
solution from pH 5 to 7, further study is required using NMR spectroscopy to identify
the resulting peptide species observed for all pH solutions and isolate the breakdown
products for characterisation.

86

In a similar fashion to the stability study carried out for tetrapeptide 68, its Sercontaining AA analogue 67 was also purified and studied in the pH 3, 5 and 7
environments. The stability profile date for the Ac-His-Val-Ser-Lys-OH 67
tetrapeptide is presented in Figure 49, tracking the parent peak at 3.72 minutes.
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Figure 49: Stability Profile of Ac-His-Val-Ser-Lys-OH (67) at pH 3, 5 and 7
Interestingly, tetrapeptide 67 displays a higher stability than 68 across the pH range of
the study. It is not until day 25 that there is a significant decline in the % of peptide
remaining, with the fastest decline seen at pH 3, in comparison to 68 which was not
observed at pH 3. Again, the breakdown ions are very similar in each pH sample with
the most abundant ions being 406.1963, 354.7050, 296.1716, 217.1178 and 145.1351
m/z. The similar breakdown ions could be due to the same mechanism of degradation,
while the change in the solution pH may affect the rate of degradation in solution.

Stability Study of pentapeptide fragments of the nisin tail
Following the study of the tetrapeptide fragments of the nisin tail, several synthesised
pentapeptide fragments were also included. The study of these peptides would not only
investigate the stability of the peptide itself, but also allow for an examination of the
effect of adding a hydrophobic AA (Ile) on the overall stability of the peptide
sequence, by comparison with the tetrapeptide precursors.
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Stability Study of Ac-Ile-His-Val-Dha-Lys-OH (72)
The first pentapeptide sequence studied was the Ac-Ile-His-Val-Dha-Lys-OH
pentapeptide (72), which included an N-terminal isoleucine residue. The stability
profile at pH 3, 5 and 7 is shown in Figure 50.
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Figure 50: Stability Profile of Ac-Ile-His-Val-Dha-Lys-OH (72) at pH 3, 5 and 7
As the stability trial progresses, in each pH system the peptide behaves in a similar
fashion, with the pH 3 sample displaying slightly lower stability than the samples at
pH 5 and pH 7, but it is not significantly different. Interestingly the presence of the
isoleucine residue almost completely protects the Dha-containing pentapeptide from
breaking down in the studied pH range. In contrast to the Ac-His-Val-Dha-Lys-OH
tetrapeptide 68 presented earlier, the pH 3 sample of the pentapeptide (72) is present
at T∅, and at each timepoint of the prolonged stability examination, with 72 also more

stable at pH 5 and 7, when compared to tetrapeptide 68. While it is expected there
would be some noise observed in the stability data, is not inherently clear for the
increase observed at 10 days which may be due to the peptide solubility. Although the
overall trend shows there is very little degradation seen at any of the studied pH’s.
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Stability Study of Ac-Ile-His-Val-Ser-Lys-OH (71)
The stability study was also carried out for the Ser-containing pentapeptide analogue
71. The stability profile data for the Ac-Ile-His-Val-Ser-Lys-OH 71 pentapeptide is
presented in Figure 51, tracking the parent peak at 4.22 minutes.
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Figure 51: Stability Profile of Ac-Ile-His-Val-Ser-Lys-OH (71) at pH 3, 5 and 7
There are significant differences observed in the stability of 71 in all the studied pH
values, with the serine-containing pentapeptide degrading rapidly in comparison to
Dha-containing analogue 72, which was stable throughout the duration of the study.
There is no notable difference observed between the pH 5 and 7 samples, both of
which decline rapidly between days 1-10. The pH 3 sample also behaved in a similar
fashion until day 32, by which point the peak at 4.22 minutes was absent.
There were no significant changes in the stability of pentapeptide 71 as a function of
the changing solution pH, with the most abundant breakdown ions being 455.1983 and
228.1532 m/z in all cases, with a number of smaller ions also observed. So, the
replacement of the Dha moiety with a Ser AA may not be preferred due to the lower
stability in aqueous solution. There is a significant contrast between the stability of 67
and 68, where 68 (Dha-containing) was much less stable than 67 (Ser-containing),
with 68 seemingly decomposition mainly to 67.
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Stability Study of Ac-Ile-His-Val-Dha-His-OH pentapeptide (74)
In a similar fashion the pentapeptide Ac-Ile-His-Val-Dha-His-OH (74) was also
studied. This pentapeptide was synthesised with the C-terminal lysine replaced by a
histidine residue, which has a lower side-chain pKa. The stability profile data are
presented in Figure 52 for the peak eluting at 5.20 minutes.
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Figure 52: Stability profile of Ac-Ile-His-Val-Dha-His-OH (74) at pH 3, 5 and 7
There are two different trends emerging within Figure 52, for both the pH 3 and pH 5
samples the stability profiles are almost identical to one another, whereas the pH 7
sample shows a more rapid decline in the peak area. As there is only been one AA
change between 72 and 74, the observed differences are likely due to the presence of
the second histidine residue. The histidine side-chain pKa is significantly lower than
that of lysine ranging between 6-7,196 compared to 9-10 for the Lys side-chain being
described as “perpetually charged”.197 So, both histidine side-chains are likely to be in
their deprotonated neutral forms at pH 7. The decline in the stability may stem from
this change in the charge state of the peptide, probably initiating a conformational
change. However, these interactions and phenomena would require significant further
study using both CD and NMR spectroscopy.
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Stability Study of pentapeptide Ac-Ile-His-Val-Ser-His-OH (73)
Also isolated during the preparative HPLC purification of the di-histidine containing
peptide 74 was the peptide 73, with a serine in the position of the Dha residue. The
stability profile for 73 is shown in Figure 53, tracking the peak at 4.88 minutes.
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Figure 53: Stability profile of Ac-Ile-His-Val-Ser-His-OH (73) at pH 3, 5 and 7
The stability data displayed in Figure 53 shows some distinct differences in
comparison to its Dha analogue. Firstly, the sample prepared at pH 3 seems to start
degrading from 10 days whereas the pH 3 sample of the Dha-containing peptide 74
was very stable throughout the experiment. The second interesting observation is that
when a serine residue is present, as opposed to a Dha residue, the pH 5 and pH 7
sample profiles are now almost identical, with the breakdown ions observed also very
similar. Interestingly, there is some evidence of dehydration of the Ser AA with
formation of a 616.3198 m/z ion after 18 days in the pH 3 sample and 25 days at pH
5 and 7. Also in all samples there are similar ions of 461.2206 and 145.1344 m/z
present. By replacing the supposedly more reactive Dha residue, with a more stable
serine residue there has been a significant change in the stability profile of the peptide,
as it is more susceptible and degrades faster in the acidic pH range. Unfortunately,
there is no indication as to why the serine derivative breaks down faster at pH 3, but it
does highlight that even one amino acid substitution can hugely alter the chemical
properties and stability of peptides.
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Stability Study of pentapeptide Ac-Ile-Lys-Val-Dha-Lys-OH (76)
Following on from the stability trial of the di-histidine Dha-containing pentapeptide
74, which displayed interesting results in terms of its stability at pH 7, the pentapeptide
in which both histidine residues were replaced with lysine residues (76) was studied,
again in order to assess the impact of the side-chain pKa on peptide stability. At
physiological pH the amino group of the lysine side-chain will usually always remain
charged. This begs the question as to whether this retention of a charged species would
increase peptide stability at pH 7.
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Figure 54: Stability Profile of Ac-Ile-Lys-Val-Dha-Lys-OH (76) at pH 3, 5 and 7
The stability profile data for the di-lysine-containing pentapeptide analogue 76 at pH
3, 5 and 7 are shown in Figure 54. Again, the switching of the charged AAs in this
case has a significant effect on the peptide stability. The samples prepared at pH 5 and
7 behave in a near identical fashion, showing full stability at all timepoints. Possibly
the higher pKa of the lysine side-chain, retaining the charged species helping increase
its stability. However, the sample at pH 3 showed a dramatic decline in its stability
after 25 days, with evidence of hydration of the Dha due to the presence of the
616.4011 m/z ion. It would seem that, with the incorporation of a second lysine
residue, the peptide seems to be susceptible to acidic breakdown. It is not inherently
clear as to why at pH 3 the di-lysine pentapeptide (76) breaks down, but possibly could
be due to the loss of an aromatic side-chain, i.e. the imidazole of the histidine
interacting with the Dha residue in the acidic pH range, possibly via π-π interactions
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or a cation-π interaction, thus protecting the Dha from acidic cleavage. But further
expanded studies, including NMR, LC-MS/MS at a wide range of pH values might
elucidate why this peptide is more susceptible to breakdown at pH 3.

Stability Study of pentapeptide Ac-Ile-Lys-Val-Ser-Lys-OH (75)
Again, also isolated during preparative HPLC purification of the di-lysine containing
peptide 76 was the analogue containing a serine residue (75), and the stability profile
data is presented in Figure 55.

Ac-Ile-Lys-Val-Ser-Lys-OH

140

% PEAK AREA

120
100
80

pH 3

60

pH 5

40

pH 7

20
0

0

10

20

30

40

50

TIME (DAYS)

Figure 55: Stability Profile of Ac-Ile-Lys-Val-Ser-Lys-OH (75) at pH 3, 5 and 7
The presence of a serine residue in place of a Dha moiety changes the stability profile
of the peptide when compared to its Dha counterpart (see Figure 55). The pH 5 and 7
samples are behaving differently when compared to the Dha-containing 76, with the
peptide’s stability being lower when a Ser residue is present. However, for the sample
at pH 3, although there is a steady decline in terms of the quantity of peptide present
in solution, after 39 days there is still a significant amount (41%) of the pentapeptide
75 remaining. For the Dha-containing analogue, pentapeptide 76, although it is more
stable at pH 5 and pH 7, at pH 3 it is fully degraded at this timepoint. The lower
stability of the Ser-containing pentapeptide 75 may be an indication that replacement
of the Dha moiety in nisin with a serine would not be preferred, as the trend and rate
of degradation seems to be accelerated at pH 5 and pH 7.
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Stability Study of Hexapeptide fragments of the nisin tail
In the following section the stability profile studies of the synthesised hexapeptide
fragments are presented, with replacement of the Dha moiety, to assess their stability
and potential as more stable structural analogues of the native nisin tail. The SPPS
synthesis of the native nisin tail fragment Ac-Ser-Ile-His-Val-Dha-Lys-OH (78) was
conducted and the purification of this fragment was successful based on initial
analytical HPLC (Figure 56).

Figure 56: Analytical HPLC of hexapeptide Ac-Ser-Ile-His-Val-Dha-Lys-OH
(78), following semi-preparative HPLC
The hexapeptide fragment (78), was isolated in a very low yield of 4.0 mg (2.6%),
post purification, analysis by analytical HPLC shows the hexapeptide was pure
directly after semi-preparative LC purification, as can be seen in Figure 56 where it
elutes at 4.37 minutes. However, prior to full characterisation it had degraded, showing
it to be very unstable even when stored at a fridge temperature of ~ 4oC, the same
conditions used for all other purified fragments.
Unfortunately, unlike the other peptides discussed in this chapter, hexapeptide 78 was
not present at T∅ of the stability trial. The elongation of pentapeptide 74 with a Ser

residue seems to have completely changed its stability in aqueous solution, with the
peptide 78 breaking down relatively easily. Therefore, it was not possible to conduct
the pH 3, 5 and 7 stability time-course studies.
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Stability Study of hexapeptide Ac-Ser-Ile-His-Val-Ser-Lys-OH 77
The isolated Ser-containing hexapeptide (77), 80% purity (crude yield) was used to
study the stability of the nisin tail, with replacement of the Dha residue with a serineresidue. The serine containing hexapeptide which eluted from the C18 LC column at
4.60 minutes was used to generate the stability profile data shown in Figure 57.
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Figure 57: Stability Profile of Ac-Ser-Ile-His-Val-Ser-Lys-OH (77) at pH 3, 5
and 7
The data shows a steady decline in the peptide in all three pH solutions. When
compared to the Dha-containing hexapeptide, the serine analogue is more stable as the
native nisin tail fragment 78 degraded prior to its stability study. Indeed, for the sample
prepared at pH 3, the peak at 4.60 minutes, corresponding to the serine analogue, was
completely absent in the sample after 25 days, the incorporation of the second Ser
residue, hexapeptide 77 behaves in a similar to pentapeptide 71 which was also
unstable at each pH value (see Figure 51). Although further isolation and purification
studies are required to characterise the resulting degradation products, based on our
observations, there are similar breakdown ions present, but they are not identical, as
shown in Figure 58.
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Figure 58: TIC of the breakdown ions of Ac-Ser-Ile-His-Val-Ser-Lys-OH (77) at
pH 3 and 7
The ions present after the breakdown of the Ser-containing hexapeptide 77 in each pH
solution are similar, for example the breakdown peaks contain the 398.2050 m/z and
the 420.1842 m/z ions present in greatest abundance at pH 3. Other ions in the
spectrum also vary depending upon the pH value. The isolation and characterisation
of these breakdown products would be required to study the degradation mechanism
of the peptide fragment.
There is a common trend emerging for most of the peptide fragments which contain a
Ser residue in the place of the Dha residue, showing lower stability in aqueous solution
with exception of hexapeptide 77. This might indicate that the replacement of the Dha
residue with a serine residue may not be preferred in terms of increasing the overall
stability of the nisin tail region. It would be of real interest to see how the stability of
a full nisin A or Z analogue, with a serine in position 33, would compare to the native
Dha-containing peptides.
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Stability Study of Ac-Ser-Ile-His-Val-AC3C-Lys-OH
Since the Dha33 moiety of the nisin peptide structure is implicated in the breakdown
of nisin at physiological pH,198 in an attempt to overcome the stability issues, an
alternative to the reactive Dha moiety was sought. As described in Chapter II the
structural mimic for the Dha moiety, 1-aminocyclopropane-1-carboxylic acid (AC3C),
was used. Interestingly this unusual amino acid has a cyclopropane as its side-chain
and so although the α-carbon of the AC3C amino acid is sp3 hybridised, its constrained
system gives rise to a bond angle between 115-118o, close to the Dha angle of
approximately 120o.178
As before, solutions of 0.5 mg/mL of the AC3C-containing hexapeptide were prepared
at pH 3, 5 and 7. The AC3C-containing hexapeptide eluted from the column at 4.72
minutes in 10% acetonitrile in water, containing 0.1% formic acid.
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Figure 59: Stability profile of Ac-Ser-Ile-His-Val-AC3C-Lys-OH (85) at pH 3, 5
and 7
Figure 59 shows the stability profile for the nisin tail analogue 85. At the three pH
values studied the peptide appears to be stable, with very little difference seen between
each pH for the full duration of the study. This encouraging result, based on the
stability profile data, may mean that the AC3C amino acid is a suitable replacement
for the Dha moiety, while also possibly maintaining its geometry. However,
significant further synthetic studies to prepare all the analogues discussed (tetra-,
penta- and hexapeptide) would need to be undertaken in order to give the full picture.
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Unlike the Dha-containing peptide fragments which were presented earlier, the AC3Ccontaining tail fragment was not only stable but also behaves in a similar fashion
across the whole pH range studied. The observed difference in the appearance on the
1

H NMR spectra of Ser-containing hexapeptide 77 and 85 could indicate they display

different solution conformations. The different conformations in solution may be
related to the increased rate of degradation and lower stability of the Ser-containing
77, in comparison to the AC3C-containing hexapeptide 85. However, further studies
would be required to confirm this observation.

Chapter Conclusions
The pH stability studies described have revealed some very interesting results and
possible insights into the stability of the tail region of nisin. There are significant
differences identified in the stability of the synthesised analogues of the nisin tail. As
presented earlier the tetrapeptide fragment 68 (Ac-His-Val-Dha-Lys-OH) degraded
instantly at pH 3, but displayed higher stability at pH 5 and 7. This observation alone
is not characteristic of the Dha moiety contained in the native nisin tail, which is
reported to have its maximum stability at pH 3-4.112 As the tail fragment was elongated
to incorporate an N-terminal isoleucine residue, the stability data showed the
pentapeptide was now stable across the full pH range studied. The presence of the
hydrophobic isoleucine residue seemed to increase the stability of the tail fragment at
pH 3, protecting the peptide from breakdown in acidic pH.
Substitution of the C-terminal lysine by a histidine residue to give pentapeptide 74
was most stable at pH 3 and 5, while beginning to breakdown at pH 7. At physiological
pH the imidazole sidechain of both histidine residues would be in their deprotonated
neutral form and may lead to an increased susceptibility to breakdown at pH 7 and
above. These stability studies show the importance of retaining the overall charge of
the peptide at neutral pH. In order to investigate this, the His31 residue was replaced
with a lysine residue, as the amino side-chain is described as being perpetually charged
at physiological pH. This analogue showed greater stability at pH 7, further indicating
the importance of retaining the charge at physiological pH. However, incorporation of
a lysine residue in place of the histidine residue compromised the peptide’s stability
at pH 3, causing its breakdown. Therefore, the presence of a His residue may play a
significant role in protecting the peptide from degradation in the acidic pH range.
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Replacement of the Dha33 moiety by a serine residue surprisingly displayed lower
overall stability compared to the Dha-containing peptides. The serine-containing
hexapeptide 77 showed a significant decline in stability at pH 3, 5 and 7. It is not
known yet why the serine-containing peptides seem more prone to degradation, but it
suggests that a serine is not an appropriate stabilising replacement for a Dha residue
in the tail region of nisin. For the hexapeptide 78, the native nisin tail fragment seemed
to be very unstable, as the purified compound degraded quickly prior to an intended
stability examination.
In contrast to the diminished stability observed for the serine- and Dha-containing
peptides, the incorporation of an AC3C amino acid as a structural mimic for the Dha
showed very promising initial results. The hexapeptide fragment 85 showed good
stability over the pH range for the full duration of the study, suggesting its potential
use as a bioisostere in the replacement of the Dha. Therefore, the AC3C residue may
be a possible candidate to replace the Dha moiety, thus increasing the overall stability
of the peptide at physiological pH. This increase in the stability at neutral pH observed
using the AC3C residue may increase the stability of the nisin peptide as its breakdown
is known to involve the Dha33 in the tail region. The incorporation of an AC3C residue
into the nisin tail in vivo, would involve engineering the unnatural AA into the nisin
peptide by, for example, genetic code reprogramming to generate the recombinant
peptide sequence.199
From the data presented in Chapter III, the stability studies conducted on several nisin
tail analogues have shown some potential targets and possibly more insight into the
stability of the nisin tail. Perhaps changing the His31 amino acid in the nisin tail to a
lysine residue may increase its stability significantly at physiological pH. The stability
studies highlight that not only is the charge of the peptide important for maintaining
stability at physiological pH, but also maintaining the geometry of the AA in place of
the Dha moiety.
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Future Work
The stability studies of the fragments and analogues of the nisin tail showed some
interesting insights into its stability. However, significant further studies are required
in order to fully understand the observations; although the nisin tail fragment 78 was
purified by semi-preparative LC, it degraded prior to the stability examination.
Therefore, the re-synthesis and detailed pH stability study of the native nisin tail would
allow for further insights and a direct comparison of the stability compared with the
AC3C-containing fragment.
Further studies are required to isolate and purify the many degradation products of the
synthesised peptide fragments. As some Dha-containing peptides degraded
(tetrapeptide 68), the m/z ion of their serine equivalent was observed. Characterisation
of the resulting degradation products by NMR spectroscopy would determine if the
observed ion corresponds to the formation of a serine residue or an α-hydroxy-alanine.
This study would aid considerably in the determination of the mechanism of
degradation of the nisin tail. Also required would be the preparation of the AC3Ccontaining tetra- and pentapeptide fragments in sufficient quantities to examine them
in detail by NMR and LC-MS/MS. These studies could be used to compare the AC3Ccontaining peptide fragments to the Dha-containing peptide fragments.
Detailed NMR studies, including selective 1D NOE experiments at a range of pH
values should also be conducted, to assess any possible interactions involving the
histidine, lysine and Dha amino acid side-chains. When the histidine was replaced
with the non-aromatic lysine residue, the stability of the peptide at pH 3 diminished.
There could possibly be a protective stabilisation interaction involving the His residue
in the acidic pH region. These studies could elucidate the observed contradictory
stability of the Dha moiety of nisin at pH 3-4 and its behaviour at physiological pH
values.
Although the stability profile data was favourable for the AC3C-containing tail
fragment, the increased stability does not account for any possible changes or loss in
the antimicrobial activity of the peptide due to the absence of the Dha moiety. Further
study is required to assess the impact of replacing the Dha on the biological activity
of nisin. Incorporation of the AC3C into nisin at position 33 and subsequent activity
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testing in partnership with our collaborators in UCC would show the effect of AC3C
on both nisin’s stability and also its antimicrobial activity.
There remains an important question as the studies so far have been solely focussed
on the tail region of nisin. Would the presence of the remainder of the nisin peptide
change its overall solubility and stability at physiological pH? One possible method to
explore this would be to study the stability of the nisin22-34 fragment, as this fragment
of nisin contains not only the tail region but also the interlocking D and E rings.
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Figure 60: Cleavage of nisin at position 22 using cyanogen bromide (CNBr)
As described by Rijkers and co-workers,150 nisin in the presence of cyanogen bromide
(CNBr) initiates cleavage of the peptide between Met21 and Lys22. So, following a
CNBr digestion of the nisin peptide to afford nisin22-34, this study could be done for
both nisin A and Z, which would allow investigation of the importance of the second
His residue in nisin A (His27) in the overall stability of the peptide. The stability data
for this nisin fragment could also be compared to the unstable native nisin tail fragment
78.200
As the stability studies have shown some interesting insights, the tail fragments could
also be synthesised using a Rink amide resin to incorporate a C-terminal amide
functional group. This would allow investigation of the effect of a C-terminal
carboxylic acid/ carboxylate on Dha stability and also on peptide solubility.
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These studies could also be expanded to include different tail mutants which contain
the Dha moiety, to further investigate the effect of the flanking AAs on the stability of
the tail fragments. Recent publications have shown a number of synthetic tail
analogues which contain a Dha and are similar to the nisin tail (Figure 61).201,202 These
modifications may aid in the design of more stable nisin derivatives and aid in the
investigation of the nisin degradation mechanism at physiological pH.
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Figure 61: Naturally occurring Dha-containing tail analogues of the nisin
tail201,202
The stability studies of different tail mutants could allow for targeted design of a new
nisin analogue which could be studied with our APC Microbiome Ireland
collaborators in UCC. These could be assessed for bioactivity, pH stability and by
NMR studies to compare directly with the native nisin A and Z.
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Chapter IV
Spectroscopic Solution Studies of Nisin
A and Z
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4.0 Introduction
The majority of journal and food reports detailing the use of nisin A or Z, is as a 2.5%
w/w suspension in a high salt concentration of ~80%, with the remainder being milk
solids. In this chapter preliminary studies on the effect of ionic strength on aqueous
solution of the peptides were investigated. One question is whether such high salt
concentrations affect its stability and/or conformation in solution. There are some
literature reports which mention nisin and ionic strength, but only with NaCl.203
The purpose of this study is to examine the possible effect that different salts can have
on the aqueous solution properties of nisin. There is a significant number of
publications dealing with nisin (A and/or Z) and its use as a food preservative.
However, there are no standardised protocols for its use, with reports using different
concentrations, different solution pH values, and different buffers, while sometimes
not even mentioning which form of nisin (A or Z) is being used. It is known that nisin
A and Z only target Gram-positive bacterial species, but a recent report has indicated
that highly purified nisin Z can attack Gram-negative species (i.e. E.coli), but that high
NaCl concentrations can inhibit its activity.191
In this chapter NMR and CD (Circular Dichroism) spectroscopies have been utilised
to study possible interactions between nisin (A and Z) and a number of different salts.
This is to investigate the impact of both ionic strength, and the additives themselves,
on the properties of nisin in aqueous solution, using highly purified samples of nisin
A and Z.

NMR studies of nisin A and Z
Both the nisin A and Z samples (Figure 62) used during the ionic strength studies were
commercially available as highly purified powders with ≥ 95% purity, with the
remainder being mainly water. The 1H NMR spectra of both nisin A (Figure 63) and
of nisin Z (Figure 64) were obtained in 10% D2O/90% H2O at 25 oC using a 3 mM
concentration, with 640 scans being acquired for each 1H NMR experiment, using a
BBFO (broadband fluorine observed) NMR probe (unless otherwise stated), as these
were the conditions used in the published literature.204
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Figure 62: Structure of nisin A and Z
The NMR spectra of nisin (A and Z) contain a number of distinct features which are
labelled. In both cases the 1H spectra show two peaks at 5.44 and 5.55 ppm,
corresponding to the two vinyl protons of the Dha residue at position 5, with the
corresponding N-H of this residue being at 9.84 ppm for nisin A. Surprisingly, both
vinyl protons of Dha33 appear as a broadened single peak at 5.72 ppm, and its N-H is
observed at 9.66 ppm. This shows that the two Dha residues, though identical in
chemical structure, have quite different local conformations and/ or local
environments.
Other spectral features which are shared by both nisin A and Z include the Dhb
(dehydrobutryine) vinyl proton, as a quartet at 6.61 ppm, with the N-H of Dhb not
observed within the sweep width of the 1H NMR spectrum.205 Nisin A and Z also
contain a histidine residue at position 31, as shown in Figure 63 and Figure 64. The
C4-H of the imidazole of His27 is seen at 7.30 ppm, and is absent in the 1H NMR
spectra of nisin Z (Figure 64), as this residue is replaced with an asparagine residue.206
The published chemical shift assignments for nisin A and Z in 10% D2O/H2O were
then used to examine,204 as far as possible, all of the changes in the N-H chemical
shifts present.
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Figure 63: The N-H region of the 1H NMR spectrum of nisin A (3 mM) in 10% D2O:H2O at 25oC (DSS internal reference)207
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Figure 64: The N-H region of the 1H NMR spectrum of nisin Z (3 mM) in 10% D2O:H2O at 25oC (DSS internal reference)207
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Ionic strength titration studies
All of the following NMR titration studies were conducted at a 3 mM concentration of
nisin A or Z, unless otherwise stated. Figure 65 shows an NMR titration study of nisin A
with an increasing concentration of NaCl being added. At the bottom of the spectral stack
is shown the N-H region of pure nisin A (wine), up to the top spectrum with 300 mM
NaCl (purple). As the ionic strength is increased there are a number of small spectral
changes observed, with the majority of these changes being in the N-H region of the
spectra. The increasing ionic strength, in most cases, causes the chemical shifts of the NHs of the amide backbone of the peptide to move upfield or become less deshielded, with
the N-H of Dha5 moving upfield by 0.13 ppm. The two vinyl protons of Dha5 also show
changes, with the C-H at 5.54 ppm becoming deshielded slightly, moving downfield by
0.02 ppm. For Dha33, which was a broad single peak at 5.72 ppm at zero ionic strength,
as the ionic strength is increased the peak is seen to separate into two distinct peaks, for
each of the C-H protons, at 300 mM NaCl, becoming more chemically non-equivalent.

Figure 65: The N-H region of the 1H NMR spectrum of nisin A (3 mM) with
increasing NaCl concentrations, in 10% D2O/90% H2O, at 25oC
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Also, on the addition of NaCl, the N-H amide protons of Leu6 and Abu8 show changes
in their observed chemical shift. The Leu6 N-H peak at 8.93 ppm becomes more shielded
or less deshielded, moving upfield by 0.054 ppm, while the amide N-H of Abu8 moves
slightly upfield when compared to its observed chemical shift at zero ionic strength.
Figure 66 shows the NMR titration study of nisin Z with an increasing concentration of
NaCl being added. At the bottom of the spectral stack is shown the N-H region of pure
nisin A (wine), up to the top spectrum with 300 mM NaCl (purple). Similar to nisin A,
there is a change in the chemical shift of only one of the vinyl protons of Dha5, with the
peak at 5.56 ppm becoming more deshielded moving downfield by 0.04 ppm, while its
N-H proton at 9.85 ppm becomes more shielded moving upfield by 0.114 ppm. For the
Dha33 residue contained in the tail region of nisin Z, its appearance changes from a broad
single peak into two separate peaks, with no observed change in chemical shift for the
amide N-H of Dha33.
The Leu6 amide N-H also shows an upfield movement of 0.042 ppm, becoming slightly
less deshielded. For the zero ionic strength spectrum of nisin Z, the amide N-Hs of Leu6
and Abu8 were observed as two separate peaks, but in the presence of 300 mM of NaCl
both N-H resonance signals are overlapping. This is due to the upfield shift of the Leu6
N-H and the slight deshielding of the N-H of Abu8.
In each case, for both nisin A and Z, there are also AA residues not affected by the
addition of NaCl. For example, there was no change observed for the resonance signals
associated with vinyl proton of the Dhb2 residue or for the NH2 peaks of either Asn20 or
27.
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Figure 66: The N-H region of the 1H NMR spectrum of nisin Z (3 mM) with increasing NaCl concentrations, in 10% D2O/90%
H2O, at 25oC
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As the NaCl concentration was increased for nisin Z it was seen that the overall spectral
changes are different when compared to nisin A. Sometimes the N-H protons, which
became more shielded in nisin A become more deshielded in nisin Z, for example
methionine at position 22.

Figure 67: Changes in the chemical shift of the N-H protons of nisin A and Z in 300
mM NaCl, when compared to each peptide alone.
Figure 67 shows the comparative N-H proton shift graphs presented for nisin A and Z in
300 mM NaCl, against their chemical shifts in the absence of NaCl. Overall, nisin A
shows larger chemical shift changes in the region corresponding to the A and B rings
(residues 1-11), becoming less deshielded, with the biggest effect shown for Dha5. Nisin
Z also shows distinct changes with the largest change also seen being for the N-H of the
Dha 5. Although there is only one AA change between nisin A and Z, overall there are
definite differences observed spectroscopically. The biggest chemical shift changes in
both cases are associated with the residues present in the A and B ring region of the
peptide, the same region that is implicated in the binding to the pyrophosphate moiety of
lipid II.102
These results highlight that nisin A and Z may be interacting differently with NaCl in
solution. Of course it is not known if the changes are due to different interactions of nisin
A or Z with the Na+ and Cl- ions themselves, or whether the differences are due to the
impact on the hydration shells around the peptides (different for nisin A and Z).208 The
possibility of specific cation and anion effects are described further on in this chapter.
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One possible reason that only one of the vinyl protons of Dha5 moves downfield may be
due to a conformational change within the Dha residue itself, bringing one of the vinyl
C-Hs closer to the adjacent carbonyl of the amide bond (shown in Figure 68). This
interaction could explain the behaviour of the vinyl C-H observed during NMR
experiments.
Interaction with carbonyl oxygen
O
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H Rotation around the Φ dihedral
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Figure 68: Dha moiety Φ dihedral rotation causing closer alignment of one vinyl
proton with the adjacent amide carbonyl oxygen
Interactions forming 6-membered ring like structures are reported in both peptide and
protein chemistry. These interactions can act as a stabilisation force and form via the
resonance-assisted intramolecular H-bond closing and formation of the flat six-member
ring (Figure 69).209,210
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Figure 69: Formation of six-membered interaction via resonance-assisted
rearrangement211
The amide N-H of the Dha5 also shows some significant shielding on the addition of
NaCl. This may be a further result of possible conformational changes in which the
adjacent carbonyl is brought out of the plane of the N-H and therefore becomes more
shielded due to a weaker interaction, if any, with the carbonyl oxygen.
It is possible that rotation of the Dha moiety through the Ψ dihedral angle causes a
conformational change (Figure 70), showing the formation of a C5-interaction.190 This is
a weak interaction between the amide N-H and the lone pairs of the carbonyl oxygen
which are within the same residue: its formation is favoured when the dihedral angles
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mirror each other (adjacent).212 So the planar geometry of the Dha moiety may favour the
formation of such an interaction. In the literature “the C5” is described as a H-bond, but
with the presence of the partially polarised N-H and carbonyl functional groups, this
could also be a dipole-dipole interaction, with both possibilities shown in Figure 70;
further conformational studies would be required to identify this interaction.213

Figure 70: Rotation of the Ψ dihedral angle, bringing the carbonyl out of the plane
shielding the Dha N-H proton212, 213
As the concentration of salt is increased, the N-H amide proton of the Dha5 becomes
more shielded: this may be due to a local conformational change of the Dha moiety,
resulting in the carbonyl being brought out of the plane of the amide N-H. This
conformational change could weaken the interaction between the N-H and the oxygen of
the carbonyl, with it ultimately becoming more shielded.
In the literature there are differences in the stability of the Dha5 and Dha33 residues, with
the Dha33 being the least stable and is broken-down first by hydrolysis.214 It is most
probable that the Φ and ψ dihedrals are quite different in Dha5 and Dha33, as Dha5 is
conformationally constrained within the peptide’s A-ring, whereas Dha33 is in the
flexible tail region. As indicated by the 1H NMR analysis of nisin, it would seem that
although identical in chemical structure, they behave quite differently in NMR analysis.
It was next decided to study whether this was an effect of NaCl specifically or whether it
was a general ionic strength effect. Therefore, the experiments were repeated using a
range of different ionic salts, and Table 25 lists the salts which were included in the study.
These salts were chosen so that not only could the ionic strength effect be studied, but
also the effect/interaction that the presence of different species of anions and cations may
have on the chemical shifts of the residues within nisin A and Z.
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Shown in Table 25 is a full list of salt which were included in the NMR studies of nisin
A and Z and are available in the appendices. The NMR spectra in the presence of fluoride
salts are not included due to the poor quality of the NMR spectra and complete absence
of the N-H amide region.
Salts included in study
KCl
LiCl
MgCl2
NaBr
KBr
LiBr
Tetrabutylammonium bromide
NaI
KI
NaF
KF
LiF
Tetrabutylammonium Fluoride
Tetrabutylammonium Iodide
Tetraethylammonium perchlorate
Tetrabutylammonium
tetrafluoroborate
Tetrabutylammonium
hexafluorophosphate

Appendix of 1H NMR spectra
Nisin Z
Nisin A
Appendix 13
Appendix 14
Appendix 16
Appendix 17
Appendix 19
Appendix 20
Appendix 22
Appendix 23
Appendix 25
Appendix 26
Appendix 28
Appendix 29
Appendix 31
Appendix 32
Appendix 34
Appendix 35
Appendix 37
Appendix 38
Not Included
Not Included
Not Included
Not Included
Not Included
Not Included
Not Included
Not Included
Appendix 40
Appendix 41
Appendix 43
Appendix 44
Appendix 46

Appendix 47

Appendix 49

Appendix 50

Table 25: Organic and inorganic salts included in the ionic strength NMR study of
nisin A and nisin Z
For example, using tetrabutylammonium chloride (TBAC) the increased ionic strength
causes changes in the N-H region of the nisin A proton spectrum (Figure 71), with the NH of Dha5 shifting upfield by 0.23 ppm, as it becomes more shielded, or less deshielded.
The vinyl protons of Dha 5 also show changes as the C-H at 5.54 ppm becomes more
deshielded moving downfield by 0.10 ppm. The vinyl C-Hs of Dha33, which was a broad
peak at zero ionic strength, shows little or no change as a result of the increasing
concentration of TBAC. The spectrum of Nisin Z (Figure 72) demonstrates how the N-H
of Dha5 exhibits an even larger movement upfield of 0.27 ppm, while one of the vinyl CH protons of Dha5 moves downfield by 0.10 ppm. The peak at 5.71 ppm for the vinyl CHs of Dha33 moves slightly upfield by 0.02 ppm, while its amide N-H is also less
deshielded, moving upfield by 0.03 ppm. This suggests that again this salt is interacting
slightly differently with nisin A than nisin Z (Figure 71 and Figure 72).
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Figure 71: The N-H region of the 1H NMR spectra with increasing tetrabutylammonium chloride (TBAC) concentrations, for
nisin A (3 mM) in 10% D2O/90% H2O at 25oC
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Figure 72: The N-H region of the 1H NMR spectra with increasing tetrabutylammonium chloride (TBAC) concentrations, for
nisin Z (3 mM) in 10% D2O/90% H2O at 25oC
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As the cation was changed from the Na+ ion to the Bu4N+ ion there were spectral changes
observed, not only between nisin A and Z, but also differences depending on the identity
of the cation added to each particular nisin isomer. The Bu4N+ cation is significantly
larger than the sodium ion. For example, the TBAC showed significantly more
deshielding of one of the vinyl protons of Dha5, when compared to NaCl. In Figure 73
the comparative N-H proton shift bar graphs are presented for the N-H protons of nisin
A and Z in 300 mM TBAC. Although both nisin A and Z were tested using the same
conditions, again their response to a different salt is not identical, regardless of the fact
that ionic strength remained constant.

Figure 73: Changes in chemical shift of the -NH protons of nisin A and Z in 300 mM
tetrabutylammonium chloride, when compared to each peptide alone
Again, the amide N-H of the Dha5 showed significant shielding on addition of Bu4N+,
with the resonance signals for Dha33 remaining unchanged. The effects do not seem to
be dependent on ionic strength of the solution, but rather the salt composition. In
comparison to Figure 67 in the presence of NaCl, the changes are significantly larger in
the presence of TBAC, especially for the N-H amide of Dha5. This proton moves upfield
by 0.231 ppm compared to 0.115 ppm in NaCl-containing solution. For nisin Z in the
presence of NaCl, there are several resonances which become more deshielded moving
slightly downfield, including Ala3 and 7, Gly10 and His31. Interestingly, these amide
resonances all show a slight upfield movement in the presence of TBAC which highlights
that it is not a pure ionic strength effect.
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Examination of the impact on nisin A and Z in solution of the presence of
a range of different salts
After seeing the observed differences for both nisin A and Z in the presence of Na+Cland Bu4N+Cl-, the study was expanded to include other salts, varying the anion and cation
present in solution. This was to further investigate whether the observed changes are
indeed dependant on the ionic strength or due to the identity of the salt. The effect of the
addition of a variety of different salts is presented in Table 26, showing the change in the
1

H NMR chemical shift of N-Hs of Dha5, Leu6 and the vinyl protons of Dha 5 and Dha33

Anion

in nisin A in comparison to their chemical shifts in the absence of added salt.

@ 500 MHz

Dha5 N-H
(ppm)

Leu6 N-H
(ppm)

Dha5 C-H
gap
(Hz)

Dha33 C-H
gap
(Hz)

Nisin A

9.852

8.933

57.3

0.0

∆δ (ppm)

∆δ (ppm)

∆δ (Hz)

∆δ (Hz)

LiCl

+0.128

+0.054

9.1

11.5

NaCl

+0.115

+0.042

10.4

11.4

KCl

+0.137

+0.065

9.8

9.8

TBAC

+0.231

+0.008

38.9

4.0

LiF

N.O.

+0.008

2.1

7.5

NaF

N.O.

N.O.

1.0

20.9

KF

N.O.

N.O.

1.2

22.0

TBAF

N.O.

N.O.

14.8

10.0

LiBr

+0.182

+0.081

13.6

11.4

NaBr

+0.186

+0.084

13.4

10.1

KBr

+0.216

+0.106

14.6

11.6

TBABr

+0.253

+0.024

53.9

3.2

NaI

+0.240

+0.120

19.1

10.7

KI

+0.267

+0.134

20.0

10.8

TBAI

+0.155

+0.039

9.9

3.5

TBA PF6

-0.013

-0.004

-1.0

0.0

Misc.

Iodides

Bromides

Fluorides

Chlorides

+ Salts

TBA BF4
+0.048
+0.018
5.3
0.0
Table 26: Effect on selected chemical shifts in nisin A in the presence of salts (300
mM)
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For the fluoride salts, some of the peaks for the Dha5 and Leu6 N-Hs were not visible,
which may be due to the solubility of the nisin A, as the solutions were cloudy, and shown
as not observed (N.O.) in Table 26. However, the chemical shift changes show that it is
not purely an overall ionic strength effect,but depends greatly on the specific ionic
composition of the salt. The changes observed after the addition of each salt vary
significantly with the biggest change in chemical shift being for TBABr, in which the
Dha5 N-H showed an upfield movement of +0.253 ppm. There was also an upfield shift
of one of the vinyl C-Hs of Dha5, as shown in the +53.88 Hz change in the spacing
between the vinyl proton signals. This indicates a significant change in the local chemical

Anion

environment of the A-ring of nisin A.

@ 500 MHz

Dha5 N-H
(ppm)

Leu6 N-H
(ppm)

Dha5 C-H
gap
(Hz)

Dha33 C-H
gap
(Hz)

Nisin Z

9.845

8.932

58.6

3.1

∆ (ppm)

∆ (ppm)

∆ (Hz)

∆ (Hz)

LiCl

+0.136

+0.058

8.6

8.9

NaCl

+0.114

+0.042

8.6

8.8

KCl

+0.153

+0.068

8.6

8.1

TBAC

+0.268

+0.009

42.9

0.4

LiF

+0.506

+0.003

0.6

6.5

NaF

N.O.

N.O.

1.3

23.6

KF

N.O.

N.O.

-0.4

29.7

TBAF

N.O.

-0.041

16.8

11.4

LiBr

+0.179

+0.080

12.4

9.0

NaBr

+0.198

+0.098

13.0

8.9

KBr

+0.204

+0.103

13.1

8.9

TBABr

+0.325

+0.028

54.7

0.0

NaI

+0.241

+0.128

18.3

8.8

KI

+0.256

+0.137

19.6

8.4

TBAI

+0.157

+0.043

20.2

2.2

TBA PF6

+0.003

-0.003

1.0

0

Misc.

Iodides

Bromides

Fluorides

Chlorides

+ Salts

TBA BF4
+0.060
+0.026
6.3
0.6
Table 27: Effect on selected chemical shifts in nisin Z in the presence of salts (300
mM)
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Interestingly, for both the TBA PF6 (tetrabutylammonium hexafluorophosphate) and
TBA BF4 (tetrabutylammonium tetrafluoroborate) solutions, which are described as noncoordinating anions,215 although the ionic strength remains constant there were negligible
changes to the chemical shift of these protons in comparison to other added salts.
A similar examination was conducted for nisin Z, with the changes in chemical shifts for
Dha5, Leu6 and Dha33 displayed in Table 27. There are again differences depending on
the identity of the salt, but also differences observed between nisin A and nisin Z. For
example, the largest spectral change for Dha5 in nisin Z was in the presence of TBABr
(+0.325 ppm), while in comparison nisin A showed a smaller upfield movement of
+0.253 ppm. In fact, the largest change seen in the nisin A spectra was in the presence of
KI, with the amide N-H of Dha5 becoming more shielded and moving upfield by +0.267
ppm (0.256 ppm for nisin A). Again, for the fluoride salts some of the peaks are not
observed due to solution being cloudy, but there are differences observed between nisin
A and Z. In the case of potassium fluoride (KF) the effect on the spacing of the two vinyl
protons of Dha5 is interesting, as nisin Z shows a smaller change (-0.35 Hz), while nisin
A the spacing is increased by 1.19 Hz. Once again this shows that nisin A and Z do not
behave in an identical manner and it not only depends on the salt type but also on the
nature of the ion.
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The effect of increasing salt concentration on the pH of nisin-containing
solutions
As it is known that the ionic strength can alter the pH of a solution,216 the pH was
measured for all solutions, of both the nisin A and Z with 300 mM of each salt. They
were compared to the pH of pure nisin A (pH 4.08) and nisin Z (pH 3.26) solutions alone,
in zero ionic strength (Table 28). It is interesting that the response to the addition of salts
is different for both nisin A and Z. For example, it can be seen that for NaCl the changes
in the pH show an opposite response, with the solution pH of nisin A decreasing by 0.15,
while the nisin Z solution increased by the same value.
300 mM
NaCl
KCl
LiCl
MgCl2
Tetrabutylammonium chloride
LiBr
NaBr
KBr
Tetrabutylammonium bromide
NaI
KI
Tetrabutylammonium iodide
Tetraethylammonium perchlorate
Tetrabutylammonium
tetrafluoroborate
Tetrabutylammonium
hexafluorophosphate

Δ pH
Nisin A
-0.15
-0.07
-0.12
0.03
-0.11
-0.06
-0.09
-0.14
-0.21
-0.11
-0.08
-0.28
-0.12

Δ pH
Nisin Z
0.15
0.07
0.01
0.04
-0.06
0
0.09
0.16
-0.06
0.07
-0.02
-0.03
-0.03

-0.15

-0.16

-0.08

0

Table 28: pH changes observed in aqueous solution as result of the addition of 300
mM salt, to both nisin A and Z
Table 28 shows the change in solution pH after the addition of each salt, since large pH
variations may also contribute to changes in the proton chemical shifts of either nisin A
or Z (see Chapter V). At the highest concentration of salt added (300 mM), the pH
changes were +0.15 to -0.28, with the highest value of -0.28 for the tetra-butylammonium
iodide. The majority of the pH changes ranged between 0-0.15 pH units, with no dramatic
changes being observed and all values still being in the pH range at which nisin is known
to have maximum stability (pH 3-4).195 Therefore, the NMR spectral changes which have
been observed are due to the addition of each salt, rather than any large changes in the
pH of the solution.
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Investigation of H-bonding by 1H NMR spectroscopy
From the results shown in sections 4.2 and 4.3, which demonstrate significant changes in
the amide N-H chemical shifts of the polypeptide backbone, the deshielding of these
protons could be due to the disruption of hydrogen bonds (H-bonds). The increase in
temperature has been shown to affect and/or disrupt hydrogen bonding causing an upfield
movement of donor X-H signals.217 So, to examine the extent of H-bonding present in
aqueous solutions of both nisin A and Z, variable temperature (VT) 1H NMR studies were
conducted.

Variable temperature (VT) 1H NMR studies
The changes in the chemical shift of the amide N-H of Dha5 as a function of temperature
are shown in Figure 76. Both nisin A (Figure 74) and nisin Z (Figure 75) were studied
using VT NMR over a temperature range of 20 to 45oC. These chemical shift changes in
response to the increasing temperature can be attributed to the N-H proton becoming
more shielded, possibly due to disruption of H-bonding associated with nisin.218

Figure 74: Variable temperature 1H NMR spectrum of pure nisin A (3 mM),
conducted at 5oC intervals (20-45oC) in 10% D2O: H2O
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Figure 75: Variable temperature 1H NMR spectrum of pure nisin Z (3mM) conducted at 5oC intervals (20-45oC) in 10% D2O:
H2O
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Figure 76: Dha5 amide N-H proton chemical shifts as a function of temperature
for nisin A and Z
As shown in Figure 74 (Nisin A), Figure 75 (Nisin Z) and Figure 76, for the N-H of
Dha33, as the temperature is increased there is an upfield shift of the amide N-Hs,
showing disruption of either intra- or inter-molecular interactions. As with the correlation
of temperature and changes in the chemical shift described above, Leu6 also showed a
strong correlation with its N-H amide moving upfield because of the increased
temperature, as is seen in appendix 42.
Although the VT 1H NMR studies show the presence of H-bonding, its intermolecular or
intramolecular nature was not known. A paper published by Raines show that most
peptides at this concentration are monomeric, so it is unlikely that these interactions are
of an intermolecular nature.212
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Intermolecular or Intramolecular H-bonding
To investigate the intermolecular or intramolecular nature of the H-bonding observed
during the VT NMR experiments, a concentration gradient of 1-5 mM was conducted for
both nisin A and Z using 1H NMR spectroscopy at 25oC.

Figure 77: Concentration gradient of nisin A (1-5 mM) in 10% D2O: H2O at 25oC
As the concentration of peptide was increased from 1 mM to 5 mM the peak height
increases were due to the increase in concentration. However, no chemical shift changes
or peak broadness were observed, for either peptide, (nisin A Figure 77 and nisin Z
Appendix 57). This confirms the intramolecular nature of any H-bonding, in both
peptides.
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1

H-15N HSQC NMR studies of nisin A and Z

As shown during the course of the 1H NMR studies of both nisin A and Z, the N-H amide
region of the spectrum is overcrowded and in some cases the proton resonances are
overlapping. To try and further examine the changes based on the addition of a specific
salt, the use of 1H-15N HSQC was employed. The 1H-15N HSQC NMR studies of peptides
and proteins are usually conducted using 15N-enriched peptides to increase resolution and
sensitivity.219 However, due to the instability issues with aqueous solutions of nisin A
and Z, this was not practical. The studies were conducted using a 600 MHz Agilent NMR
spectrometer equipped with a cryoprobe, to measure the effect on the individual amide
N-Hs, at the natural abundance of

15

N at 0.4%.220 Due to the limitation of the

commercially available nisin A and Z samples not being

15

N-enriched, the cryogenic

NMR probe allows for significant enhancement and increased sensitivity, to allow for the
low-abundance of 15N to be observed. However, the drawbacks were that only 150 mM
of salt additions was possible, with each experiment taking up to 5 hours of instrument
time. Figure 78 shows the 2D 1H-15N HSQC experiment of nisin A stacked before and
after the addition of 150 mM of NaCl.

Figure 78: 1H-15N HSQC of 3 mM nisin A (Blue) and after addition of 150 mM NaCl
(Black) in 10% D2O: H2O at 25oC
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The second dimension of the spectrum allows for the separation of the amide N-H
resonances which overlap in the 1D proton NMR spectra of both nisin A and Z. There
are differences observed between the nisin A spectrum after the addition of NaCl,
especially corresponding to the N-H of Dha5 which displays the largest upfield shift,
while amide N-Hs of Ile4, Leu6, Abu8 and Gly10 also show a upfield movement (see
Figure 78). These AA residues are in the important A- and B-ring binding regions of both
nisin A and Z.
The 1H-15N HSQC experiment is in agreement with the previous NMR studies, showing
the major effects and/or interactions are associated with the A- and B-rings of nisin,
which is known to be involved in its binding to lipid II. Such interactions may also impact
on the antimicrobial activity of nisin as there is a report which shows that purified nisin
Z displays activity against both Gram-positive and Gram-negative bacteria. However,
nisin Z, in the presence of a high NaCl concentration, shows a reduction in activity against
Gram-negative species.221 The 1H-15N HSQC of nisin Z in the absence and in the presence
of 150 mM NaCl is shown in Figure 79.

Figure 79: 1H-15N HSQC of 3 mM nisin Z (Blue) and after addition of 150 mM NaCl
(Black) in 10% D2O: H2O at 25oC
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For nisin Z, the addition of 150 mM of NaCl again shows slight changes to the observed
chemical shift of the amide N-Hs. Again, the main spectral changes observed are
associated with the AAs located in the A- and B-rings of nisin, such as Ile4, Leu6 and
Abu8. Interestingly, Gly10 in nisin A which showed an upfield shift, shows no change in
its chemical shift in nisin Z.
Both nisin A and Z were also examined using two other different salts (NaBr and TBAC)
with the complex overlay of the 1H-15N HSQC spectra shown in Figure 80, at a constant
ionic strength of 150 mM (NaCl, NaBr and TBAC). The number of salts studied was
restricted by available NMR time on the 600 MHz instrument. Each of the three different
salts show some differences depending on the salt, with the TBAC having the greatest
effect on the Dha5 moiety, showing the N-H in the presence of 150 mM TBAC
significantly less deshielded, as well as significant movement of the amide N-Hs of Ile4
and Leu6, in comparison to the other salts.
It is still not clear whether there is a direct interaction of the cation or anion with nisin or
whether it is having an impact on the local solvent environment. If there is some kind of
“binding” interaction of the A- and B-rings with a cation or anion, we would expect to
see it using the 1H-15N HSQC studies. For example, if the chloride anion (Cl-) is binding,
then it would be expected that for NaCl and TBAC spectral changes would be similar.
Likewise, if the Na+ cation is binding, then the NaCl and NaBr spectra would be similar.
But this is not the case, where each of the different salts seem to interact differently with
each nisin species in solution.
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Figure 80: 1H-15N HSQC of Nisin Z (Blue); 150 mM addition of NaCl (Black); NaBr (Green); TBAC (Maroon) in 10% D2O: H2O at
25oC
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Biological Buffer Components
As the largest effect of added salts is shown to be in the A-ring region of nisin, this may
help to explain the reported reduction of nisin Z bioactivity against Gram-negative
bacteria. Possibly interactions between the anions, cations or salt and the A-ring region
of nisin interferes with the binding to the polyoxygenated pyrophosphate moiety (Figure
81) of the lipid II cell wall precursor.
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Figure 81: Structure of the polyoxygenated pyrophosphate moiety of lipid II
Therefore, the effect of common buffer components, used in a wide range of biological
research, on both nisin A and Z in aqueous solution was of interest. One example of a
common buffer used to examine nisin in a range of bioassays is phosphate-buffered saline
(PBS). This widely used buffer system contains polyoxygenated phosphate Na2HPO4
(Figure 82) as the main component in excess of 100 mM, as well as 137 mM of NaCl and
other salts depending on the type of assay being conducted.222 in the context of PBS, there
are two relevant anions in solution, H2PO4- and HPO42-, in ~ equal concentration. Could
the presence of a polyoxygenated phosphate species, present in the buffered solution, act
in a similar way to the pyrophosphate and interact or bind to the A and B rings of either
nisin A or Z?
HO
Na O
O
P
HO
OH

NaH2PO4

KO
O
P
K O OH

N
N

S

O
O
H
N

HO

S

O
O

HO

K2HPO4

HEPES

CAPS

Figure 82: Chemical structures of common biological buffer components
Also shown in Figure 82, are the chemical structures of two common biological buffer
components (HEPES and CAPS), which contain polyoxygenated sulfonic acid functional
groups.
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There is also a possibility that these components could interact and bind to nisin during
bioassays and assessment of its biological activity, possibly inhibiting its bioactivity. The
NMR studies were also extended to include perchlorate salts as, although they not used
commonly in biological buffering systems, they are used commonly used in organic
chemistry. Both sodium perchlorate and tetraethylammonium perchlorate (TEA
perchlorate) shown in Figure 83 were studied in the presence of both nisin A and Z.
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Figure 83: Chemical structures of sodium perchlorate and TEA perchlorate,
polyoxygenated salts
The NMR studies using common biological buffer components and polyoxygenated
anions such as sodium perchlorate and tetraethylammonium perchlorate (TEA ClO4)
were examined as before using 3 mM nisin and 300 mM of the respective buffered
component and the pH was adjusted to the solution pH of nisin in the absence of the
additive.
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Examining the effect of biological buffer components using 1H NMR
spectroscopy
The effect of sodium dihydrogen phosphate (NaH2PO4), a very common buffer
component, was investigated at pH 3.1, shown in Figure 84. The main phosphate species
in solution at pH 3.1 would be H2PO4-, (~89% from Henderson-Hasselbalch) as only one
of the acidic protons will be deprotonated, due to the pKa values of H3PO4 being reported
to be 2.2, 7.2 and 12.3.223

Figure 84: Nisin A (wine) in the presence of 300 mM NaH2PO4 (blue) both at pH 3.1
in 10% D2O: H2O at 25oC
In the presence of NaH2PO4, nisin A displayed some interesting spectral changes, with
some of the observed changes not being seen in the presence of other ionic species. As
can be seen in Figure 84, the C2 and C4 protons of the histidine side-chain imidazole
showed an upfield shift of 0.03 ppm, which is interesting as the histidine side-chain
chemical shift did not vary in the study of either nisin A or Z in the presence of different
salts. The C-H vinyl protons of Dha5 show a slight upfield shift in comparison to nisin A
alone, while its N-H amide resonance is slightly deshielded, an opposite response to what
was observed in the presence of other salts. The vinyl proton of the Dhb2 also shifted
slightly upfield, while the amide N-H of Leu6 and Abu8 moved slightly downfield by
0.018 ppm and 0.100 ppm respectively, indicating that the interactions in the presence of
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NaH2PO4 seem to be localised in the A-ring region of nisin. The observed changes to the
1

H spectrum of nisin A could possibly be due to interactions or binding of the phosphate

to the A-ring, in a similar way that nisin binds the pyrophosphate of the lipid II.
Each of the other polyoxygenated compounds were also studied, and in each case there
were significant spectral changes in the observed chemical shift of the amide N-H of the
AAs located in the A ring of nisin A. Table 29 shows the observed changes in the
chemical shift of the Dha5, Leu6 and Dha33 residues, in comparison to their chemical
shift on the absence of additive.

@500 MHz

pH

Nisin A

Polyoxygenated

+ Additive

Dha5 N-H
(ppm)

Leu6 N-H
(ppm)

Dha5 C-H
gap
(Hz)

Dha33 C-H
gap
(Hz)

9.852

8.933

57.3

0

∆ (ppm)

∆ (ppm)

∆ (Hz)

∆ (Hz)

NaH2PO4

3.10

-0.031

+0.018

2.4

7.6

K2HPO4

3.10

+0.108

+0.051

7.4

9.7

HEPES

4.30

+0.124

+0.003

16.3

6.0

CAPS

4.30

+0.109

0.000

22.0

0.0

NaClO4

4.15

+0.087

+0.057

6.2

5.9

TEA ClO4
4.15
+0.220
+0.083
24.1
7.1
Table 29: Effect on selected chemical shifts of nisin A (3 mM), in the presence of
common polyoxygenated components (300 mM)
There are differences observed depending on the identity of the additive. The two
phosphates, NaH2PO4 and K2HPO4, showed different spectral changes, the N-H of Dha5
showed a downfield movement in NaH2PO4 of -0.031 ppm compared to the upfield shift
of 0.108 ppm in the presence of K2HPO4. The phosphate samples were made using either
NaH2PO4 or K2HPO4 with the pH of these solutions are the same, the phosphate species
in solution will be the same, so the contrasting downfield movement of the amide N-H of
Dha5 in the presence of K2HPO4 may be due to the K+ cation concentration being double
that of the Na+ in the NaH2PO4 solution. The HEPES component, containing a sulfonic
acid moiety, shows a large upfield movement for the amide N-H of Dha5 of 0.124 ppm.
In the presence of CAPS, also containing a sulfonic acid moiety, the amide N-H of Dha5
also showed upfield shift of +0.109 ppm while there were negligible changes observed
for the chemical shift of the N-H of Leu6 or for the C-H vinyl proton signal of the Dha33.
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Nisin A in the presence of the two perchlorate salts also displayed differences, with the
largest changes being observed for TEA perchlorate. The Dha5 amide N-H became less
deshielded, moving upfield by 0.220 ppm, overlapping with the N-H amide of Dha33.
The C-H vinyl protons of Dha5 displayed a change in the measured gap between each
proton resonance signal, increasing by 24.1 Hz. Interestingly, nisin A in the presence of
sodium perchlorate did not show big spectral changes in comparison to the other
polyoxygenated anions except NaH2PO4, again showing that nisin A interacts differently
depending on the composition of the additive.
A similar examination was also conducted for nisin Z. The effect on the Dha5, Leu6 and
Dha33 is shown in Table 30, with the spectral changes again being more prominent in
the A-ring of nisin Z.
pH
@500 MHz
Nisin Z

Polyoxygenated

+ Salts

Dha5 N-H
(ppm)

Leu6 N-H
(ppm)

Dha5 C-H
gap
(Hz)

Dha33 C-H
gap
(Hz)

9.845

8.932

58.6

3.05

∆ (ppm)

∆ (ppm)

∆ (Hz)

∆ (Hz)

NaH2PO4

3.10

+0.021

+0.013

3.0

6.4

K2HPO4

3.10

+0.142

+0.073

7.7

9.6

HEPES

3.40

+0.117

+0.034

14.8

4.8

CAPS

3.40

+0.119

+0.008

21.3

0.0

NaClO4

3.50

+0.062

+0.045

4.1

3.0

TEA ClO4
3.50
+0.225
+0.091
25.3
3.3
Table 30: Effect on selected chemical shifts in nisin Z (3 mM), in the presence of
common polyoxygenated buffer components (300 mM)
Similar to nisin A, there are significant spectral changes in the nisin Z spectra depending
on the buffer component present in aqueous solution. With the addition of the phosphatecontaining buffer components, there are significant differences in the observed spectral
changes depending on the phosphate species, with the K2HPO4 greatly shielding the
amide N-H of Dha5, moving upfield by 0.142 ppm in comparison to an upfield movement
of 0.021 ppm in the presence of NaH2PO4, while in both cases there is a slight upfield
movement of the N-H amide of Leu6 of 0.073 ppm and 0.013 ppm, respectively. In
comparison to nisin A in the presence of polyoxygenated buffer components, there is a
very similar trend for nisin Z. Like nisin A and Z after the addition of common salts there
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are significant differences observed, with all polyoxygenated species interacting with the
A-ring AAs in solution.
Although there have been interesting spectral results observed in the presence of
polyoxygenated species, one of the limitations of 1H NMR spectroscopy is the complexity
of the proton spectra due to spectral overlap in both the aliphatic and amide N-H regions.
In an attempt to overcome this issue, 2D-TOCSY (Total Correlation Spectroscopy) was
employed, in order to try to resolve the overlapping proton resonance signals by bringing
them into a second dimension.224 The 2D-TOCSY NMR technique is a useful tool in the
identification and examination of effects on individual amino acid residues within
peptides, as described in Section 2.4.10.225,226
The TOCSY NMR technique was used to examine the effects of K2HPO4 on individual
AA residues contained within nisin Z (Figure 85).
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Figure 85: TOCSY NMR spectrum of nisin Z (blue) and in the presence of 300 mM K2HPO4 (H2PO4 species-~89%) (red) in 10% D2O:
H2O at 25oC
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In comparison to nisin Z alone (blue), in the presence of the phosphate (red) there are
slight upfield shifts in the A-ring which could be an indication of possible
conformational changes as a result of interactions with the phosphate in solution. The
Dha5 N-H shows the largest change becoming less deshielded, which was also
observed during the 1H NMR study. An upfield shift movement of the Leu6 N-H
amide was also seen. However, shown in the TOCSY spectrum (Figure 85) the sidechain methyl group of the isopropyl also moves upfield becoming more shielded. This
may be an indication of binding and/or interactions of the phosphate ion with the nisin
A-ring in solution, which could have an impact on the antimicrobial activity and the
binding to the pyrophosphate of the lipid II. There are also changes to a number of the
aliphatic resonance signals, corresponding to the AA side-chains. This could be also
an indication of changes to the solution conformation of nisin Z; further study is
required using NMR and CD spectroscopy to assess the conformational changes in the
presence of polyoxygenated species in solution.
To further investigate the effect of the sulfonic acid-containing biological buffer
components, the 2D-TOCSY NMR was also conducted for nisin Z in the presence of
HEPES buffer shown in Figure 86.
It can be seen that there are upfield shifts in the N-H region with the largest being for
Dha5, similar again to what was seen for nisin Z in the presence of K2HPO4. Based
on both the 1H and TOCSY NMR spectra of nisin Z there is an indication that the
HEPES component of biological buffers can bind and interact with nisin.
From the 1H and TOCSY NMR studies, the nature of how the polyoxygenated species
interact with both nisin A and Z in solution is not inherently clear. However, it is clear
for both nisin A and Z, that these species in solution seem to selectively interact with
the A-ring region, which is associated with binding lipid II.
If there was a direct interaction between the negative oxygens of the buffer
components with any of the amide N-Hs, it would be expected that they would display
a deshielding in the NMR spectra. The deshielding of the amide N-H of Dha5, Abu8
and Gly10 were observed nisin in the presence of lipid II in DMSO-d6, reported by
Breukink.98 Further study is required to examine the nature of the interactions, by 1H15

N HSQC, in aqueous solution to compare with the reported literature.
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Figure 86: TOCSY NMR spectrum of nisin Z (blue) and in the presence of 300 mM HEPES (red) in 10% D2O: H2O at 25oC at pH 3.4
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Circular Dichroism (CD) studies of nisin A and Z
CD spectroscopy is widely used to study the solution conformations of peptides and
proteins.227 The studies reported here were undertaken in the Centre for Synthesis and
Chemical Biology (CSCB) in UCD; the spectra were collected at 190-260 nm allowing
for examination of any changes in the secondary structure of nisin.227 The CD data
which is presented has been analysed using the CD Tool software, which was supplied
by Birkbeck, University of London.228 All CD spectra were converted into molar
ellipticity (molar delta epsilon), which is the commonly used units of CD
spectroscopy, and is required for compatibility with the currently published CD
analyses of nisin.229
The CD studies include similar ionic strength studies to those conducted using 1H and
1

H-15N HSQC NMR spectroscopy. From the outset, there were significant issues

acquiring CD spectra, due to solubility of nisin in solution, so the concentration of the
samples was decreased from 3 mM to 0.3 mM. This method allows for a comparison
with the NMR experiments described in section 4.2, as changes in the CD spectrum
of nisin A or Z could be an indication of conformational changes attributed to the ionic
strength and/or salt composition. Collection of nisin CD spectra is difficult due to the
lack of aromatic AA residues, i.e. Phe, Trp and Tyr. Figure 87 shows the CD spectrum
of nisin A showing peaks at 205 and 209 nm.
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Figure 87: CD spectrum of 0.3 mM nisin A in H2O at 25oC
Also, the CD analysis of nisin Z (Figure 88) showed a peak at 210 nm. It is not known
why nisin A is negative and nisin Z is positive as all instrument settings were identical
in both cases. All of the CD spectra for nisin A and Z, with increasing ionic strength
on addition of salts, were studied for comparison with the pure samples, in order to
observe any changes.
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Figure 88: CD spectrum of 0.3 mM nisin Z in H2O at 25oC
Examples of all CD spectra acquired for nisin A and Z, after the addition of 30 mM of
different salts, can be seen in the attached appendices.
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Nisin A
NaCl
KCl
LiCl
TBAC
MgCl2

Figure 89: CD spectrum overlay of nisin A in H2O and after addition of chloride
salts (30 mM)
After the addition of a variety of chloride salts, there are noticeable differences in the
CD spectrum for nisin A (Figure 89). Interestingly, not all of the experiments
displayed changes: for example, in the presence of the KCl salt the CD spectrum is
identical to that of the pure nisin A. The largest change in the CD spectra was after the
addition of TBAC which showed a significant change, in comparison to pure nisin A
(Figure 89). At short wavelength (λ), there is a very obvious difference in the CD
spectra between the TBAC and the MgCl2, but it is also notable that the metal ions
Na+ and Li+ show differently from K+ and Mg2+ above 220 nm.
The CD spectra, like NMR spectra, also showed that the nisin A spectral changes are
dependant on the identity of the salt, as there are different spectral changes in the nisin
A CD spectrum. This again shows that interactions between the salt and nisin may
cause a change in the overall solution conformation, as indicated by the observed
differences in the CD spectra. As ionic strength in all cases remains constant, the
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differences observed are due to the type of salt, nature of the ions and the nisin form
present in aqueous solution.
Following on from the CD analyses of nisin A, a similar study was conducted to assess
the effect of the presence of the chloride salts on nisin Z in solution, shown in Figure
90. When compared to nisin A (Figure 89) there are significant differences based on
the addition of salts.

Nisin Z
NaCl
KCl
LiCl
LiI

TBAC

Figure 90: CD spectrum overlay of nisin Z in H2O and after addition of chloride
salts (30 mM)
Although the spectra are inverted in comparison to nisin A, the CD spectra of nisin Z
in the presence of the other chloride salts did not show significant spectral changes.
The TBAC which showed a significant change in the CD spectrum of nisin A, showed
little or no change for nisin Z. Again, at λ > 220 nm, Na+/Li+ show differently from
K+ ion in solution.
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There were significant issues encountered while collecting the CD data, with the
absence of the nisin peaks on duplicate samples. So further optimisation is required to
ensure consistency and reproducibility of all of the studies. All the CD spectra of both
nisin A and Z in the presence of each salt are available in the Appendices, as detailed
in Table 31.
Salts included in study
KCl
LiCl
MgCl2
Tetra-butylammonium chloride
NaBr
KBr
LiBr
Tetrabutylammonium bromide
NaI
Tetraethylammonium perchlorate
Tetrabutylammonium
tetrafluoroborate
Tetrabutylammonium
hexafluorophosphate

Appendix
Nisin A
Appendix 55
Appendix 57
Appendix 59
Appendix 61
Appendix 63
Appendix 65
Appendix 67
Appendix 69
Appendix 71
Appendix 73

Nisin Z
Appendix 56
Appendix 58
Appendix 60
Appendix 62
Appendix 64
Appendix 66
Appendix 68
Appendix 70
Appendix 72
Appendix 74

Appendix 75

Appendix 76

Appendix 77

Appendix 78

Table 31: Organic and inorganic salts included in ionic strength CD study of nisin
A and nisin Z

Comparison of 1H NMR and CD spectral changes
Both 1H NMR and CD spectral analyses have shown that nisin A and Z interact
differently with salts, depending on their composition. During the 1H NMR studies,
there were large changes associated with the amide N-H of the Dha5 in both nisin A
and Z after addition of 300 mM TBAC, but by CD analyses, there is little or no spectral
change for nisin Z in the presence of TBAC. There is a similar observation for nisin
Z, in which the largest change in the CD spectrum was in the presence of KCl which
showed no change in the CD spectrum of nisin A. In both cases the 1H NMR studies
show the amide N-H of Dha5 moved upfield by +0.137 ppm and +0.153 ppm for nisin
A and Z, respectively, as well as chemical shift changes involving Leu6 and a change
in the appearance of the Dha33 C-H vinyl protons. So, it would have been expected
that there would be CD spectral changes for both nisin A and Z in the presence of KCl
and TBAC in solution.
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Similarly, nisin Z showed very little change to the addition of chloride salts while nisin
A showed significant changes. It is clear from the nisin A studies that each salt
demonstrated a different effect on nisin A in solution, but the CD studies of nisin Z
need to be optimised further.

Chapter Conclusions
The NMR spectroscopic studies of both nisin A and Z have shown very interesting
results as there are spectral differences depending on the identity of the salt used: each
salt has shown slightly different chemical shift changes for nisin A and Z in the amide
N-H region of the 1H NMR spectra. It is not purely an overall ionic strength effect,
since the BF4- and PF6- anions showed no changes in the 1H NMR spectra, for either
nisin A or nisin Z. It was also determined that nisin does not participate in
intermolecular H-bonding and so is in its monomeric form within the studied
concentration range. Therefore, the observed amide N-H chemical shift changes are
likely due to disruption of intramolecular H-bonding, which may indicate a
conformational change, the degree of which is dependent on the salt composition (i.e.
the nature of the cations and anions present in solution) and its concentration.
Following on from the 1H NMR studies, 1H-15N HSQC was employed to study more
closely the added salt effects on the amide N-H of individual AAs on both nisin A and
Z. Although these studies where limited to 150 mM of salt, the amide N-H of Dha5,
Abu8, Gly10 and Dha33 showed the biggest upfield movement in the presence of the
added salts. The changes in the observed chemical shifts of some AA side-chains
indicates a change in their local environment and possible local conformational
changes in the presence of a particular salt species in solution.
In the presence of common polyoxygenated buffer components there were some
chemical shift changes mainly attributed to the A and B-ring region of nisin A and Z,
which were observed by tracking of the amide N-Hs of the Dha5 and Leu6 residues.
These buffer components all contain a polyoxygenated functional group, i.e. a
phosphate, sulfonic acid or perchlorate, which may be the feature interacting with the
A- and B-rings. In the presence of TEA perchlorate, the amide N-H of Dha5 showed
significant shielding, moving upfield by 0.220 ppm and 0.225 ppm for nisin A and Z,
respectively. In all cases there are different changes observed depending on the
polyoxygenated species present in solution. The interaction of the polyoxygenated
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species in solution may cause a change in the A-ring conformation, potentially
affecting its biological activity. As these interactions involve the A-ring at the Nterminal end of the peptide, the buffer components could compete in binding with the
pyrophosphate moiety of Lipid II.
The CD analysis shows that any spectral changes are very dependent on the type of
salt and ions present in solution, and also shows that nisin A and Z do not show the
same changes in response to the same environment. The changes appear to be due to
the salt composition rather than the overall ionic strength of the solution, although in
the case of nisin Z, only KCl showed any significant effect in CD analysis. For nisin
A, each of the chloride salts had a different effect, except for KCl which was identical
to the pure nisin A CD spectrum.
For salts which showed large changes in the 1H NMR spectra - for example the amide
N-H of Dha5, Leu6 and Gly10 for nisin A - they also showed changes in the CD
spectrum. It is interesting that nisin Z in the CD studies showed very little change on
addition of different salts, especially since there were some significant changes
observed during the NMR studies. For example, nisin Z in the presence TBAC showed
changes in the NMR chemical shifts of the amide N-H of Dha5, Leu6 and Gly10 but
no changes were seen in the CD spectra, except for KCl, but even its spectral change
was not as pronounced as what was seen for nisin A. Both nisin A and Z showed
changes in the CD spectrum in the presence of TBABr (Appendix 60 and 61), which
by 1H NMR also showed significant chemical shift changes in the amide N-H region.
Further optimisation of the CD acquisition method is required to ensure the spectral
changes, or lack of change, are correct and reproducible.
As the two derivatives of nisin (A and Z) interact and behave differently in aqueous
solution, they cannot be used interchangeably. It matters not only what type of nisin
is present, but also the pH, the salts and buffer components in the media.
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Future NMR and CD studies of nisin A and Z
Although there are spectral differences found between nisin A and Z in the presence
of different salts, the nature and significance of these interactions are not known. The
changes in the amide N-H chemical shift, and also changes in the CD spectra, indicate
that a change in the solution conformation needs to be investigated. As all of the NMR
studies conducted within this chapter have been in the pH 3-4 range, the studies should
be expanded to study the interactions of nisin A and Z in the presence of salts and
polyoxygenated species at closer to pH 7.0. There are limitations in terms of solubility,
which lowering the nisin and additive concentration may overcome, but would require
in longer acquisition times for both NMR and CD spectra. This would allow for
comparison and investigation of the behaviour of nisin A and Z at physiological pH,
which would be more applicable to therapeutic applications and biological assays.
Further studies should be carried out using both 2D-TOCSY and nOesy (nuclear
Overhauser Enhancement spectroscopy) to investigate in detail the conformational
changes and the specific interactions involving the AA side-chains. 2D-nOesy NMR
was used during this research but further optimisation of the NMR method, including
duration of the pulse and relaxation are required, as these proved difficult due to the
experiment being conducted in aqueous solution. The use of nOe NMR techniques
may give further insight into the exact conformational changes, by irradiation of the
protons in side-chains and observing the through-space coupling and interaction rather
than through bonds to the closest AA residue. This would allow the use of the
determined nOe constraints to model the solution conformations of nisin A and Z, in
the presence of both salts and polyoxygenated species. It would also allow for the
study of the extent and strength of any binding, possibly helping to determine the
nature of the observed interactions.230
In addition, in-depth conformational studies of both nisin A and Z at varying pH
should be conducted, using 2D-TOCSY, nOe NMR and CD spectroscopy. This would
allow a study of the conformational stability of both nisin A and Z in aqueous solution,
which may shed some light on the decline in nisin solubility at physiological pH. Use
of NMR and analytical HPLC, in the presence of salts or additives, would allow an
examination of the decrease or increase in the rate of decomposition of either nisin A
or Z in aqueous solution over time.
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The lipid II molecule within the bacterial cell wall contains a pyrophosphate moiety
to which nisin binds (see section 1.3.2.). Using the commercially available diethyl acid
pyrophosphate (Figure 91) as a model for the lipid II molecule could allow for further
study in relation to binding the nisin A- and B-ring region. This would involve an
investigation of possible interactions and also conformational changes of nisin (A and
Z), as a result of the pyrophosphate of the lipid II binding to either nisin A or Z. For
both the lipid II and the diethyl acid pyrophosphate (Figure 91), although the exact
pKa values of the pyrophosphate in lipid II or diethyl acid pyrophosphate are not
known, it is highly likely that both are fully deprotonated at physiological pH. (The
full structure of the lipid II molecule can be seen in section 1.3.2.)
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Figure 91: Structure of lipid II highlighting the pyrophosphate moiety and its
model compound, diethyl acid pyrophosphate
It would also be beneficial to study both nisin A and Z at pH 7 with a reduced
concentration of lipid II, phosphates (including diethyl acid pyrophosphate) and
polyoxygenated buffer components, to study their binding affinity to both nisin A and
Z. This would allow for competitive binding assays to be conducted, to determine if
the presence of these additives completely inhibits or displaces the lipid II molecule.
It is extremely important in terms of assessing biological activity, and potential
interactions of these molecules with nisin, and ultimately assess if these possible
interactions could significantly reduce/affect nisin’s measured biological activity in a
range of assays.
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Chapter V
pH Studies of Nisin A and Z by NMR
Spectroscopy
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5.0 Introduction
In the previous chapter all of the NMR spectroscopic studies were conducted in a pH
range of 3-4. It is also important to study the effect of a change of pH on nisin,
especially as nisin as used usually at a pH between 6.5 and 7.5. Therefore, NMR
spectroscopy was used to study both nisin A and Z at different pH values, due to its
sensitivity to the changes in the chemical environment. Both 1H and 2D-TOCSY NMR
techniques were used to study the effect of changing the pH of the aqueous solution,
in attempt to study the specific effects of pH on individual AA residues with either
nisin A or Z.
The following chapter describes the studies of nisin A and Z in different pH
environments. Firstly, both nisin derivatives were studied in a pH range of ~3.0-7.7,
to investigate any spectral changes based on the pH of the solution. As previously
stated, the solubility of both nisin A and Z dramatically drops above pH 6.231 The cause
of the change in the solubility is of significant interest, especially in the context of
utilizing nisin as a future therapeutic treatment. An important question is: does any
change in the solution pH affect the conformation of the nisin peptide? So, studying
both nisin A and Z in different pH environments, to investigate the effects on specific
AAs or regions of nisin is paramount, especially as published CD studies have reported
a conformational change as a result of changing the solution pH,179 possibly due to the
imidazole side-chain(s) of the His residue(s) going from protonated to neutral.

Effect of pH on 1H NMR spectra of nisin A and Z in aqueous solution
The studies were all carried out in a similar fashion to those described in Chapter III,
that is in 10% D2O: H2O, with a reference tube containing 1% DSS in D2O external to
the nisin sample. As the solubility of nisin is reported to significantly diminish at pH
~6 and above, the concentration of nisin used was lowered, from 3 mM to 0.5 mM, in
an attempt to prevent the likely precipitation of the peptide and resistant distortion of
the observed NMR resonances. The pH values of the 0.5 mM nisin-containing
solutions were adjusted using HCl or NaOH (0.1 M), to obtain the desired pH for
analyses. Each NMR experiment was conducted at 25oC, with the residual water
(HOD) peak being suppressed using an excitation sculpting routine.232
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Figure 92: 1H NMR spectra of nisin A (0.5 mM) in 10% D2O: H2O at pH 7.7 (top),
6.0 and 2.9 at 25oC
Figure 92 shows the 1H NMR spectrum of nisin A at three different solution pH values
(7.7, 6.0 and 2.9), and it is immediately obvious that there are significant differences
between the spectra. Adjusting the pH has prompted a significant change to the local
chemical environment of the Dha33 at pH 6.0 and above. The resonance signal for the
two vinyl protons of Dha33 with a small spacing of only 0.01 ppm at pH 2.9, has
increased significantly to 0.09 ppm at pH 7.7, resembling the spacing seen for signal
for the Dha5 residue located within the nisin A-ring. All of the amide N-H resonance
signals also disappear at the higher pH values (Figure 92). Showing that the N-H’s
may be exchanging rapidly at higher pH, with only the C-H resonance signals visible,
it is noticeable that the effect is similar to complete exchange with D2O (see Figure
96, of nisin in 10% D2O versus nisin in 100% D2O).
This could be due to the solubility of the peptide in aqueous solution at pH 6 and
above, as solutions at higher pH values were slightly cloudy. However, due to the
clear resolution of the proton resonances in Figure 92, it is more likely that the change
in the solution pH caused an increase in the rate of hydrogen(protium)-deuterium
exchange.
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It is reported that at higher pH values, the D (2H) in D2O-containing solutions
exchanges more rapidly with the N-H amide protons; for example, the amide N-Hs of
some AAs, where the exchange is ~3 minutes at low pH (pH 3.0), while this is
significantly decreased to ~6 ms at pH 7.233 This could explain the disappearance of
the amide N-H protons in the pH 7.7 spectrum.
Importantly, the C-H protons of the imidazole rings of the histidine residues present
in nisin A (His27 and His31) show the largest chemical shift changes, with the C2
protons of His27 and 31 moving upfield (shift) by 0.86 ppm (Figure 92). This change
in the chemical shift is likely due to the deprotonation of the imidazolium ion to form
an imidazole, its conjugate base (Figure 93).

Figure 93: pH-dependant equilibrium of the imidazolium ion to form imidazole
The change in the appearance of the vinyl protons of Dha33 as the pH of the aqueous
solution increases is very interesting, which may be a result of significant changes in
the solution conformation of the nisin tail region. Since His27 and His31 are close to
Dha33, their deprotonation could impact the local conformation of the Dha33 residue,
which now resembles the appearance of the Dha5 residue in the 1H NMR spectrum.
Could this change in the local environment of Dha33 be responsible for the reported
loss in solubility, stability and activity of nisin A and Z at physiological pH? The
solubility drop of nisin A at physiological pH is most likely due to the overall change/
loss in the polarity of the peptide in solution, due to the deprotonation of the two
histidine residues (reduction of two positive charges).
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Figure 94: 1H NMR spectra of nisin Z (0.5 mM) in different pH environments (pH 9.0, 7.0, 5.0 and 2.0) in 10% D2O/H2O @ 25oC
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A pH titration (pH 2.0-9.0) was also conducted for nisin Z (Figure 94). As was seen
previously for nisin A there is a similar change in the resonance pattern observed for
the two vinyl protons of the Dha33 residue, but what is apparent is that this is a gradual
change. As the pH of the solution increases to physiological pH and beyond, the effect
and change of the chemical environment is more pronounced. There are negligible
changes in the chemical shifts, or appearance, of the signals for the vinyl protons of
Dha5 or Dhb2 residues. The changes seem to be isolated to the C-terminal tail region,
of both nisin A and Z, with not only a change in appearance of the vinyl protons of
Dha33 but also a slight deshielding, with an overall movement downfield.

Determination of the pKa values of the imidazole side-chains of the
histidine residues of nisin A and Z
Following on from the observed changes in the 1H NMR spectra for both nisin A and
Z as the pH of the solution increases, it is possible that the histidine residues play a
key role in the changes observed for Dha33. For nisin A this change is seen at pH 6
and above, and for nisin Z the changes are seen at pH 5 and above. These observations
further indicate that the two forms of nisin do not act in an identical manner. The
observed changes reside in the pH range that the pKa of the imidazole side-chains of
the histidines may lie.187
Although it has been proposed that the pKa of the histidine side-chain may lie within
this range, it has never been measured accurately. Therefore, the determination of their
relevant pKa values may increase the understanding of the sudden decline in solubility
and stability of nisin at pH 6 and above. The determination of the pKa values could
also shed some light on the exact nisin state in different pH environments, which is
very important as nisin is used as a food preservative in a wide variety of different
food products, including cheeses, canned food, juices and meat products. These food
types have different pH environments ranging from orange juice at pH 3.3, up to meat
and dairy products which can be up to pH 7.0.234 Therefore, the pH of the food system
is likely to have a significant effect on the biological activity and thus the effectiveness
of nisin as a food preservative, as well any potential application in human and
veterinary medicine, with the bloodstream pH being ~7.4.
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The determination of pKa values for side-chain protons, contained within peptides and
proteins is extremely important, especially for the study of conformational stability
and potential intramolecular interactions between AA residues.235 This is especially
true for histidine residues, which are described as one of the most active and versatile
members that play multiple roles in protein-protein interactions.236 The side-chain
imidazole can be involved in a variety of different interactions, which include: (i)
cation-π interactions, in which the imidazole acts as the aromatic π-motif in its neutral
form, or plays the cationic role in the protonated imidazolium form (Figure 93); (ii) ππ stacking interactions between histidine and other aromatic amino acids.237,236
To accurately determine the pKa values of the histidine side-chain, present in both
nisin A. Using the changes in the chemical shift of both the imidazole C2 and C4
protons were measured as a function of the pH of the solution (Figure 95), using more
pH data points than employed in the initial studies of Figures 92 and 94.238
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Figure 95: Nisin A (0.5 mM) 1H NMR pH titration at pH 2.0-8.3 (10% D2O/H2O @ 25oC)
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Figure 95 shows the pH titration for nisin A between pH 2.0 and 8.3. As expected,
there is a change in the observed resonance signal corresponding to Dha33. The most
dramatic change occurs at ~pH 6 when the signal shows baseline resolution. Also, as
the solution pH is increased the peaks for the C2 and the C4 protons of the imidazole
rings of His27 and His31 move upfield, due to the deprotonation of the imidazolium
ion.
The pH titration above was conducted in 10% D2O/ H2O at 25oC and although there
are significant pH-dependant chemical shift changes, they proved to be quite difficult
to track, due to the crowded amide N-H region. So, in order to only observe the desired
NMR resonance signals the sample was prepared in pure D2O (Figure 96).

Figure 96: 1H NMR spectral comparison of nisin A in pure D2O and 10% D2O/
H2O
The change to pure D2O allows for complete hydrogen to deuterium exchange of the
amide N-Hs of the peptide backbone to occur, leading to the disappearance of these
peaks in the 1H NMR spectra (Figure 96). This allowed for convenient tracking and
observation of changes to the chemical shifts of the relevant imidazole C-H protons,
which are resolved from each other as seen in Figure 96.239
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Deuterium Isotope Effect on pH measurements
As the examination and determination of the pKa of the histidine side-chain was
studied in neat D2O solutions, the effect of the deuterium isotope needs to be taken
into account. The presence of deuterium gives the heavy water slightly different
properties to its hydrogen counterpart, which impacts on the measurement of pH in
deuterium oxide solutions.240 The differences in the measured pH in both solutions
stems from the variation in the auto-ionisation constant (Kw) of H2O and D2O at 25oC,
in which the deprotonation forms a hydroxide ion due to its amphiprotic nature.241, 242
pH + pOH = 14.000

Eqn 1

For H2O, pKwH = 13.995
For D2O, pKwD = 14.951
Since pH = ½ pKw
∴ neutral pH is different by 0.47(8)
i.e.

14.951
2

−

13.995
2

= 0.47(8)

This gives rise to a separate pD scale when measuring the pH/D of a solution in heavy
water. For our pKa determinations the Gross–Butler–Purlee theory was used, based on
the different activities of the H+ and D+ ions. So, if using a pH meter calibrated using
pH buffers in H2O, there is a simple relationship to correlate pH to pD.243,244
pD = meter reading + 0.44

Eqn 2

So, for the pD NMR titrations to determine the pKa of the histidine side-chain, the
results obtained will take into account the effect of the deuterium isotope, for the
conversion of pD to pH, i.e. pH = pD – 0.44, in order to correlate the pKa in D2O to
its H2O counterpart.

Effect of Ionic Strength on pKa value
As the pD NMR titrations of nisin A and Z will be used to determine the specific pKa
of each imidazole of the histidine side-chains, the ionic strength of the aqueous
solution is also of paramount importance. Without taking the ionic strength of the
aqueous solution into account, the results would be reported as a ‘practical’ or
‘conditional’ pKa, denoted as pKa′.243 This is defined within the Debye-Hückel theory,
in which solutions that contain ionic solutes do not behave ideally.245 The presence of
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ionic species in solution can affect the pKa. In the case of acetic acid, the pKa is
lowered due to the stabilisation of the charged species resulting from the proton
dissociation. Conversely, for acids such as Et3N+H, pyridinium or imidazolium, the
protonated nitrogen is favoured and stabilised by the ionic species in solution, and so
is more difficult to deprotonate, thus increasing the pKa.243,246 The ionic strength can
be calculated by the summation shown in equation 3, where ci is the concentration of
each ion type and z is its charge.247
1

I = ∑(𝑐𝑐𝑖𝑖 𝑧𝑧 2 )

Eqn 3

2

Taking this summation into account, for simple salts such as NaCl, KCl, etc., their
molar concentration is equal to the ionic strength of the solution. To account for the
ionic effect on pKa, a modification of the Debye-Hückel equation is used, which takes
into account the ionic strength, charge type and temperature of the experiment.248
Equation 4 does not include temperature explicitly, with the contains value varying
with temperature (A is a constant at a particular temperature, and is 0.512 at 25oC).
Eqn 4

𝑝𝑝𝑝𝑝𝑎𝑎 = +

𝐴𝐴𝑧𝑧 2 √𝐼𝐼

(1+ √𝐼𝐼)

− 0.1𝑧𝑧 2 𝐼𝐼

The pD NMR titrations, which follow in this chapter, were conducted using a 0.5 mM
solution of compound in pure D2O, with DSS in D2O in a reference tube separate to
the sample, and in the presence of NaCl (50 mM) in order to keep the ionic strength
of the solutions constant, at 25oC. Using the described sample preparation, the ionic
strength correction can be determined to calculate/ convert to the thermodynamic pKa,
using equation 4.
𝑝𝑝𝑝𝑝𝑎𝑎 = +

(0.512)12 √0.050
�1 + √0.050�
=+

− (0.1)(12 )(0.050)

0.114(4)
− 0.0050
1.223(6)

= +0.0934 − 0.0050
= +0.088(4)
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As the ionic strength effect on pyridinium- and imidazolium-type acids is known to
increase the pKa, the correction of 0.088(4) is subtracted from the pKa′ to obtain the
thermodynamic pKa at 25oC and zero ionic strength.241
1

H NMR pD titration of imidazole to determine its pKa

A validation of the described published methods of utilising NMR spectroscopy to
determine specific pKa values is desirable, especially for protons contained within
peptides and proteins can be difficult to determine using conventional titration
techniques, due to their complex nature. 1H NMR chemical shifts are exquisitely
sensitive to local ionisation events and serve as excellent reporters in pH titrations,
and so are widely utilised.249,250 The side-chain of histidine contains an imidazole
moiety with the chemical shift movements in each case comparable to those of His
residues in nisin A and Z. So, imidazole itself was studied to validate the use of NMR
spectroscopy to determine the pKa of the side-chains of the histidine residues of nisin
A and Z. The acid dissociation constant for the imidazolium ion was determined in
deuterium oxide (D2O) using a 0.5 mM solution of imidazole, in 50 mM NaCl at 25oC.
The NMR titration was performed using individual NMR samples for each different
pD measurement in the experiment, to ensure that a consistent concentration of analyte
is present among samples throughout the pD titration.
The 1H NMR spectral stack of imidazole in pure D2O at pD 2.34 and 9.19 is presented
in Figure 97, highlighting the upfield movement of both the C2 and C4 protons as a
function of the increasing pD of the solution.

160

Figure 97: 1H NMR spectral stack of imidazole pD 9.19 (top) and 2.34
The data obtained from the pD NMR titration of imidazole was used to generate the
titration curves shown in Figure 98, by plotting the pD of the each NMR tube sample
versus the 1H chemical shift of both the C2 and C4 protons of the imidazolium/
imidazole ring.

Observed Chemical shift (ppm)

pD Titration Curve
8.8000
8.6000
8.4000
8.2000
8.0000
7.8000
7.6000
7.4000
7.2000
7.0000

C2 proton
C4 proton

1.90

3.90

5.90

7.90

9.90

pD

Figure 98: 1H NMR pD titration curve for the C2 and C4 protons of Imidazole
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Table 32 shows the pD-dependant NMR chemical shifts of the imidazole C4 proton.
The ratio of protonated to deprotonated imidazole species in solution are also
presented as pKa, based on each proton’s chemical shift, in acidic or basic aqueous
media. The XB and XBH+ are determined by the ratio of the chemical shift of the proton
in the most acidic solution relative to its chemical shift in base, with the pKa calculated
using the Henderson-Hasselbalch equation.
Measured
pD

Chemical Shift of
Proton (ppm)

(Deprotonated) (Protonated)
[XB]
[XBH+]

2.34
7.4733
~0
~1
2.95
7.4712
0.006
0.994
3.32
7.4736
0.000
1.000
3.61
7.4721
0.003
0.997
3.99
7.4731
0.001
0.999
4.20
7.4730
0.001
0.999
4.53
7.4730
0.001
0.999
4.70
7.4737
0.000
1.000
5.12
7.4719
0.004
0.996
5.66
7.4679
0.015
0.985
5.88
7.4669
0.018
0.982
6.28
7.4604
0.037
0.963
6.48
7.4499
0.067
0.933
6.95
7.4215
0.148
0.852
7.00
7.4212
0.149
0.851
7.51
7.3461
0.364
0.636
7.80
7.2836
0.542
0.458
8.20
7.1943
0.797
0.203
8.39
7.1868
0.819
0.181
8.87
7.1464
0.934
0.066
9.19
7.1234
~1
~0
Table 32: 1H NMR pD titration monitoring the C4 proton of imidazole

pKa
N/A
(5.17)
(5.17)
(6.07)
(7.23)
(7.27)
(7.60)
(7.62)
(7.52)
(7.46)
(7.61)
(7.70)
(7.62)
(7.71)
7.76
7.75
7.73
7.61
7.73
7.72
N/A

The change in the observed chemical shift of the C2 proton was also used to determine
the pKa′ of the imidazolium N-H. The change in the proton chemical shift was used to
determine the pKa using the Henderson-Hasselbalch equation, shown in equation 5
(below), where the chemical shift relative to the most acidic and basic solutions were
used to determine the ratio of protonated and deprotonated species in solution to
calculate the imidazole pKa.
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pKa = 𝑝𝑝𝑝𝑝 + log �

Eqn 5

𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠

�

For example the imidazole solution at pD 6.95, the imidazole pKa can be calculated
for the solution, using equation 5. At this solution pD is shows that the imidazole is
mainly in its protonated imidazolium form (~85%).
0.852

pKa = 6.95 + log �

0.148

�

pKa = 6.95 + log(5.756)
pKa = 7.71

The determined pKa′ in D2O, based on the chemical shift changes of each proton are
in close agreement. Shown in Table 33 are the pKa′ and pKa values of the imidazolium
N-H in both D2O and H2O media. These values were obtained using the calculated
ionic strength and deuterium isotope effect on pH and pKa, as discussed in Section
5.2.1 and 5.2.2.
As the experiment was conducted in pure D2O, the determined pKa′ corresponds to the
conditional pKa′ in NaCl 50 mM. So, for the thermodynamic pKa the ionic strength
effect needs to be subtracted, i.e. 0.088, to give the pKa of the imidazole at zero ionic
strength. Also shown on the right in Table 33 are the pKa′ and pKa of the imidazolium
in H2O, which is determined by subtracting the deuterium isotope effect of 0.44.
D2O
(NaCl)

Ka′

D2O
(Thermo)

Ka

H2O
(NaCl)

Ka′

H2O
(Thermo)

Ka

1.95
2.40
5.37
7.62
7.27
7.18
x10-8
x10-8
x10-8
1.86
2.29
5.13
C4
7.73
7.64
7.29
7.20
x10-8
x10-8
x10-8
Table 33: Determined pKa′ and pKa using the C2 and C4 protons of imidazole
C2

7.71

6.60
x10-8
6.31
x10-8

Following on from the pKa determination, the average Ka value for the C2 and C4
protons was taken for each different medium, then converted to determine the both
pKa′ and the thermodynamic pKa (Table 34). This shows the average pKa′ and pKa of
the imidazolium N-H to be 7.28 and 7.19, respectively.
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Average Ka
(C2 and C4 Proton)

Average
pKa

pKa′ D2O (NaCl)

1.90 x10-8

7.72

pKa D2O (Thermodynamic)

2.35 x10-8

7.63

pKa′ H2O (NaCl)

5.25 x10-8

7.28

pKa H2O (Thermodynamic)
6.46 x10-8
Table 34: Average Ka and pKa values for imidazole N-H

7.19

Imidazole

@ 25oC

1

H NMR pKa determination of imidazole side-chains of His27 and His31
of nisin A in pure D2O

In a similar fashion to the pKa determination of imidazole, a pD NMR titration of nisin
A was conducted to determine the pKa of each imidazolium N-H of the histidine sidechains. The experiment was conducted using 0.5 mM of nisin A and 50 mM NaCl in
D2O. Again, each pD data point was prepared as an individual NMR tube sample to
avoid changes in sample concentration on pH adjustment. The chemical shift of the
C2 and C4 protons of both His27 and His31, measured at different solution pD values
were used to construct the titration curves, with the pD titrations conducted in
triplicate, by performing three independent titrations. The 1H NMR pD titration of
nisin A is in Figure 99, showing the upfield movement of the C2 and C4 protons of the
His27 and His31 imidazole rings. The measurement of the pH was conducted using a
Hamilton-Spintrode pH Electrode, 180 mm x 3 mm. with a required immersion depth
of 7mm. calibrated in H2O, so conversion of the measured pH to its pD value was done
using equation 2 (pD = meter reading + 0.44) .
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Figure 99: Nisin A pD NMR titration in D2O, 50 mM NaCl (pD 2.06-8.30) at 25oC
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There is significant change to the signal for the vinyl protons of Dha33, where the two
previously overlapping vinyl protons at 5.69 ppm are resolved into two distinct
resonance signals at higher pH values (between pH 5 and 6). This shows that the
change in the solution pH has a significant affect on the local chemical environment
of the Dha33 residue.

NMR Peak position (ppm)

Nisin A 0.5 mM
His31 C4 Proton
7.35
7.3
7.25
7.2
7.15
7.1
7.05
7
6.95
6.9

0.00

2.00

4.00

6.00

8.00

10.00

pD

Figure 100: 1H NMR pD titration curve of the His31 C4 proton of nisin A
Figure 100 shows the constructed pD titration curve for the His31 residue using the
imidazole C4 proton. The basic region of the curve in typical titration experiments
would usually plateau showing the point of full deprotonation. Due to the solubility
issues associated with nisin in pH/D systems at pH 6 and higher, it proved extremely
difficult to obtain data above pD 8.7, even after reducing the concentration of the nisin
used in the NMR titration from 3 mM to 0.5 mM. Regardless of the solubility issues
encountered during the pD NMR experiments, three independent 1H NMR titrations
were conducted of nisin A which were reproducible, and in close agreement.
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Measured
pD

Chemical Shift of
Proton (ppm)

2.06
2.29
2.55
2.88
3.09
3.51
3.60
3.93
4.24
4.70
4.94
5.19
5.62
5.94
6.21
6.40
6.61
6.93
7.35
7.56
7.81
8.30

7.288
7.288
7.288
7.285
7.285
7.280
7.280
7.277
7.276
7.271
7.269
7.259
7.247
7.232
7.213
7.204
7.171
7.121
7.088
7.034
7.004
6.966

(Deprotonated) (Protonated)
[XBH+]
[XB]
~0
~0
~0
0.009
0.009
0.025
0.025
0.034
0.037
0.053
0.059
0.090
0.127
0.174
0.233
0.2609
0.3634
0.5186
0.6211
0.7888
0.8820
~1

~1
~1
~1
0.991
0.991
0.975
0.975
0.966
0.963
0.947
0.941
0.910
0.873
0.826
0.767
0.739
0.637
0.481
0.379
0.211
0.118
~0

pKa
N/A
N/A
N/A
(4.91)
(5.12)
(5.10)
(5.19)
(5.38)
(5.65)
(5.95)
(6.14)
(6.19)
(6.46)
(6.62)
6.73
6.85
6.85
6.90
7.14
6.99
6.94
NA

Table 35: pD NMR titration of imidazole C4 proton of His31 of nisin A (0.5 mM)
Table 35 shows the results of one of the NMR titrations, for the imidazole C4 proton
of His31, using the change in chemical shift to determine the ratio of protonated to
deprotonated species in solution. The pD NMR titrations were conducted in triplicate,
to obtain the average side-chain pKa for both His27 and His31 residues present in nisin
A.
These results (Table 35) show the determined pKa′ values for both the C2 and C4
protons of the imidazole ring. Using the previously discussed deuterium isotope and
ionic strength effect corrections on the determined pKa, the pKa′ and pKa are reported
for both His27 and His31, in both D2O and H2O media.
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D2O
(NaCl)

Ka′

D2O
(Thermodynamic)

Ka

H2O
(NaCl)

Ka′

H2O
(Thermodynamic)

Ka

T1

6.96

1.10 x10-7

6.87

1.35 x10-7

6.52

3.02 x10-7

6.43

3.72 x10-7

T2

6.95

1.12 x10-7

6.86

1.38 x10-7

6.51

3.09 x10-7

6.42

3.80 x10-7

T3

6.94

1.15 x10-7

6.85

1.41 x10-7

6.50

3.16 x10-7

6.41

3.89 x10-7

Average

6.95

1.12 x10-7

6.86

1.38 x10-7

6.51

3.09 x10-7

6.42

3.80 x10-7

T1

6.96

1.10 x10-7

6.87

1.35 x10-7

6.52

3.02 x10-7

6.43

3.72 x10-7

T2

6.94

1.15 x10-7

6.85

1.41 x10-7

6.50

3.16 x10-7

6.41

3.89 x10-7

T3

6.94

1.15 x10-7

6.85

1.41 x10-7

6.50

3.16 x10-7

6.41

3.89 x10-7

Average

6.95

1.13 x10-7

6.86

1.39 x10-7

6.51

3.11 x10-7

6.42

3.83 x10-7

T1

6.93

1.17 x10-7

6.84

1.45 x10-7

6.49

3.24 x10-7

6.40

3.98 x10-7

T2

6.91

1.23 x10-7

6.82

1.51 x10-7

6.47

3.39 x10-7

6.38

4.17 x10-7

T3

6.89

1.29 x10-7

6.80

1.58 x10-7

6.45

3.55 x10-7

6.36

4.37 x10-7

Average

6.91

1.23 x10-7

6.82

1.51 x10-7

6.47

3.39 x10-7

6.38

4.17 x10-7

T1

6.90

1.26 x10-7

6.81

1.55 x10-7

6.46

3.47 x10-7

6.37

4.27 x10-7

T2

6.88

1.32 x10-7

6.79

1.62 x10-7

6.44

3.63 x10-7

6.35

4.47 x10-7

T3

6.88

1.32 x10-7

6.79

1.62 x10-7

6.44

3.63 x10-7

6.35

4.467 x10-7

Average

6.89

1.30 x10-7

6.80

1.60 x10-7

6.45

3.58 x10-7

6.36

4.40 x10-7

pKa at 25oC

His27
C2

His27
C4

His31
C2

His31
C4

Table 36: Determined Ka and pKa values for His27 and His31 of nisin A at 25oC, with T1-T3 referring to the individual titration
experiments
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Table 36 shows the determined pKa values for His27 and His31 of nisin A. The
experiments were conducted in triplicate (T1, T2, T3, with the %relative stand
deviation calculated to be 2.3% RSD) and were found to be reproducible, with the
resulting pKa values in close agreement. In each case, both the C2 and C4 protons of
the imidazole ring were used in each pD titration to give the average pKa′ values. The
determined pKa′ was then converted to a Ka value to ensure that there was not an
exaggeration of errors due to the logarithmic nature of the pKa values reported. Taking
into consideration the effect of both ionic strength and deuterium on the measurement
of pKa′, using the corrections described previously in Section 4.2.1 and 4.2.2, both the
average conditional pKa′ and thermodynamic pKa values can be reported in both H2O
and D2O solution environments (Table 37).
Average Ka
(C2 and C4 Proton)

Average

pKa′ in D2O (50 mM NaCl)

1.13 x10-7

6.95

pKa in D2O (Thermodynamic)

1.39 x10-7

6.86

pKa′ in H2O (50 mM NaCl)

3.10 x10-7

6.51

pKa in H2O (Thermodynamic)

3.82 x10-7

6.42

pKa′ in D2O (50 mM NaCl)

1.26 x10-7

6.90

pKa in D2O (Thermodynamic)

1.56 x10-7

6.81

pKa′ in H2O (50 mM NaCl)

3.48 x10-7

6.46

pKa in H2O (Thermodynamic)

4.29 x10-7

6.37

Determined at 25oC

Histidine
27

Histidine
31

pKa

Table 37: Imidazolium N-H pKa′ and pKa values of His27 and 31 of nisin A
determined using their average Ka values at 25oC
The determined average pKa′ and pKa are displayed in Table 37 and are reported for
several solution environments at 25oC. Interestingly there is a difference in the
observed pKa of His27 and His31 with the conditional pKa′ values in H2O determined
to be 6.51 and 6.46, respectively. The difference in the two pKa values could be due
to interactions with the flanking AA residues, with the His27 contained in the nisin Ering and the His31 residue located in the linear tail region.
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Calculation of the side-chain imidazole N-H pKa of both His27 and
His31 of nisin A at 38oC
If nisin is to be utilised as a therapeutic agent, it is also important to estimate the pKa
of these histidine residues near the physiological temperature of 38oC. The effect of
changing the solution temperature from 25oC to 38oC can be accounted for using a
temperature correction for the imidazole. For most acids the dissociation process is
endothermic, so according to Le Châtelier's Principle as heat is applied to an
endothermic process the equilibrium is shifted to the right. Therefore, at higher
temperatures the Ka increases, subsequently lowering the pKa.251
The correction for increasing temperature of an imidazole functional group has been
stated that “for every 1oC increase in the solution temperature the pKa of an imidazole
is lowered by 0.020”.243 So a change from 25oC to the physiological temperature of
38oC, would lower the pKa of each histidine imidazole by 0.26 units (12 x 0.020 =
0.260).243
This change in temperature would also alter the effect of ionic strength on the
determined pKa′ values. The ionic strength correction can be recalculated, changing
the temperature constant from 0.512 which corresponds to 25oC to 0.524 for 38oC.243
𝑝𝑝𝑝𝑝𝑎𝑎 = −

(0.524)12 √0.050
�1 + √0.050�

=−

− (0.1)(12 )(0.05)

0.117(1)
− 0.0050
1.223(6)

= 0.095(7) − 0.0050
= -0.090

The subtraction of the ionic strength effect (-0.090) and the solution temperature effect
at 38oC (-0.260), gives an overall correction of -0.351 units. Incorporating these
corrections, the results for the imidazole pKa values of His27 and His31 in nisin A are
shown in Table 38.
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D2O
(NaCl)

Ka′

D2O
(Thermodynamic)

Ka

H2O
(NaCl)

Ka′

H2O
(Thermodynamic)

Ka

T1

6.70

1.20 x10-7

6.61

2.46 x10-7

6.26

5.50 x10-7

6.17

6.76 x10-7

T2

6.69

2.04 x10-7

6.60

2.51 x10-7

6.25

5.62 x10-7

6.16

6.92 x10-7

T3

6.68

2.09 x10-7

6.59

2.57 x10-7

6.24

5.75 x10-7

6.15

7.08 x10-7

Average

6.69

2.04 x10-7

6.60

2.51 x10-7

6.25

5.62 x10-7

6.16

6.92 x10-7

T1

6.70

1.20 x10-7

6.61

2.46 x10-7

6.26

5.50 x10-7

6.17

6.76 x10-7

T2

6.68

2.09 x10-7

6.59

2.57 x10-7

6.24

5.75 x10-7

6.15

7.08 x10-7

T3

6.68

2.09 x10-7

6.59

2.57 x10-7

6.24

5.75 x10-7

6.15

7.08 x10-7

Average

6.69

2.06 x10-7

6.60

2.53 x10-7

6.25

5.67 x10-7

6.16

6.97 x10-7

T1

6.67

2.14 x10-7

6.58

2.63 x10-7

6.23

5.89 x10-7

6.14

7.24 x10-7

T2

6.65

2.24 x10-7

6.56

2.75 x10-7

6.21

6.15 x10-7

6.12

7.59 x10-7

T3

6.63

2.34 x10-7

6.54

2.88 x10-7

6.19

6.46 x10-7

6.10

7.94 x10-7

Average

6.65

2.24 x10-7

6.56

2.76 x10-7

6.21

6.17 x10-7

6.12

7.59 x10-7

T1

6.64

2.29 x10-7

6.55

2.82 x10-7

6.20

6.31 x10-7

6.11

7.76 x10-7

T2

6.62

2.40 x10-7

6.53

2.95 x10-7

6.18

6.61 x10-7

6.09

8.13 x10-7

T3

6.62

2.40 x10-7

6.53

2.95 x10-7

6.18

6.61 x10-7

6.09

8.13 x10-7

Average

6.63

2.36 x10-7

6.54

2.91 x10-7

6.19

6.51 x10-7

6.10

8.00 x10-7

pKa at 38oC

His27
C2

His27
C4

His31
C2

His31
C4

Table 38: Calculated Ka and pKa values for the imidazolium N-H of His27 and His31 of nisin A at 38oC, with T1-T3 referring to the
individual titration experiments
171

Table 39 shows a summary of the extensive data presented for the calculated pKa
values of nisin A at 38oC.

Histidine
27

Histidine
31

Determined at 38oC

Average Ka
(C2 and C4 Proton)

Average

D2O (50 mM NaCl)

2.050 x10-7

6.69

D2O (Thermodynamic)

2.522 x10-7

6.60

H2O (50 mM NaCl)

5.646 x10-7

6.25

H2O (Thermodynamic)

6.946 x10-7

6.16

D2O (50 mM NaCl)

2.302 x10-7

6.64

D2O (Thermodynamic)

2.832 x10-7

6.55

H2O (50 mM NaCl)

6.339 x10-7

6.20

H2O (Thermodynamic)

7.799 x10-7

6.11

pKa

Table 39: Imidazole pKa′ and pKa values of His27 and 31 of nisin A, determined
using their average Ka at 38oC
It is very important to calculate the pKa of the histidine residues at near physiological
temperature, if nisin was to be used as a therapeutic agent, as the lowered pKa may
significantly impact on its stability at this elevated temperature. Table 39 shows the
calculated imidazolium N-H, pKa′ and pKa values for both His27 and His31, with the
conditional pKa′ values in H2O determined to be 6.25 and 6.20, respectively. The
comparative results of the pKa values at 25oC and 38oC are shown in Table 40.
Comparison of pKa values at 25oC and 38oC

Histidine
27

Histidine
31

Average pKa
At 25oC

Average pKa
At 38oC

pKa′ in D2O (50 mM NaCl)

6.95

6.69

pKa in D2O (Thermodynamic)

6.86

6.60

pKa′ in H2O (50 mM NaCl)

6.51

6.25

pKa in H2O (Thermodynamic)

6.42

6.16

pKa′ in D2O (50 mM NaCl)

6.90

6.64

pKa in D2O (Thermodynamic)

6.81

6.55

pKa′ in H2O (50 mM NaCl)

6.46

6.20

pKa in H2O (Thermodynamic)

6.37

6.11

Table 40: Comparison of determined pKa values of the imidazolium N-H of His27
and His 31 of nisin A at 25oC and 38oC
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In comparison to the pKa determined at 25oC, at physiological temperature the pKa of
the histidine side-chain is significantly lower at 38oC. The determined pKa′ lies within
the pH range in which nisin is known to suffer a significant decrease in aqueous
solubility, possibly due to the change in the overall polarity of the peptide above the
histidine side-chain pKa. It can be seen in Table 40 that, at physiological pH (7.4),
both histidine residues will predominantly be in the neutral form, at both temperatures.
During the pH titration studies, it was found that it was in this pH range that there is a
significant change to the signal of the Dha33 (C-H) residue in the 1H NMR spectra. In
Figure 101, for pH 2-8, the Dha33 amide N-H signal moves slightly upfield and then
subsequently disappears, while the amide N-H of the Dha5 remains constant over the
same pH range. The C-H vinyl protons of the Dha33 residue showed the biggest
change in appearance, moving downfield signifying a change in their local chemical
environment and probably its conformation. It seems that the pH changes specifically
affect one region of nisin (the tail region) but is very difficult to see any changes in
other AAs due to the disappearance of the N-H signals at higher pH values.

Figure 101: 1H NMR spectral stack of nisin A (0.5 mM) in pH range 2-8 in 10%
D2O/ H2O at 25oC
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This is the opposite to what was seen on the addition of salts, where the amide N-H of
Dha5 moved upfield while the Dha33 remained relatively stable. This change in
conformation could expose the Dha33 moiety and may promote its degradation. This
implies that the salts affect one region (A- and B-rings), while the change in pH affects
a different region (the tail region).
It has been shown that at pH values around the pKa values of the His residues, there
are significant changes to nisin A, which may compromise its stability. Since nisin is
mainly used in the food industry and many foods are stored at lower temperatures (e.g.
fridge at 4-7oC or freezers at -20oC), it is also important to investigate the changes in
the side-chain imidazolium N-H pKa value. Using the calculated temperature
correction, the pKa was calculated at a range of lower temperatures from +20 to -20oC,
and the results are in Table 41.
@
25oC

@
20oC

@
15oC

@
10oC

@
5oC

@
0oC

@
-20oC

pKa′ in D2O (50 mM NaCl)

6.95

7.05

7.15

7.25

7.35

7.45

7.85

pKa in D2O (Thermodynamic)

6.86

6.96

7.06

7.16

7.26

7.36

7.76

pKa′ in H2O (50 mM NaCl)

6.51

6.61

6.71

6.81

6.91

7.01

7.41

pKa in H2O (Thermodynamic)

6.42

6.52

6.62

6.72

6.82

6.92

7.32

pKa′ in D2O (50 mM NaCl)

6.90

7.00

7.10

7.20

7.30

7.46

7.80

pKa in D2O (Thermodynamic)

6.81

6.91

7.01

7.11

7.21

7.31

7.71

pKa′ in H2O (50 mM NaCl)

6.46

6.56

6.66

6.76

6.86

6.96

7.36

pKa in H2O (Thermodynamic)

6.37

6.47

6.67

6.67

6.77

6.87

7.27

Histidine 31

Histidine 27

Calculated pKa values at low
temperature

Table 41: Calculated pKa values of the imidazole N-H side-chain of His27 and
His31 of nisin A at low temperatures
At lower temperatures the pKa of the imidazole is increased, for example at -20oC the
pKa′ in H2O of the imidazole of His31 is increased by 0.90 units from 6.46 at 25oC to
7.36 at -20oC (freezer storage). Quite how this change would impact on nisin A’s food
preservation properties is not known as most bacteria do not grow at this temperature.
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1

H NMR pKa determination of His31 of nisin Z in neat D2O

A similar study was also conducted for nisin Z, which contains only one histidine
residue, His31 being located within the tail region of the peptide. The chemical shift
data obtained from each of the individual 1H NMR experiments at each different pD
value are presented in Table 42.
Measured
pD

Chemical Shift of
Proton (ppm)

2.00
2.30
2.70
2.80
3.10
3.48
3.60
3.90
4.30
4.64
5.10
5.30
5.44
5.90
6.10
6.50
6.60
7.07
7.40
7.69
7.8
8.30
8.70

8.615
8.613
8.611
8.610
8.612
8.609
8.607
8.606
8.598
8.598
8.589
8.577
8.584
8.505
8.483
8.439
8.483
8.175
8.058
7.005
7.005
6.966
6.928

(Deprotonated) (Protonated)
[XB]
[XBH+]
~0
0.003
0.005
0.005
0.004
0.006
0.008
0.009
0.019
0.019
0.028
0.040
0.033
0.117
0.140
0.187
0.140
0.466
0.589
0.773
0.773
0.894
~1

~1
0.997
0.995
0.995
0.996
0.994
0.992
0.991
0.981
0.981
0.972
0.960
0.967
0.883
0.860
0.813
0.860
0.534
0.410
0.227
0.226
0.106
~0

pKa
N/A
(4.86)
(5.04)
(5.10)
(5.54)
(5.69)
(5.67)
(5.93)
(6.02)
(6.36)
(6.64)
(6.68)
(6.91)
6.78
6.89
7.14
7.39
7.13
7.24
7.16
7.27
7.37
N/A

Table 42: pD NMR Titration of the His31 C2 proton of nisin Z (0.5 mM) in D2O
at 25oC
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D2O
(NaCl)

Ka′

D2O
(Thermodynamic)

Ka

H2O
(NaCl)

Ka′

H2O
(Thermodynamic)

Ka

T1

7.13

7.413 x10-8

7.04

9.120 x10-8

6.69

2.042 x10-7

6.60

2.512 x10-7

T2

7.09

8.128 x10-8

7.00

0.0000001

6.65

2.239 x10-7

6.56

2.754 x10-7

T3

6.97

1.072 x10-7

6.88

1.318 x10-7

6.53

2.951 x10-7

6.44

3.631 x10-7

Average

7.06

8.752 x10-8

6.97

1.077 x10-7

6.62

2.411 x10-7

6.53

2.966 x10-7

T1

7.08

8.318 x10-8

6.99

1.023 x10-7

6.64

2.291 x10-7

6.55

2.818 x10-7

T2

7.10

7.943 x10-8

7.01

9.772 x10-8

6.66

2.188 x10-7

6.57

2.692 x10-7

T3

6.95

1.122 x10-7

6.86

1.380 x10-7

6.51

3.090 x10-7

6.42

3.802 x10-7

7.04

9.160 x10-8

6.95

1.127 x10-7

6.60

2.523 x10-7

6.51

3.104 x10-7

T1

6.87

1.349 x10-7

6.78

1.660 x10-7

6.43

3.715 x10-7

6.34

4.571 x10-7

T2

6.83

1.479 x10-7

6.74

1.820 x10-7

6.39

4.074 x10-7

6.30

5.012 x10-7

T3

6.71

1.950 x10-7

6.62

2.398 x10-7

6.27

5.370 x10-7

6.18

6.607 x10-7

Average

6.80

1.593 x10-7

6.71

1.959 x10-7

6.36

4.386 x10-7

6.27

5.397 x10-7

T1

6.82

1.514 x10-7

6.73

1.862 x10-7

6.38

4.167 x10-7

6.29

5.129 x10-7

T2

6.84

1.445 x10-7

6.75

1.778 x10-7

6.40

3.981 x10-7

6.31

4.898 x10-7

T3

6.69

2.042 x10-7

6.60

2.512 x10-7

6.25

5.623 x10-7

6.16

6.918 x10-7

pKa at 25oC

His31
C2

His31
C4

Average
pKa at 38oC
His31
C2

His31
C4

Average
6.78
1.667 x10-7
6.69
2.051 x10-7
6.34
4.591 x10-7
6.25
5.648 x10-7
Table 43: Determined and calculated Ka and pKa values for His31 at both 25oC and 38oC of nisin Z, with T1-T3 referring to the individual
titration experiments
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The pD NMR titration of nisin Z is shown in Appendix 79, showing pH/D dependant
upfield movement of the C2 and C4 for His31, as the solution pD is changed from 2.3
to 8.7. There is also significant change to the resonance signal associated with the
vinyl C-H protons of Dha33, similarly to what was seen for nisin A. The two
previously overlapping vinyl protons at 5.69 ppm are resolved at higher pD, into two
distinct resonance signals, resembling the appearance of the Dha5. This is a possible
indication of a conformational change within the tail region of nisin, more than likely
due to the deprotonation of the imidazolium N-H of the His side-chain, with its pKa′
value in H2O determined to be 6.61. Therefore, it will substantially be in its
deprotonated neutral form at physiological pH, for pH versus 7.4 (physiological) ratio
would be ~6 B: 1 BH+.
Average Ka
(C2 and C4 Proton)

Average
pKa

pKa′ in D2O (50 mM NaCl)

8.956 x10-8

7.05

pKa in D2O (Thermodynamic)

1.102 x10-7

6.96

pKa′ in H2O (50 mM NaCl)

2.467 x10-7

6.61

pKa in H2O (Thermodynamic)

3.035 x10-7

6.52

pKa′ in D2O (50 mM NaCl)

1.630 x10-7

6.79

pKa in D2O (Thermodynamic)

2.005 x10-7

6.70

pKa′ in H2O (50 mM NaCl)

4.489 x10-7

6.35

pKa in H2O (Thermodynamic)

5.522 x10-7

6.26

Determined at 25oC

Histidine
31

Determined at 38oC
Histidine
31

Table 44: Imidazolium pKa′ and pKa value of His31 of nisin Z determined using
the average Ka at 25oC and 38oC
The determined pKa and Ka values for the His31 side-chain of nisin Z are quoted for
both 25oC and 38oC. Interestingly, the pKa′ in H2O is higher than that determined for
the His31 side-chain of nisin A, though it is not immediately clear as to why this is the
case. Could the presence of a second histidine residue (His27) in nisin A cause the
lower pKa?
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Throughout the NMR studies it is apparent that although nisin A and Z have a very
similar structure they do not behave in an identical manner. This is further confirmed
by the differences in the determined pKa values of the His31 residues (Table 45).
Determined at 25oC

Histidine
31

Nisin A

Nisin Z

pKa′ in D2O (50 mM NaCl)

6.90

7.05

pKa in D2O (Thermodynamic)

6.81

6.96

pKa′ in H2O (50 mM NaCl)

6.46

6.61

pKa in H2O (Thermodynamic)

6.37

6.52

Table 45: Comparison of determined pKa values of the imidazole side-chain of
His31 for both nisin A and Z at 25oC
There is a significant difference in the determined pKa′ in H2O of 6.61 for nisin Z
compared to 6.46 for nisin A, a difference of 0.15 units. The higher relative pKa of the
His31 in nisin Z may be responsible for the slightly higher reported solubility of nisin
Z at physiological pH.56 As for nisin A, the effect of lower temperatures on the
determined pKa values were also calculated for nisin Z, and are presented as Table 46.
@
25oC

@
20oC

@
15oC

@
10oC

@
5oC

@
0o C

@
-20oC

pKa′ in D2O (50 mM NaCl)

7.05

7.15

7.25

7.35

7.45

7.55

7.95

pKa in D2O (Thermodynamic)

6.96

7.06

7.16

7.26

7.36

7.46

7.86

pKa′ in H2O (50 mM NaCl)

6.61

6.71

6.81

6.91

7.01

7.11

7.51

pKa in H2O (Thermodynamic)

6.52

6.62

6.72

6.82

6.92

7.02

7.42

Histidine 31

Calculated pKa values at low
temperature

Table 46: Calculated pKa values of the imidazole N-H side-chain of His31 of nisin
Z at low temperatures
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Nisin-Metal Binding in physiological pH systems
As previously stated, in physiological pH systems, nisin suffers from a dramatic
decline in solubility and stability. Although its antimicrobial activity has been reported
to remain the same, the solubility and stability of nisin are pH-dependent.195,252
Therefore, methods for increasing the solubility of nisin while maintaining its solution
stability are key, if nisin is to be used in human or veterinary medicine. As determined
earlier, the pKa′ in H2O of the imidazole side-chain of His27 is 6.51 in nisin A, and
the His31 is 6.46 and 6.61 for nisin A and nisin Z, respectively. These values lie within
the region in which the solubility of nisin declines significantly. The deprotonation of
the imidazolium N-H may play an important role in the conformational stability and
solubility of nisin.
There have been reports of nisin binding metals ions such as cobalt, iron and zinc, in
attempts to increase its stability at physiological pH.253,254 Copper(II) is described as
a “histidine-binding ion”, and in the presence of nisin A and Z may complex to the
neutral imidazole side-chain of the histidine residues following deprotonation of the
imidazolium N-H between pH ~5.5 and 7.0.255 This begs the question, could the
binding of copper stabilise nisin from any pH-dependant degradation, while also
incorporating a “bioactive” antibacterial copper ion? 256
This complexation of the metal ion in solution may increase the solubility of both nisin
A and Z, and in turn increase their therapeutic potential and future applications.
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UV/vis wavelength scan (400-1000 nm) of copper(II) chloride
A 3 mM solution of copper (II) chloride at pH 6.6 (green solution) was measured using
a wavelength scan from 400-1000 nm. The green-coloured solution was expected to
absorb in the visible region of the UV-Vis spectrum, as shown in Figure 102. The free
copper in solution showed an absorbance for a d-d transition band, which can be seen
between 800 and 900 nm. To confirm that the UV-Vis band between 800 and 900 nm
is the Cu(II) ion in solution, the solution was serially diluted and as the concentration
of Cu(II) is decreased there is a corresponding decrease in the intensity of the d-d
transition band at 800-900 nm.

Figure 102: UV/Vis wavelength scans of serial dilutions of the 3 mM solution of
copper(II) chloride at pH 6.6

Nisin in the presence of copper(II) chloride
To investigate the ability of both nisin A and Z to bind Cu(II) ions, initially a 3 mM
solution of nisin A and Cu(II) chloride in a 1:1 molar ratio was prepared in 10 mL of
water (pH 4.1). The solution was then adjusted to pH 6.6 with 0.1 M NaOH. It was
noted that as the pH of the copper-containing nisin solution was increased to pH 6.6
the colour of the solution changed from pale green to light blue. This is a likely
indication of nisin binding to the Cu(II) ions. To confirm the binding, a UV-vis
wavelength scan was conducted (Figure 103) which shows a band at 550 nm. This
band was previously absent for solutions of both nisin A and copper(II) chloride alone,
at pH 6.6.
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Figure 103: UV/Vis wavelength scan of nisin A and copper(II) chloride (1:1 molar
ratio) at pH 6.6
A serial dilution of the samples was conducted, while maintaining the solution pH
value at 6.6, to ensure that the band was indeed associated with the prepared solution.
Overall, Figure 103 shows that as the concentration of nisin and copper in the sample
increases so too does the intensity of the corresponding absorbance band at 550 nm,
confirming that it is a new species present in solution, with the nisin A binding the
Cu(II) ion. The highest concentration possible in the study was a 0.3 mM solution of
nisin A, as light scattering in the UV-vis spectrometer for higher concentration
samples of nisin A was observed.
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An identical set of experiments was also conducted for nisin Z in the presence of Cu(II)
ions (Figure 104), which again shows binding of the Cu(II) ions in solution by nisin
Z.

Figure 104: UV/Vis wavelength scan of Nisin Z and copper(II) chloride (1:1
molar ratio) at pH 6.6
The 0.3 mM sample of nisin Z in the presence of copper is interesting, as the maximum
absorbance at 550 nm is more pronounced, when compared to the nisin A coppercontaining UV spectrum.
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UV-vis pH Titration of Nisin in the presence of Copper (II) ions
Both nisin A and Z bind Cu(II) ions at pH 6.6; however, the UV-Vis experiments as
outlined do not give any insight into the pH-dependant nature of the binding
interaction. In order to investigate the effect of the solution pH on the binding
capability of nisin A and Z, a UV-vis pH titration was conducted, in the pH range of
4.0-7.1.

Figure 105: UV-Vis pH titration (pH 4.0-7.1) of nisin A (0.3 mM) in the presence
of Cu(II) ions
Figure 105 shows the results, where the absorbance band at 550 nm is absent in the
spectra for the solutions with pH values below 5 but can be seen at pH 5.4. As the pH
of the solution is increased to pH 6 and above, the intensity of the absorbance band at
550 nm also increases. This shows that as the pH approaches the determined pKa
values of the two histidine residues, there is evidence of copper binding. As the
solution pH is increased to physiological (pH) the colour of the nisin solution also
changes from green to blue, another indication of copper binding.
It was seen previously that for nisin A alone, in solutions above pH 6, it usually
precipitates out of solution, due to its low solubility. However, in the presence of
Cu(II) ions in solution, there was no observed precipitate formed between pH 6.0 and
7.1 for nisin A. It may be the case that the binding of Cu(II) to the neutral imidazole(s)
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mimics the “polarity” of the imidazolium ion, thus keeping the nisin A in solution at
pH values close to, and above, the pKa value.
A similar pH titration for nisin Z was conducted in the pH range of 4.1-7.0 (Figure
106).

Figure 106: UV-Vis pH titration (pH 4.0-7.1) of nisin Z (0.3 mM) in the presence
of Cu(II) ions
Figure 106 shows that there is a slight difference with the band at 550 nm present at
pH 6.1 and above. There are differences observed between the nisin A and nisin Z pH
titrations, with nisin A binding the Cu(II) ion at pH 5.4, while the solution of nisin Z
at pH 5.5 showed little noticeable change. Nisin A contains two histidine imidazoles
to bind the Cu(II), while nisin Z only contains one, so perhaps nisin A can attain a
geometry in which both of the imidazole side-chains can bind a single Cu(II) ion. This
may be a stronger binding interaction, promoting the formation of the nisin-copper
complex. The histidine side-chain pKa values for nisin A are lower in comparison to
nisin Z, and may aid binding of the Cu(II) ions at lower pH values. Both nisin A and
nisin Z exhibit Cu(II) binding at pH 7 meaning they would both have copper bound at
physiological pH. Nisin may also help keep the Cu(II) in solution at higher pH, where
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OH- can precipitate Cu2+ as Cu(OH)2, i.e. complex mutually solubilises both nisin and
copper in solution.

Stability of the binding of copper(II) by nisin as the pH varies
The pH value of the nisin A and Cu(II) solution (1:1 ratio of 0.3 mM) was adjusted
and cycled back and forth between pH 4.0 and 6.9, using HCl and NaOH (0.1 M) to
assess the stability of the nisin A: Cu(II) interaction, after its formation at pH 6.9. The
results of this pH cycling experiment are shown in Figure 107.

Figure 107: Nisin A and copper(II), pH cycling between pH 4.0 and 6.9
As the pH of the solution was the adjusted back to pH 4.0 using 0.1 M HCl, the UVvis absorbance band at 550 nm disappeared in the spectrum. The process of cycling
the pH value of the solution between pH 4.0 and 6.9 was repeated. Each time the pH
of the solution was adjusted to pH 6.9 using 0.1 M NaOH, the absorbance band at 550
nm was present, but absent at pH 4.0.
The pH-cycling of the copper-containing nisin A solution not only confirmed again
the pH-dependant nature of the metal binding, but also that this is a reversible process.
Nisin A binds the Cu(II) ions in solution at physiological pH, but is not at pH 4.0,
showing that the presence of acid eliminates complexation. This reversible process
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could be considered as the Cu2+ and H+ competing for the histidine site(s). The nisinH+ binding equilibrium will be fast (diffusion-controlled i.e. essentially
instantaneous). The nisin-Cu2+ binding equilibrium would also be expected to be fast
(in both directions), so the overall nisin (Cu2+/H+) equilibria are expected to be rapidly
established and freely reversible.
The same pH cycling experiment was also conducted for the copper-containing nisin
Z solution, again cycling between pH 4.0 and 6.9. Figure 108 shows that nisin Z acts
in a similar way to nisin A.

Figure 108: Nisin Z and Copper(II), pH cycling between pH 4.0 and 6.9
The observed interaction and binding of the copper (II) ion has been shown not only
to be pH-dependant, but it also acts as a possible pH-dependant molecular switch.257
This is indicated by the copper binding displaying pH dependence that can alternate
between bound and unbound copper species in solution, based on the pH of the
solution.
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The exact mode of binding of copper by both nisin forms is not known from the UVvis analysis. However, the effect on the increased solubility visible at physiological
pH, of both nisin A and Z, by binding to Cu(II) is very interesting and would merit a
further in-depth investigation.
Figure 109 shows the effect of the concentration of Cu(II) in solution in relation to a
constant nisin concentration (0.3 mM) at pH 6.9. The lower Cu(II) concentration of
0.003 mM at pH 6.9 shows the light being scattered in the UV-vis spectrometer for
nisin A as it precipitates near physiological pH. However, as the concentration of
Cu(II) in solution is increased, the UV band at ~550 nm is observed, and the light
scattering is greatly reduced. A similar result was found for nisin Z (see Appendix 70).

Figure 109: Nisin A (0.3 mM) copper(II) titration at pH 6.9
For the solutions containing a copper concentration of 0.15 mM and above, at pH 6.9
there is no precipitation observed. This is very encouraging and confirms that after
binding the Cu(II) ion in solution, there is an apparent increase in the solubility of both
nisin forms (A and Z) at physiological pH.
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Chapter Conclusions
Based on the pH NMR titrations of both nisin A and Z, there were significant changes
observed for the peak at 5.6 ppm of the vinyl protons of the Dha33 residue of both
nisin species A and Z. As the pH of the solution environment was increased, a change
in appearance of this signal was observed, from an overlapping single peak to two
distinct peaks at pH ~6 and above. This could be an indication of a change in nisin’s
conformation in solution, mainly within the tail region of the peptide as few other
notable changes have been observed as a consequence of changing the pH.
The two histidine residues in nisin A, and one in nisin Z, were of interest as it was
thought that their pKa values lie within this pH region (pH 6-7). 1H NMR spectroscopy
was used to measure the pD-dependant upfield movement of the chemical shifts of
both the C2 and C4 protons of the histidine residues’ imidazole rings. The relevant
side-chain pKa′ values in H2O were determined at 25oC in 50 mM NaCl and for His
27 side-chain pKa′ value of nisin A was determined to be 6.51, while the side-chain
pKa values of His31was determined to be 6.46 and 6.61 for nisin A and nisin Z,
respectively. Interestingly the pKa value of the His31 residue in nisin Z is higher that
its nisin A counterpart. However, at physiological pH the determined pKa values show
that histidine residues would be mainly in their neutral deprotonated state.
As the tail region of nisin is directly involved in its antimicrobial mechanism of action,
the indication that there is a conformational change in this region could potentially
affect its activity. Also the deprotonation of the histidine residues is likely to be partly
responsible for the decline in the aqueous solubility, due to the overall change in the
number of charged AA residues within the nisin peptide structures, at pH values of 6
and above.
Regarding the use of nisin for therapeutic applications, if its application is for internal
use then nisin would be circulating in the bloodstream at pH ~7.4 and at 38oC, or if
for an external application the pH and temperature of the environment will differ
greatly. Therefore, it is important to also study the impact of a change in temperature
on both nisin species. As presented the pKa′ values of the histidines were determined
to be significantly lower at higher temperature, with the temperature correction
determined to be -0.26. The adjusted pKa′ value at 38oC for the His27 in nisin A was
determined to be 6.25, and for the His31 in both nisin A and Z was determined to be
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6.20 and 6.35 respectively. So, at body temperature and physiological pH the
histidines will be even more substantially in their neutral deprotonated form.
The Dha33 residue is implicated in the degradation of nisin A and Z at physiological
pH, due to its breakdown and cleavage at pH 7 and above. The Dha33 residue is most
stable at lower pH values of 3-4. From the pH studies using 1H NMR spectroscopy
there was a significant change associated with signals for the two vinyl C-H protons
of Dha33 at higher pH, so its stability at acidic pH values may be as a result of it being
“protected” in some way. Therefore, at higher pH values, a conformational change
may cause the Dha33 to become more susceptible to breakdown and cleavage. As was
observed in Chapter III, Dha-containing peptide fragments, which also contained a
His AA residue, showed lower stability at pH 7, which may be a result of the change
in the conformation of the tail fragment of both nisin A and Z.
Both nisin A and Z have also shown the ability to bind copper(II) ions in solution in
pH systems above pH 5.5, by UV-vis spectroscopy. This metal-binding ability of nisin
appears to involve the deprotonated neutral imidazole ring of the histidine residues
contained within nisin. The binding of the copper(II) ion also increases the solubility
of nisin at pH 6 and above, as the metal binding overcomes the precipitation of nisin
A and Z in this pH range. The pH-dependant binding interaction of nisin A and Z to
Cu(II) is reversible, as shown by pH cycling experiments, by changing the pH from
4.0 to 6.9, and then back and forth. This may be useful as the binding acts as a pH or
molecular switch.
The investigation of both species of nisin A and Z in different pH environments may
be a starting point in the understanding of the possible changes to their conformations
in solution. These changes may well be the reason for the decline in the solubility and
stability in neutral pH systems, as well as aiding the design of nisin analogues with
enhanced activity, stability and solubility at physiological pH.
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Future Work
Further study of both nisin A and Z is required to investigate the pH-dependant
changes in the solution conformation of the peptides. A variety of additional NMR
spectroscopic techniques including 1D and 2D NOESY should be employed to
investigate the changes in the solution conformation using through-space coupling
rather than via atoms directly bonded to one another. These nOe constraints will aid
in conformational modelling to determine the solution structures, as well as helping
the study of interactions between amino acids and if there are any interactions
disrupted as a result of the changing pH. In particular, studies of the interactions
involving the Dha33 residue are important, as the resonance signal of this residue
displayed significant changes as the pH/D of the aqueous solution was increased from
2 to 8.
Similarly, the study of the ability of nisin to bind metal ions should be further
expanded to include other metals described as “histidine-binding ions”, which include
nickel, cobalt, zinc and silver. Also, the exact mode of how nisin binds copper(II) ions
should be investigated using mass spectrometry, to ascertain whether more than one
nisin molecule is participating in the metal binding. This will aid in the study of the
stability/ reactivity and conformations of both nisin A and Z. The isolation of the nisinmetal complexes would allow for both their structural analysis and for evaluation of
their biological activities (if any), compared to nisin A and Z alone. As the pH of the
solution changes, it is also important to determine the exact species of copper ion
present in each pH system, possibly using pH potentiometry studies to distinguish the
different metal species that could be involved in binding nisin. This may also provide
additional insight into the mode of copper binding by both nisin A and Z.
It would also be interesting to study nisin in the presence of copper and metal ions at
physiological pH using CD spectroscopy. It is reported that the CD spectrum of nisin
changes with pH, due to conformational changes. As the solubility of nisin was
increased at physiological pH in the presence of copper, a key question is whether the
resulting nisin-metal complexes maintain the charge and conformation of nisin (A and
Z) in aqueous solution at physiological pH.
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Chapter VI
Overall Conclusions
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Synthesis and stability studies of nisin tail fragment analogues
The use of SPPS allowed for the successful incorporation of a Dha moiety into a target
peptide, on a Wang resin, using a masked serine by a selective dehydration step, via a
mesylate intermediate. The formation of the Dha moiety on the resin did not convert
the serine to a Dha completely, so both the serine and Dha analogues were isolated by
semi-preparative HPLC. Although the synthesis of several Dha-, Ser- and AC3Ccontaining peptides were successful, and the synthesis of the native nisin tail was
shown to be present by HRMS, its purification nevertheless proved extremely difficult
resulting in the isolation of only 4 mg of a very impure compound. This degraded
rapidly prior to characterisation and stability examination (32% purity).
The series of tetra-, penta- and hexa-peptides described in Chapter II were then used
to examine the impact of changing the AA residues on the stability of the tail
fragments. It is quite clear from these stability studies of the peptide tail fragments that
significant differences were observed. The tetrapeptide 69, which contained a Dha
moiety, broke down instantly at pH 3, while it was stable at both pH 5 and 7. In
comparison, for the Dha-containing pentapeptide 71, the elongation of the tail to
include an isoleucine residue increased the stability at pH 3, showing that the
isoleucine may play a role in protecting the tail from degradation in acidic pH
environments.
Interestingly, there were significant effects on the peptide stability when changing the
charged AA residues. Pentapeptide 73, which contains a histidine in the place of a Lys
residue, displayed lower stability at pH 7 compared to pentapeptide 71, while
maintaining stability at lower pH values. Interestingly, replacement of His with a Lys
residue showed greater stability at pH 7, but was compromised at pH 3. The stability
studies highlighted the importance of the side-chain pKa, with the Lys residues’
replacement proving to be more stable at physiological pH. The AC3C-containing
hexapeptide was consistently stable across the full studied pH range.
From the stability studies, the increased stability at physiological pH of both the diLys-containing (present in Nisin H) and AC3C-containing peptides, may indicate them
to be possible targets to study their activity with our collaborators in APC Microbiome
Ireland at UCC.
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and Z

Effects of salts and polyoxygenated buffer components on nisin A

During the course of the NMR study of both nisin A and Z in the presence of various
salt species, it became apparent that each nisin form behaves differently, depending
on the identity of the salt, rather than just on the overall ionic strength of the solution.
The addition of the salts seemed to alter the solution conformation of both nisin A and
Z, with the largest effect being observed for the Dha5 residue. The interaction of salt
at the A-ring of nisin may explain why nisin Z, in the presence of NaCl, is no longer
active against Gram-negative bacteria.
Using NMR spectroscopy, the effect of biological buffer components on both nisin A
and Z was studied. In the presence of these polyoxygenated species, again there were
chemical shift changes in the A-ring region of the peptides, with the largest change
being for the amide N-Hs of both Dha5 and Leu6. The interaction, or binding of the
buffer components, indicates that they may bind to the A-ring, possibly in a similar
fashion in which nisin binds the pyrophosphate moiety of lipid II. So, the presence of
these polyoxygenated species in solution may have an impact on the biological activity
of nisin and also on its ability to bind the pyrophosphate component of lipid II.
Many of the observed spectral changes are associated with the A- and B-ring regions
of nisin, which are directly involved in the binding of lipid II. So the presence of
polyoxygenated species in solution could potentially compete with the pyrophosphate
in binding with the A and B-rings, possibly affecting its biological activity. This
highlights that is in important to be conscious of not only the composition of the salts
in solution, but also the buffers used in the antimicrobial testing of nisin and its
derivatives, in a variety of assays.
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pH Studies of nisin A and Z
Following on from the NMR studies of nisin in the presence of different salts and
additives, the effect of pH was also studied. Using 1H NMR spectroscopy both nisin
A and Z were studied in the pH range of 2.0-8.0, and it was found that as the solution
pH was altered there were significant changes observed in the proton spectra. For the
pH NMR titrations of both nisin A and Z, there were significant changes observed for
the vinyl protons of Dha33 at 5.6 ppm. As the solution pH approached physiological
pH, the vinyl protons which were superimposed at low pH became resolved. The
significant change in the observed resonance signals for the two vinyl protons could
be a strong indication of a conformational change in the tail region of both nisin A and
Z. It is at pH 6, and above, that nisin shows a dramatic loss in its solubility and stability,
which may stem from this change in solution conformation.
The His27 side-chain pKa′ value was determined to be 6.42 in nisin A, while for His31
the pKa′ values were determined in 50 mM NaCl, to be 6.46 and 6.61 for nisin A and
nisin Z, respectively. As predicted the pKa values lie in the pH region where nisin
suffers a drop in solubility, most likely due to the change in the overall polarity and
charge of the peptides. It is interesting that the histidine-containing peptide tail
fragments also have a lower stability, compared to lysine-containing peptide
fragments. Based on the stability studies of the nisin tail fragments, retention of the
charge side-chain at physiological pH may increase the stability of nisin at
physiological pH, and broaden its possible applications and allow its potential use as
a therapeutic agent.
The ability of both nisin A and Z to bind copper(II) ions at pH values near and above
the determined pKa values of histidine side-chains was very encouraging. The
resulting nisin-copper complex also increased the solubility of nisin at physiological
pH. The increase in solubility may be a result of retaining a charge in higher pH
environments and could possibly enhance the biological activity of nisin, based on the
metal ion used (copper, silver, iron or zinc). In addition to studying the effect of
changing AA residues, the use of nisin-metal complexes may also be a method of
increasing nisin’s potential therapeutic applications by also expanding activity to the
targeting of Gram-negative species.
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The addition of salts, and changes to the solution pH, seemed to affect two different
regions of both nisin A and Z. So, it would be interesting to study if these changes are
additive. As nisin is used in the food industry, there could be significant changes in
nisin’s bioactivity or stability as a result of the varying pH and salt content of different
food types. Nisin is used across a wide variety of foods which are stored at different
temperatures. From the pH study and the calculated changes to the histidine
imidazolium N-H pKa values as a function of temperature, the conformational stability
of nisin may vary depending on the temperature.
In the literature nisin A and Z are used interchangeably, in the presence of different
buffers and in different solution environments, but from our results it is clear that based
on the salt type and buffer composition there are significant changes to both nisin A
and nisin Z, changing biologically important regions of the peptide. Therefore, it is
important not only to be conscious about the form of nisin used, but also the multitude
of salts and additives present in solution, and their differential effects on different nisin
structures.
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Chapter VII
Experimental Procedures
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7.0 General experimental procedures
All solvents used during both synthesis and purification, and salts used for NMR
studies, which were purchased from VWR, Lennox or Sigma Aldrich. Petroleum ether
40-60o was used for all purifications described, unless otherwise stated. Melting points
(MP) were determined for solid samples using a Stuart Melting Point SMP30
apparatus.
NMR spectroscopy was performed using a Bruker Avance 500 MHz spectrometer,
with chemical shifts reported in parts per million (ppm, δ). The instrument operated at
500 MHz (1H NMR with a typical resolution of 0.28 Hz) and at 125 MHz (13C NMR
with a typical resolution of 0.45 Hz). 1H NMR spectral assignments were aided with
DEPT 90, DEPT 135, HH-COSY, HMBC and HSQC experiments. Tetramethylsilane
(TMS) was used as an internal standard for all 1H and 13C NMR experiments unless
otherwise stated.
NMR analysis was conducted using, ultra-pure nisin A and Z (95% purity with the
remainder mainly water) were purchased from Handary, and also in high ionic strength
solutions, were conducted in 9:1 H2O: D2O (18.2 Mohm.cm H2O, D2O 99%) with all
spectra acquired at 25oC (+/- 0.1oC), with the exception of VT NMR experiments. 1%
w/v of DSS (4,4-dimethyl-4-silapentane-1-sulfonic acid) in pure D2O was used as a
reference in an external capillary tube to the nisin solution. 640 scans were acquired
for each 1H NMR experiment, using a BBFO (broadband fluorine observed) NMR
probe.
NMR studies in NUI Galway for the 1H-15N-HQSC spectra were conducted on an
Agilent DD2 NMR 600 MHz 54mm ASC Spectrometer, triple resonance (TXI)
equipped with a cryoprobe, using a 3 mM nisin concentration and 150 mM
concentration of the salt under investigation. All samples were prepared in 10%
D2O/H2O at 25oC and scanned for a 4-hour period with 1% w/v of DSS in pure D2O
was used as a reference in an external capillary tube to the nisin solution.
IR spectra were recorded on a Shimadzu IR Prestige-21 with 4 cm-1 resolution, over a
frequency range of 600–4000 cm-1, in transmittance mode. Solid samples were
prepared as dispersions in KBr discs and liquid samples as a thin film between sodium
chloride plates.
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Liquid Chromatography/ Mass Spectroscopy (LC/MS) were performed using an
Agilent Technologies 6530 Accurate-Mass Q-TOF LC/MS, using the Mass Hunter
software. Samples were dissolved in HPLC grade acetonitrile, with injection volumes
between 0.5-2.0 μl, mobile phase of 10% acetonitrile, 70% water and 0.1% formic
acid, with a flow rate of 0.2 mL/min.
Semi-Preparative HPLC was conducted in the Department of Chemistry, Maynooth
University, using a Gilson Semi-preparative HPLC system equipped with a VP-250/21
Nucleosil 100-5 C18 Column, with a detector wavelength of 214 nm. A gradient flow
of 5-20 % acetonitrile in water for 3 minutes and then plateaued for 20 minutes as 20%
acetonitrile in water was used. The water and acetonitrile with 0.1% TFA used for the
purifications was filtered and sonicated for 5 minutes prior to HPLC injection. The
peptide-containing fractions were then freeze-dried overnight, affording fluffy-white
solids.
Thin Layer chromatography (TLC) was performed using Merck aluminium-backed
sheets with silica gel 60 F254. Isolation of products using flash chromatography was
on silica gel (0.040-0.063 mm, 230-400 mesh) purchased from VWR.
Manual SPPS was conducted in a 25 mL CEM reaction vessel at room temperature.
All AAs and resins were purchased from Iris Biotech GmbH. The SPPS resin was
swollen in 5 mL of DCM for 30 minutes. The removal of the Fmoc protecting group
was performed using 40% piperidine in DMF (double deprotection). The Fmoc
removal was confirmed using ninhydrin stain to demonstrate the presence of the free
amine. The coupling of amino acids was performed using 3 molar equivalents of
COMU, Oxyma-pure and NMM; a one-hour double coupling was done for each step
of the SPPS synthesis. Capping/ acetylation of the N-terminus was done using 50:50
Ac2O:DMF, with a catalytic amount of DMAP added to the solution. After each step
of the manual SPPS, the resin was consecutively washed using 3 x 5 mL portions of
DMF and DCM. Removal of the trityl protecting group was performed using
TFA:TIPS:DCM (2:2:96) for 1 hour. The synthesised peptide was cleaved from the
resin using TFA:TIPS:DCM (96:2:2) for 1 hour, with the TFA removed in vacuo. The
peptide was precipitated from cold diethyl ether, with the resulting off-white/yellow
solid pelleted using a centrifuge at 5000 rpm for 5 minutes.
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Circular Dichroism (CD) analysis was performed in the Centre for Synthesis and
Chemical Biology (CSCB) in UCD, using a Jasco J-810 spectropolarimeter with a
path length of 1 mm, at 25oC. Samples were recorded using 8 scans between 190-250
nm. CD spectra of each ionic strength solution, in the absence of nisin A and Z, were
also recorded and subtracted from each sample reading to eliminate background noise.
All CD spectra were processed using CD Tool software, which was supplied by
Birkbeck, University of London.228

Compound Number

Page Number in main text

Page Number in this Chapter

1

42

200

2

42

201

38

44

202

41

45

203

44

47

204

48

49

205

49

49

206

50

40

207

67

61

208

68

61

208

71

64

210

72

64

210

73

66

212

74

66

212

75

67

214

76

67

214

77

69

216

85

71

217

199

7.1 Fmoc-Ser-O-Allyl (1)115
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Fmoc-L-serine-OH (6.99 g, 21.4 mmol) and Na2CO3 (1.79 g, 1.6 mmol) were
dissolved in deionised water (50 mL) and stirred at RT. In a separate RBF, Aliquat
336 (8.66 g, 21.4 mmol) and allyl bromide (2.03 mL, 23.5 mmol) were dissolved in
DCM (50 mL) and this solution was added to the Fmoc-serine-OH-containing flask.
The resulting mixture was stirred vigorously for 72 h at RT. The mixture was extracted
with DCM (4 x 30 mL) and the combined organic fractions were washed with brine
(3 x 20 mL), dried over anhydrous MgSO4 and concentrated in vacuo. The resulting
yellow oil was purified by flash chromatography on silica gel using petroleum ether:
ethyl acetate (3:1), which gave 1 as a white solid (7.46 g, 94% yield).
MP: 82-83oC; Rf: 0.66, petroleum ether: ethyl acetate (2:1); 1H NMR: (CDCl3) δ/
ppm; 7.82 (d, 2H, J = 7.3 Hz, A), 7.61 (d, 2H, J = 6.2 Hz, B), 7.41 (pseudo t, 2H, J =
7.3 Hz, C), 7.31 (pseudo t, 2H, J = 7.3 Hz, D), 5.90 (m, 1H, L), 5.70 (d, 1H, J = 5.1
Hz, G), 5.35-5.27 (m, 2H, M, N), 4.93 (d, 2H, J = 6.1 Hz, K), 4.67-4.44 (m, 3H, E,
F), 4.12 (pseudo q, 1H, J = 7.2 Hz, H), 3.62 (d, 2H, J = 6.2 Hz, I); 13C NMR: (CDCl3)
δ/ ppm; 171.3 (C=O, ester), 143.4 (C=O, Fmoc), 142.2 and 141.1 (Cq of Fmoc), 131.1
(L), 127.8 (B), 127.1 (C), 125.1 (D), 120.0 (A), 118.9 (M, N), 67.0 (I), 66.2 (K), 63.0
(F), 60.2 (H), 47.0 (E); IR: (KBr)/cm-1; 3435 (O-H, alcohol), 3050 (C-H, alkene),
1741 (ester C=O), 1676 (C=O, carbamate); HRMS: ES+ for C21H21NO5 calculated
[M+H]+ m/z of 368.1490, observed m/z [M+H]+ at 368.1493.
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7.2 Fmoc-L-Serine(OTs)-O-Allyl (2)115
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Fmoc-L-serine-O-Allyl (2.29 g, 6.23 mmol) and p-toluenesulfonyl chloride (5.94 g,
31.16 mmol) were placed in a 50 mL RBF and the vessel was then purged with
nitrogen for 5 min, after which 10 mL of pyridine was added and the solution was
stirred at 0oC for 18 h. The mixture was added to diethyl ether (100 mL), washed with
water (50 mL), 10% aqueous KHSO4 solution (4 x 40 mL), brine (3 x 20 mL), dried
over anhydrous MgSO4 and concentrated in vacuo. The resulting yellow oil was
purified by flash chromatography on silica gel using petroleum ether: ethyl acetate
(3:1), which gave 2 as a clear oil (1.003 g, 32% yield).
Rf: 0.61, petroleum ether: ethyl acetate (2:1); 1H NMR: (CDCl3) δ/ ppm; 7.73-7.33
(m, 12H, A-D and J-K), 5.85 (m, 1H, N), 5.61 (d, 1H, J = 7.2 Hz, G), 5.34-5.21 (m,
2H, O, P), 4.75 (d, 2H, J = 5.3 Hz, M), 4.67 (q, 1H, J = 7.2 Hz, H), 4.67-4.59 (m, 3H,
E,F), 4.03 (q, 2H, J = 6.9 Hz, I), 2.36 (s, 3H, L); 13C NMR: (CDCl3) δ/ ppm; 168.2
(C=O, ester), 155.8 (C=O, carbamate), 142.4 and 141.3 (Cq of Fmoc), 132.1 (N), 129.9
(B), 127.9 (C), 125.2 (D), 127.7 (J), 124.6 (K), 120.3 (A), 118.7 (O, P), 69.1 (F),
66.9 (I), 65.4 (M), 57.0 (H). 47.3 (E), 21.7 (L); IR: (KBr)/cm-1; 3345 (N-H), 3056 (CH, alkene), 1741 (C=O, ester), 1674 (C=O, carbamate); 1065 (S=O, sulfonate);
HRMS: ES+ for C28H27NO7S calculated m/z [M+H]+ of 522.1586, observed m/z
[M+H]+ at 522.1584.
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7.3 N-Acetyl-Dha-methyl amide (38)
C

O
A

N
H

D
H
N
O

B

E

38

In a RBF a solution of commercially available L-serine methyl ester hydrochloride
(0.25 g, 1.6 mmol) and 33% methylamine solution in ethanol (15.15 mL, 25 mole
equivalents) was stirred at 30oC for 3 hours. The mixture was purged with nitrogen for
20 min, and 20 mL (50:50 mixture) of acetic anhydride and pyridine in DCM was
added and the mixture was stirred at 50oC for 4 h. The DCM mixture was washed with
10% aqueous citric acid solution (3 x 15 mL), brine (3 x 15 mL), dried over anhydrous
MgSO4, and removed in vacuo affording an oil. Yield was not determined due to issues
during purification of the intractable mixture.
Rf: Not determined; 1H NMR of crude product: (CDCl3) δ/ ppm; 5.97 (dd, 1H,
geminal alkene, J = 5.2 Hz, C), 5.76 (dd, 1H, geminal alkene, J = 2.3 Hz, C), 2.42 (s,
3H, A), 2.17 (s, 3H, E);

13

C NMR: (CDCl3) δ/ ppm; Carbon NMR spectrum very

weak, dominated by pyridine; unable to purify for IR analysis; HRMS: ES+ for
C6H10N2O2 calculated m/z of 145.0972, observed m/z [M+H]+ at 145.0970.
NMR also contains peaks for pyridine which are very prominent in spectra
(development of optimised purification method required).

202

7.4 Fmoc-Lys-(Boc)-O-Allyl (41)
O
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I

N H
H
O
G

O

O

M

O
N

P, Q

41

Compound 46 was prepared using a similar procedure to that used to prepare 1, using
commercially available Fmoc-L-Lys-(Boc)-OH (6.99 g, 14.1 mmol), Na2CO3 (1.25 g,
14.1 mmol), Aliquat 336 (6.81 g, 14.9 mmol) and allyl bromide (1.46 mL, 16.4 mmol).
The resulting yellow solid was purified by flash chromatography on silica gel using
petroleum ether: ethyl acetate (3:1), which gave 41 as a white solid (6.12 g, 81% yield).
Tm: 109-111oC; Rf: 0.57, petroleum ether: ethyl acetate (2:1); 1H NMR: (CDCl3) δ/
ppm; 7.75 (d, 2H, J = 7.2 Hz, A), 7.61 (d, 2H, J= 6.8 Hz, B), 7.40 (pseudo t, 2H, J =
6.8 Hz, C), 7.2 (pseudo t, 2H, J = 7.1 Hz, D), 5.91 (m, 1H, O), 5.40 (d, 1H, J = 6.3
Hz, G), 5.34-5.27 (m, 2H, P, Q), 4.64 (m, 2H, N), 4.41-4.38 (m, 3H, E, F), 4.12
(pseudo q, 1H, J = 7.2 Hz, H), 3.12 (t, 2H, J = 7.1 Hz, L), 1.62 (m, 2H, I), 1.51 (m,
2H, K), 1.43 (s, 9H, t-butyl, M), 1.37 (m, 2H, J); 13C NMR: (CDCl3) δ/ ppm; 172.3
(C=O, ester), 156.1 (C=O, Boc), 155.5 (C=O, Fmoc), 141.3 and 140.1 (Cq of Fmoc),
131.6 (O), 126.9 (B), 126.7 (C), 125.5 (D), 119.6 (A), 118.2 (P, Q), 79.5 (t-butyl Cq),
67.1 (F), 66.2 (N), 53.6 (H), 47.3 (E), 40.3 (L), 36.3 (I), 30.1 (K), 28.7 (M), 22.7 (J);
IR (KBr)/cm-1; 3327 (N-H), 3036 (C-H, aromatic), 2986 (C-H, alkene), 2943 (C-H,
aliphatic), 1734 (C=O, ester), 1691 (C=O, carbamate); HRMS: ES+ for C29H36N2O6
calculated m/z [M+H]+ of 509.2651, observed m/z [M+H]+ at 509.2642.
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7.5 Fmoc-Cys-(Me)-Lys-(Boc)-O-Allyl (44)
O
HN
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O
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G
O
H
H
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O
O

S
J
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N

N L
H
O
K

O

Q

O

S
R

T, U

44

Fmoc-L-Lys-(Boc)-O-Allyl 41 (0.10 g, 0.19 mmol) was placed in a 50 mL RBF,
treated with 50% tris-(2-aminoethyl)amine (TAEA) in DCM (5mL), and was stirred
for 30 min at RT. The reaction mixture was taken up in EtOAc (40 mL) and washed
with a 10% aqueous ammonium chloride solution (2 x 5 mL), brine (2 x 10 mL), dried
over anhydrous MgSO4 and concentrated in vacuo. After removal of the solvent,
ninhydrin staining was used to show presence of the free amine. The free amine was
then dissolved in 10% DCM: MeCN (20 mL). To this solution Fmoc-Cys-(Me)-OH
(0.147g, 2.1 molar equivalents), HBTU (0.156 g, 2.1 molar equivalents) and Et3N
(0.05 mL, 2.1 molar equivalents) were added at 0oC and stirred for 1 h at this
temperature. The solution was then stirred at ambient temperature for a further 2 h.
The reaction mixture was added to EtOAc (40 mL), washed with a 10% aqueous citric
acid solution (3 x 10 mL), saturated aqueous NaHCO3 solution (3 x 10 mL), brine (3
x 10 mL), dried over anhydrous MgSO4 and concentrated in vacuo. The resulting
yellow solid was purified by flash column chromatography on silica gel using
petroleum ether: ethyl acetate (4:1) which gave 45 as a clear oil (0.099 g, 72% yield).
Rf: 0.37, petroleum ether: ethyl acetate (3:1); 1H NMR: (CDCl3) δ/ ppm; 7.76 (d, 2H,
J = 7.6 Hz, A), 7.60 (d, 2H, J = 7.6 Hz, B), 7.41 (pseudo t, 2H, J = 7.3 Hz, C), 7.32
(pseudo t, 2H, J = 7.3 Hz, D), 6.97 (br s, 1H, G), 5.89 (m, 1H, S), 5.38 (br s, 1H, K),
5.32-5.26 (dd, 2H, J = 10.1 Hz and 9.7 Hz, T, U), 4.62 (m, 1H, R), 4.44 - 4.35 (m, 3H,
E, F), 4.24 (apparent t, 1H, J = 7.1 Hz, H), 4.12 (q, 1H, J = 7.2 Hz, L), 3.07 (br s, 2H,
I), 2.83 (m, 4H, M, P), 2.17 (br s, 3H, J), 1.49 (m, 2H, N), 1.43 (s, 9H, t-butyl, Q),
1.35 (m, 2H, O); 13C NMR: 171.6 (C=O, ester), 156.0 (C=O, Boc), 155.8 (C=O,
Fmoc), 150.4 (C=O, amide), 131.4 (S), 142.6 and 141.3 (Cq of Fmoc), 127.8 (B),
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127.15 (C), 125.1 (D), 120.8 (A), 119.1 (T, U), 66.9 (F), 65.3 (R), 57.3 (H) 52.4 (L),
47.6 (E), 40.5 (P), 36.7 (M), 33.8 (I), 31.8 (N), 29.5 (O), 28.3 (Q), 15.9 (J); IR (NaCl
plate)/cm-1; 3327 (N-H), 3066 (C-H, aromatic), 2976 (C-H, alkene), 2939 (C-H,
aliphatic), 1732 (C=O, ester), 1693 (C=O, carbamate), 1653 (C=O, amide), 848 (S-C,
thioether); HRMS: ES+ for C33H43N3O7S calculated m/z [M+H]+ of 626.2899,
observed m/z [M+H]+ at 626.2929.

7.6 Fmoc-Cys-(Me)-Gly-O-tBu (48)
J

E

O

F
O
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S K
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N H
H
O
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O
L

O

M

D
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H-Gly-O-tBu (0.30 g, 1.78 mmol), Fmoc-Cys-(Me)-OH (0.76 g, 1.20 molar
equivalents), HBTU (0.81 g, 1.2 molar equivalents) and Et3N (0.29 mL, 1.20 molar
equivalents) were added to 10% DCM: MeCN (20 mL) at 0oC in a 50 mL RBF and
the solution was stirred for 1 h at this temperature. The solution was then stirred at
ambient temperature for a further 2 h. The reaction mixture was added to EtOAc (40
mL), washed with a 10% aqueous citric acid solution (3 x 10 mL), saturated aqueous
NaHCO3 solution (3 x 10 mL), brine (3 x 10 mL), dried over anhydrous MgSO4 and
concentrated in vacuo. The resulting yellow solid was purified by flash column
chromatography on silica gel using petroleum ether: ethyl acetate (4:1), which gave
48 as clear oil (0.671 g, 79% yield).
Rf: 0.32, petroleum ether: ethyl acetate (3:1); 1H NMR: (CDCl3) δ/ ppm; 7.77 (d, 2H,
J = 7.6 Hz, A), 7.60 (d, 2H, J = 7.6 Hz, B), 7.41 (pseudo t, 2H, J = 6.9 Hz, C), 7.32
(pseudo t, 2H, J = 6.9 Hz, D), 6.83 (br s, 1H, K), 5.73 (br s, 1H, G), 4.44 (m, 3H, E,
F), 4.13 (q, 1H, J = 7.2 Hz, H), 3.96 (m, 2H, L), 2.90 (br d, 2H, J = 7.4 Hz, I), 2.16
(br s, 3H, J), 1.47 (s, 9H, t-butyl, M); 13C NMR: (CDCl3) δ/ ppm; 170.1 (C=O, amide),
168 (C=O, ester), 154.6 (C=O, Fmoc), 149.6 (C=O, amide), 142.5 and 141.6 (Cq of
Fmoc), 127.8 (B), 127.2 (C), 125.1 (D), 120.1 (A), 82.6 (t-butyl Cq), 67.1 (F), 56.6
(H), 47.3 (E), 42.3 (L), 36.4 (I), 28.3 (M), 15.9 (J); IR (NaCl plate)/cm-1; 3304 (N205

H), 2980 (C-H, aromatic), 2924 (C-H, aliphatic), 1735 (C=O, ester), 1687 (C=O,
carbamate), 1650 (C=O, amide), 856 (S-C, thioether); HRMS: ES+ for C25H30N2O5S
calculated m/z [M+H]+ of 470.1875, observed m/z [M+H]+ at 470.1866.

7.7 Fmoc-Cys-(Me)-Ala-O-tBu (49)
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Using a similar method to that used for compound 48 the synthesis of 49 was
undertaken using H-Ala-O-tBu (0.320 g, 1.76 mmol), Fmoc-Cys-(Me)-OH (0.755 g,
1.2 molar equivalents), HBTU (0.80 g, 1.2 molar equivalents) and Et3N (0.29 mL, 1.2
molar equivalents) were added to 10% DCM: MeCN (20 mL). The resulting yellow
solid was purified by flash column chromatography on silica gel using petroleum
ether: ethyl acetate (4:1), which gave 49 as a clear oil (0.614 g, 76% yield).
Rf: 0.17, petroleum ether: ethyl acetate (3:1); 1H NMR: (CDCl3) δ/ ppm; 7.76 (d, 2H,
J = 7.1 Hz, A), 7.60 (d, 2H, J = 7.1 Hz, B), 7.41 (pseudo t, 2H, J = 7.6 Hz, C), 7.32
(pseudo t, 2H, J = 7.6 Hz, D), 6.97 (br s, 1H, K), 5.76 (br s, 1H, G), 4.43 (m, 3H, E,
F), 4.32 (m, 1H, L), 4.13 (q, 1H, J = 7.1 Hz, H), 2.95 (br d, 2H, J = 8.1 Hz, I), 2.17
(br s, 3H, J), 1.46 (s, 9H, N), 1.40 (d, 3H, J = 7.2 Hz, M); 13C NMR: (CDCl3) δ/ ppm;
170.6 (C=O, amide), 168.5 (C=O, ester), 155.8 (C=O, Fmoc), 149.7 (C=O, amide),
143.4 and 141.9 (Cq of Fmoc), 127.8 (B), 127.1 (C), 125.1 (D), 120.0 (A), 82.4 (Cq
of t-butyl), 67.9 (F), 60.6 (H), 49.0 (L), 47.2 (E), 32.4 (I), 28.1 (N), 18.6 (M), 14.2
(J); IR (NaCl plate)/cm-1; 3318 (N-H), 3059 (C-H, aromatic), 2980 (C-H, aliphatic),
1732 (C=O, ester), 1691 (C=O, carbamate), 1655 (C=O, amide), 844 (S-C, thioether);
HRMS: ES+ for C29H32N2O5S calculated m/z [M+H]+ of 485.2110, observed m/z
[M+H]+ at 485.2118.
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7.8 Fmoc-Cys-(Me)-Phe-O-tBu (50)
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Using a similar method to that shown for compound 48, the synthesis of 50 was
undertaken using H-Phe-O-tBu (0.40 g, 1.55 mmol), Fmoc-Cys(Me)-OH (0.66 g, 1.1
molar equivalents) HBTU (0.71 g, 1.1 molar equivalents) and Et3N (0.25 mL, 1.1
molar equivalents) was added. The resulting yellow solid which was purified by flash
chromatography on silica gel using petroleum ether: ethyl acetate (4:1), which gave
50 as a clear oil (0.71 g, 81% yield).
Rf: 0.17, petroleum ether: ethyl acetate (3:1); 1H NMR: (CDCl3) δ/ppm; 7.77 (d, 2H,
J = 7.6 Hz, A), 7.59 (d, 2H, J = 7.6 Hz, B), 7.41 (pseudo t, 2H, J = 7.2 Hz, C), 7.32
(pseudo t, 2H, J = 7.2 Hz, D), 7.25-7.15 (m, 5H, N-P), 6.81 (br s, 1H, K), 5.66 (br s,
1H, G), 4.71 (q, 1H, J = 7.4 Hz, L), 4.35 (apparent t, 1H, J = 7.1 Hz, H), 4.35 (m, 2H,
F), 4.23 (m, 1H, J = 7.7 Hz, E), 3.10 (t, 2H J = 5.7 Hz, I), 2.83 (m, 2H, M), 2.12 (br
s, 3H, J), 1.41 (s, 9H, Q); 13C NMR: (CDCl3) δ/ppm; 171.3 (C=O, ester), 169.1 (C=O,
amide), 155.3 (C=O, Fmoc), 150.2 (C=O, amide) 143.6 and 141.5 (Cq of Fmoc), 135.3
(Cq, phenyl), 130.4 (N), 129.4 (O), 128.3 (P), 127.8 (B), 127.2 (C), 125.1 (D), 120.6
(A), 82.5 (Cq of t-butyl), 67.3 (F), 59.2 (H), 53.6 (L), 47.1 (E), 37.6 (M), 36.4 (I),
28.0 (Q), 15.7 (J); IR (NaCl plate)/cm-1; 3332 (N-H), 3064 (C-H, aromatic), 2972 (CH, aliphatic), 1718 (C=O, ester), 1697 (C=O, carbamate), 1647 (C=O, amide), 842 (SC, thioether); HRMS: ES+ for C32H36N2O5S calculated m/z of 560.7036, observed
mass [M+H]+ at 560.7031.
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7.9 Ac-His-Val-Ser/Dha-Lys-OH (67 and 68)
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A coupling solution of Fmoc-protected amino acid (3 molar eq. to resin loading),
COMU (3 molar equivalents), Oxyma-pure (3 molar equivalents) and Nmethylmorpholine (6 molar equivalents) in DMF was pre-activated for 5 min. The
solution was then transferred to the peptide reaction vessel containing pre-loaded Lys
Wang resin. The reaction vessel was agitated for 1 hr at RT. A double coupling was
performed for each step of the SPPS synthesis, with the reactants of the previous
coupling reaction removed by washing with DMF (3 x 10 mL) and DCM (3 x 10 mL),
followed by repeating the coupling step. The formation of Dha was carried out using
methanesulfonyl chloride and Et3N (both in 6 molar equivalents) in dry DCM (5 mL)
at RT, followed by elimination using DBU (6 molar equivalents). The capping/
acetylation of the N-terminus was done using 50:50, Ac2O: DMF (5 mL), with a
catalytic amount of DMAP added to the solution. The resin was washed with DMF
(3 x 10 mL) and DCM (3 x 10 mL). Cleavage of the peptide from the resin was
conducted using 10 mL of TFA: DCM: TIPS (96: 2: 2). A small sample of resin was
taken after each coupling step and the peptide was cleaved from the resin and analysed
by HRMS. Purification by semi-preparative HPLC gave tetrapeptides 67 and 68.
Characterisation of tetrapeptide 67
Yield: 30.8 mg, 28.9%; semi-preparative HPLC: 10:90 MeCN: H2O 0.1% TFA, peak
eluted at 3.72 minutes. HRMS: ES+ for C22H38N7O7 calculated m/z of 512.2840,
observed mass [M+H]+ at 512.2844. MS/MS: fragmentation of the 512.2844 m/z ion,
b ions, 180.0803, 279.1501, 366.1801; y ions, 470.2721, 333.2200, 234.1448,
147.1128.
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1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

His

8.55

4.32

3.45

Val

8.16

4.04

1.99

Ser

8.38

4.62

3.06

Lys

8.19

4.11

2.00

γ
δ
C2
C4
8.53 7.20

ε

Exchangeable

0.84
OH not observed
1.62 1.83

7.43 (NH3+)

2.76

Table 47: 1H NMR assignment of Ac-His-Val-Ser-Lys-OH (67)
The 1H NMR assignment of each peptide fragment was aided using 2D-TOCSY NMR
spectroscopy. The C-terminal carboxylic acid proton (-COOH) was not observed in
the 1H NMR spectrum.
Characterisation of tetrapeptide 68
Yield: 17.9 mg, 16.9%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 4.07 minutes, HRMS: ES+ for C22H36N7O6 calculated m/z of 494.2722,
observed mass [M+H]+ at 494.2741. MS/MS: fragmentation of the 494.2741 m/z ion,
b ions, 180.0690, 279.1294, 348.1612; y ions, 452.2616, 315.2027, 216.1271,
147.1045.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

His

8.63

4.45

2.99

Val

8.06

4.19

1.79

Dha

9.68

Lys

7.93

γ
C2
8.57

δ
C4
7.21

ε

Exchangeable

1.39

3.02

7.54 (NH3+)

1.37

5.66
4.01

2.86

1.70

Table 48: 1H NMR assignment of Ac-His-Val-Dha-Lys-OH (68)
The C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.

209

7.10 Ac-Ile-His-Val-Ser/Dha-Lys-OH (71 and 72)
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Using a similar method to that described for compound 67, the syntheses of 71 and 72
were conducted. The reaction vessel was agitated for 1 hr at room temperature, and a
double coupling was performed for each step of the SPPS synthesis. The resin was
washed with DMF (3 x 10 mL) and DCM (3 x 10 mL). Purification by semipreparative HPLC gave pentapeptides 71 and 72.
Characterisation of pentapeptide 71
Yield: 20.5 mg, 14.8%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 4.22 minutes. HRMS: ES+ for C28H49N8O8 calculated m/z of 625.3668,
observed mass [M+H]+ at 625.3689. MS/MS: fragmentation of the 625.3689 m/z ion,
b ions, 180.0768, 279.1452, 366.1772; y ions, 470.2722, 333.2132, 234.1148,
147.1128.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

γ

δ

Ile

7.89

3.92

3.02

1.48

1.13

His

8.46

4.52

2.86

C2
8.33

C4
7.02

Val

8.02

3.98

1.51

1.17

Ser

8.17

4.18

3.56

Lys

7.74

4.85

3.41

ε

Exchangeable

OH not observed
1.39

1.10

2.65

7.22 (NH3+)

Table 49: 1H NMR assignment of Ac-Ile-His-Val-Ser-Lys-OH (71)
The C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.
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Characterisation of pentapeptide 72
Yield: 11.6 mg, 8.65%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 7.31 minutes. HRMS: ES+ for C28H47N8O7 calculated m/z of 607.3562,
observed mass [M+H]+ at 607.3528. MS/MS: fragmentation of the 607.3528 m/z ion,
b ions, 156.1058, 293.1650, 392.2322, 461.2522; y ions, 452.2637, 315.2060,
216.1381, 147.1165.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

γ

δ

Ile

8.35

4.37

1.96

1.85

1.54

His

8.67

4.26

3.29

C2
8.59

C4
7.30

Val

8.28

4.16

2.15

0.96

Dha

9.72

Lys

8.10

ε

Exchangeable

3.01

7.22 (NH3+)

5.72
4.06

1.76

1.70

0.84

Table 50: 1H NMR assignment of Ac-Ile-His-Val-Dha-Lys-OH (72)
The C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.
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7.11 Ac-Ile-His-Val-Ser/Dha-His-OH (73 and 74)
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Using a similar method to that shown for compound 68, the syntheses of 73 and 74
were conducted. The reaction vessel was agitated for 1 hr at room temperature, and a
double coupling was performed for each step of the SPPS synthesis. The resin was
washed with DMF (3 x 10 mL) and DCM (3 x 10 mL). Purification by semipreparative HPLC gave pentapeptides 73 and 74.
Characterisation of pentapeptide 73
Yield: 8.70 mg, 5.40%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 4.88 minutes. HRMS: ES+ for C28H44N9O8 calculated m/z of 634.3307,
observed mass [M+H]+ at 634.3305. MS/MS: fragmentation of the 634.3305 m/z ion,
b ions, 156.0827, 293.1676, 392.2360, 479.2613; y ions, 342.1839, 243.1152,
156.0856.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

γ

δ

Ile

7.97

4.25

2.98

His

8.31

4.53

2.93

1.69
C2
8.29

0.59
C4
6.92

Val

7.75

3.74

1.44

0.48

Ser

8.14

4.13

3.48

His

8.29

4.49

2.93

C2
8.26

C4
6.96

Exchangeable

OH not observed

Table 51: 1H NMR assignment of Ac-Ile-His-Val-Ser-His-OH (73)
The C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.
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Characterisation of pentapeptide 74
Yield: 8.50 mg, 5.43%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 5.23 minutes. HRMS: ES+ for C28H42N9O7 calculated m/z of 616.3202,
observed mass [M+H]+ at 616.3203. MS/MS: fragmentation of the 616.3203 m/z ion,
b ions, 156.0829, 293.1669, 392.3348, 461.2551; y ions, 461.2551, 324.1718,
225.1039.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

Residue

N-H

α

β

γ

δ

Exchangeable

Ile

8.07

4.42

3.07

His

8.51

4.69

3.10

1.98
C2
8.46

0.76
C4
7.18

Val

7.88

3.97

1.59

0.65

Dha

9.53

His

8.53

-COOH not observed

H

5.55
4.72

3.15

C2
8.42

C4
7.14

Table 52: 1H NMR assignment of Ac-Ile-His-Val-Dha-His-OH (74)
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7.12 Ac-Ile-Lys-Val-Ser/Dha-Lys-OH (75 and 76)
NH2

NH2

O
N
H

H
N
O

O
N
H

H
N
O

O

O
N
H
OH

OH

N
H

O

H
N

O
N
H

O

H
N
O

O
N
H

OH
O

NH2

NH2

76

75

Using a similar method to that shown for compound 68, the syntheses of 75 and 76
were conducted. The reaction vessel was agitated for 1 hr at room temperature, and a
double coupling was performed for each step of the SPPS synthesis. The resin was
washed with DMF (3 x 10 mL) and DCM (3 x 10 mL). Purification by semipreparative HPLC gave pentapeptides 75 and 76.
Characterisation of pentapeptide 75
Yield: 26.6 mg, 16.3%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 5.46 minutes. HRMS: ES+ for C32H53N9O9 calculated m/z of 616.4009,
observed mass [M+H]+ at 616.4011. MS/MS: fragmentation of the 616.4011 m/z ion,
b ions, 156.1019, 284.1967, 383.2653, 470.2968; y ions, 461.3081, 333.2133,
234.1450, 147.1126.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

γ

δ

Ile

8.27

4.31

3.69

1.62

1.27

Lys

7.92

4.25

1.65

1.33

1.03

Val

8.14

4.03

2.16

1.65

Ser

8.07

4.09

3.82

Lys

7.97

4.25

1.65

ε

Exchangeable

3.70

7.36 (NH3+)
OH not observed

1.33

1.03

3.70

7.44 (NH3+)

Table 53: 1H NMR assignment of Ac-Ile-Lys-Val-Ser-Lys-OH (75)
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For pentapeptide 74, which has a serine residue in place of a Dha, the two lysine
residues overlay, showing that they are chemically similar. The C-terminal carboxylic
acid proton (-COOH) was not observed in the 1H NMR spectrum.
Characterisation of pentapeptide 76
Yield: 24.5 mg, 15.5%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 7.93 minutes. HRMS: ES+ for C28H52N7O7 calculated m/z of 598.3910,
observed mass [M+H]+ at 598.3904. MS/MS: fragmentation of the 598.9304 m/z ion,
b ions, 128.1058, 256.1850, 355.2697, 452.2852; y ions, 556.3817, 443.2969,
315.2027, 216.1335, 147.1141.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H
ε

Exchangeable

0.85

4.05

7.44 (NH3+)

1.14

3.97

7.44 (NH3+)

Residue

N-H

α

β

γ

δ

Ile

8.35

4.33

3.74

1.74

1.35

Lys

8.13

4.22

1.67

1.37

Val

8.18

4.08

2.04

0.91

Dha

9.59

Lys

8.02

5.62
4.21

1.74

1.38

Table 54: 1H NMR assignment of Ac-Ile-Lys-Val-Dha-Lys-OH (76)
Further NMR studies are required to distinguish the two lysine residues, but due to the
limited amount of material it was not possible in our hands for both 75 and 76. The
C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.
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7.13 Ac-Ser-Ile-His-Val-Ser-Lys-OH (77)
NH2

H
N
O

O

O

H
N

N
H
OH

N
H
N

O

O

H
N

OH

N
H
OH

O

HN

O

77

Using a similar method to that shown for compound 68, the synthesis of 77 was
conducted. The reaction vessel was agitated for 1 hr at room temperature, and a double
coupling was performed for each step of the SPPS synthesis. The resin was washed
with DMF (3 x 10 mL) and DCM (3 x 10 mL).
Yield: 33.0 mg, 20.7%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 4.60 minutes. HRMS: ES+ for C31H54N9O10 calculated m/z of 712.3994,
observed mass [M+H]+ at 712.4015. MS/MS: fragmentation of the 712.4015 m/z ion,
b ions, 130.0821, 243.1261, 380.1879, 479.2563, 566.2881; y ions, 583.3512,
470.2673, 333.2078, 234.1370, 147.1074.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue

N-H

α

β

γ

δ

Ser

8.41

4.40

3.72

Ile

8.12

4.08

2.02

1.95

0.81

His

8.60

4.33

3.10

C2
8.57

C4
7.21

Val

8.02

4.06

1.70

0.73

Ser

8.23

4.32

3.75

Lys

7.98

4.07

1.75

ε

Exchangeable
OH not observed

OH not observed
1.58

1.28

3.71

7.54 (NH3+)

Table 55: 1H NMR assignment of Ac-Ser-Ile-His-Val-Ser-Lys-OH 77
The C-terminal carboxylic acid proton (-COOH) was not observed in the 1H NMR
spectrum.
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7.14 Ac-Ser-Ile-His-Val-AC3C-Lys-OH (85)
NH2

H
N
O

O
N
H
OH

O

H
N

N
H
N

O

H
N
O

O
N
H

OH
O

HN

85

Using a similar method to that shown for compound 68, the synthesis of 85 was
conducted. The reaction vessel was agitated for 1 hr at room temperature, a double
coupling was performed for each step of the SPPS synthesis. The resin was washed
with DMF (3 x 10 mL) and DCM (3 x 10 mL).
Yield: 70.2 mg, 50.0%; semi-preparative HPLC: 10:90 MeCN: H2O, 0.1% TFA, peak
eluted at 5.95 minutes. HRMS: ES+ for C32H53N9O9 calculated m/z of 708.4039,
observed mass [M+H]+ at 708.4049. MS/MS: fragmentation of the 708.4049 m/z ion,
b ions, 130.0862, 243.1214, 380.1915, 479.2599, 562.2974; y ions, 562.2990,
479.2622, 380.1934, 242.1340, 147.1076.
1

H NMR: (10% D2O: H2O) δ/ppm;
1

H

Residue
C-terminus

N-H

α

β

Ser

8.15

4.29

3.68

Ile

7.94

4.04

1.65

1.17

0.69

His

8.49

4.60

3.00

Val

8.03

3.81

1.91

C2
8.47
0.74

C4
7.16

AC3C
Lys

7.78
7.53

4.20

γ

δ

ε

Exchangeable
8.85 (COOH)
OH not Observed

2.85 +
2.70
2.83 1.74

1.54

1.22

7.35 (NH3+)

Table 56: 1H NMR assignment of Ac-Ser-Ile-His-Val-AC3C-Lys-OH (85)
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Appendices
Experimental data and spectra from Chapter III - NMR and Circular Dichroism
studies of Nisin A and Z and Chapter IV – pH Studies of Nisin A and Z by NMR
Spectroscopy are presented in full form in a separate document.
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